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Summary 
Nodular thyroid disease is common (prevalence 2-6%) and is a significant risk factor for the 
development of thyroid cancer.  
My aim was to apply genome-wide- linkage-analysis to identify the defect in a large kindred 
with multi-nodular goitre (MNG) of adolescent onset progressing to papillary thyroid cancer 
(PTC).  
Genomic DNA from 18 individuals (8 affected) was hybridized to Affymetrix GeneChip® 
Human Mapping 10K 2.0 Arrays. Results were analysed with Affymetrix GTYPE software to 
produce a call rate of ~92%. Extensive quality control steps were performed (PLINK, GRR) 
prior to linkage analysis using Merlin software in multipoint non-parametric and parametric 
(dominant) model. 
A non-parametric LOD score of 3.01 was obtained on chromosome 20 across 20cM, the same 
region produced a dominant LOD score of 2.03. Haplotype analysis reduced the region of 
interest to 3.7 Mbp, (encodes 10 genes). Analysis of copy number variation in an affected 
individual (Illumina Human 660W-Quad) revealed an intronic deletion of ~1000 bp in one 
copy of Phospholipase-C β1 (PLCβ1), (the first in the 10 gene list), which is present in all 
affected family members and carriers. The deletion contained ‘ATAA’ at the junction site and 
this InDel was found in 1 of 105 healthy unrelated people, a similar variant was reported in 
the database of genomic variants in ~1% of  Europeans . The deletion was not present in 70 
unrelated PTC patients but was found in 4/81 with MNG (all European); the deletion 
frequency in the general population vs. MNG gives a X
2 
value of 5.076 (p=0.024). 
PLCβ1 expression was measured in thyroid tissues from affected family members and 
subjects free of the InDel and were significantly higher in the former (p< 0.02).  
In conclusion, the InDel identified in familial MNG occurs in a proportion of sporadic MNG. 
It predisposes to goitre formation, possibly by increasing PLCβ1 transcription and activating 
the diacyl-glycerol, PKC and MAPK pathways. 
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Chapter 1 General Introduction  
 
1.1 The normal thyroid 
1.1.1 Anatomy  
The thyroid is a butterfly-shaped endocrine gland located in the neck region and consists of 
two encapsulated lobes. The gland synthesizes thyroid hormone and calcitonin through two 
different cells, the epithelial (or follicular) cells, and the parafollicular C cells, respectively. 
Each lobe of the gland is composed of follicles, each of which consists of a single layer of 
cuboidal thyroid follicular cells (TFC) that surrounds a lumen that contains colloid. TFCs are 
the functional units of the mature thyroid and are responsible for the biosynthesis and 
secretion of the thyroid hormones (T3 and T4) (reviewed in[3]).  
Thyroid stimulating hormone receptor (TSHR) is located at the basal membrane of thyroid 
cells (Figure 1.1) and is the main regulator of the gland, when Thyroid stimulating hormone 
(TSH) binds with it. The interaction activates the sodium iodide symporter (NIS), also known 
as solute carrier family 5, member 5 (SLC5A5), which is also located at the basal membrane 
and works as an iodide (I
-
) pump. Mono carboxylate channel MCT8 (SLC16A2), is also 
located on the basal membrane, through which thyroid hormones are released into the 
extracellular fluid. On the opposite side of the cell at the apical membrane, Pendrin 
(PDS/SLC26A4) is located, through which, I
-
 is transported from the TFC to the follicular 
lumen, where colloid is located (Figure ‎1.1). Blood supply of the thyroid is via the superior 
and inferior thyroid arteries (reviewed in [3, 4].   
The colloid is composed mainly of thyroglobulin (TG), which works as a matrix for thyroid 
hormone biosynthesis as it is the source of tyrosine (Tyr), the main component for thyroid 
hormones. Iodination of tyrosine residues occurs within TG, after the I
-
 is oxidized by thyroid 
peroxidase (TPO).  
The thyroid cell nucleus contains several transcription factors; Thyroid Transcription Factor 1 
(TTF-1, also known as TITF-1/NKX2.1), Thyroid Transcription Factor 2 (TTF-2 also known 
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as FOXE-1), Paired box 8 (PAX-8), and homeobox (Hhex). These factors play a role in the 
development of the thyroid gland, as they regulate the transcription of the genes encoding 
NIS, TPO, TG, TSHR and other genes within the thyroid (Reviewed in [3, 5]). 
 
 
 
Figure ‎1.1: Schematic diagram showing the thyroid follicular cell with its major structures. Thyroid 
stimulating hormone receptor (TSHR), sodium iodide symporter (NIS) and mono carboxylate channel 
(MCT8) are located on the basal membrane. G protein s alpha (Gsα) activates the adenylyl cyclase (AC) 
and cyclic adenosine mono phosphate (cAMP) cascade. Iodotyrosine dehalogenase (DEHAL) removes 
iodine from mono-iodotyrosines (MIT) and di-iodotyrosines (DIT). The nucleus contains transcription 
factors [thyroid transcription factor 1 (TITF1), fork head box E-1 (FOXE-1), paired box 8 (PAX-8) & 
homeobox (Hhex]. Pendrin, thyroperoxidase (TPO) and other proteins involved in tri-iodothyronine (T3) 
& tetra-iodothyronine or thyroxine (T4) biosynthesis are located on the apical membrane. Using 
hydrogen peroxide (H2O2) generated by dual oxidase 1 & 2, (DUOX1 and DUOX 2), TPO oxidizes iodine; 
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the iodination of tyrosine residues within thyroglobulin (TG) then occurs. The end products are MIT & 
DIT which couple (catalysed by TPO) to form T4 and T3. Adopted from [3]. 
1.1.2 Physiological Thyroid Function 
Hormone biosynthesis by the thyroid gland starts with active transport of I
-
 into thyrocytes. 
This process is known as iodide trapping and is performed by NIS, which is activated by TSH 
via cAMP. NIS increases thyroid iodine concentration to be 40 times higher than blood, and 
depends on the electrochemical gradient generated by the Na+, K+-ATPase. Then I
-
 is 
transported into the follicular lumen by Pendrin, in a process known as I
-
 efflux. The I
-
 is then 
oxidized by TPO, using H2O2 generated by (the calcium dependent flavo-protein NADPH) 
mainly, dual oxidase 2 (DUOX 2), (which is stimulated by PLC and PKC pathway) and  
probably (DUOX1), (which is stimulated via cAMP/PKA pathway) [6]. TPO iodinates 
selected tyrosyl residues on TG in a process known as organification or iodination, which 
leads to the formation of Mono-and Di-iodotyrosines (MIT, DIT). TPO then catalyses 
coupling of one MIT and one DIT to form Tri-iodothyronine (T3), while coupling of two DIT 
forms Tetra-iodothyronine or Thyroxine (T4) , (Figure ‎1.4). On the other hand iodotyrosine 
dehalogenase 1 (DEHAL1) enzyme, (also known as iodotyrosine deiodinase) removes iodine 
from iodinated tyrosine (MIT and DIT) and re-cycles iodide inside the thyrocytes (reviewed 
in [4]). 
 Iodinated thyroglobulin is stored as colloid in the follicular lumen and T4 (∼80%) and T3 
(∼20%) are released (when required) into the blood stream, via MCT8 channel. T3 & T4 are 
bound to and carried by thyroid hormone binding proteins in the blood, such as thyroxine 
binding globulin (TBG) [7].  
Although T3 is the more active form of thyroid hormone, only 20% is produced by the gland, 
while the rest is produced by exterior deiodination of T4 (at extra thyroidal sites), by 
deiodinase enzymes (will be described in ‎1.1.4), and the released iodide is recycled for 
hormone synthesis[8].  
All reactions necessary for the production of T3 and T4 are positively regulated by TSH 
which is secreted by anterior pituitary thyrotropic cells, binds to the TSHR and activates the 
thyroid gland. Hypothalamus on the other hand enhances pituitary gland to secrete TSH via 
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synthesizing Thyrotropin Releasing Hormone (TRH). When serum concentration of T4 and 
T3 reach high levels, a negative feedback maintains the hypothalamic-pituitary-thyroid axis 
and inhibits TSH and TRH secretion (Figure ‎1.2). In addition an adequate supply of iodine is 
essential to maintain normal levels of thyroid hormone production. A daily intake of less than 
50 micrograms is associated with goitre (will describe in ‎1.5.1). On the other hand iodide 
oxidation and organification are inhibited by higher iodine intake (reviewed in [3]).   
 
 
 
 
 
 
 
 
 
Figure ‎1.2; Cartoon showing the hypothalamic-pituitary-thyroid Axis. The hypothalamus secretes thyrotropin 
releasing hormone (TRH), which stimulates the pituitary to release thyroid stimulating hormone (TSH) to bind 
to thyroid stimulating hormone receptor (TSHR) and activate the thyroid gland. Negative feedback due to high 
levels of T3 and T4, which decreases the production of TRH and TSH, is indicated by the two blue arrows  
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TSHR plays the main role in the activation and growth of the thyroid gland. TSHR is a seven-
transmembrane receptor and belongs to the G protein-coupled receptor family (GPCR). It 
couples a G protein, which contains α, β & γ subunits (Gα subunit has 4 families; Gi, Gs, Gq 
& G12/13). When TSH binds to its receptor, it dissociates the trimeric G protein in to Gsα and 
Gβγ subunits. The main activation signal is mediated through Gsα, which activates the 
Adenylyl Cyclase (AD) cascade that involves Cyclic Adenosine Monophosphate (cAMP) and 
Protein kinase A (PKA), (Figure ‎1.3). However, when TSHR is activated more e.g. by high 
TSH levels, the Gαq cascade is also involved and thus activates phospholipase C (PLC), 
which convert phosphatidylinositol bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol triphosphate (IP3). The Gβγ subunits activate many signalling cascades including 
PLC, PIP2, DAG and IP3. The last two cascades activate mitogen activated protein kinase 
(MAPK) though BRAF and Protein Kinas C (PKC), (Figure ‎1.3) [9]. 
The main determining factor of the rate of I
-
 uptake is TSH (also known as Thyrotropin), 
which controls NIS activity. TSH also regulates thyroid hormone secretion and the number 
and size of TFCs, when it binds with its receptor TSHR [10-13]. Therefore any increase in 
TSH level, activates the thyroid gland, which produces more hormone, if excess hormone is 
produced it is known as hyperthyroidism (will be described in ‎1.3.1). That enhances the 
growth of the gland leading to its enlargement, a phenomena known as goitre (will be 
described in ‎1.5.1). On the other hand less production of TSH causes decreased activation of 
the gland, which leads to a low production of the hormones, if too little T4 is produced it is 
known as hypothyroidism (will be described in ‎1.3.2). 
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Figure ‎1.3; Cartoon showing a G protein-coupled receptor (GPCR) signalling cascade; 1) Ligands which 
signal through G protein α‎subunit‎(Gsα) activate cyclic adenosine monophosphate (cAMP) and protein 
kinase A (PKA). 2). Ligands which signal via Gαq subunits activate protein kinase C (PKC) and mitogen 
activated protein kinase (MAPK) via phospholipase C (PLC) and B- rapidly accelerated fibrosarcoma (B-
RAF). A full description is in the text. Modified from; Ladas I et al 2013 (poster) and 
htp://www.qiagen.com/products/genes 
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1.1.3 Functions of thyroid hormone 
Thyroid hormones are important for normal growth and development of the newborn, mainly 
for brain development, thyroid defect in neonates  can cause irreversible brain damage[14]. 
The World Health Organisation (WHO) considers iodine deﬁciency to be ‘the single most 
important preventable cause of brain damage’ worldwide[15]. Thyroid hormone plays a 
critical role in the maturation of other organs as well including skeletal, brown adipose tissue 
(BAT), liver, lungs, and heart[16]. T3 controls the basal metabolic rate (BMR) in adults by 
affecting the intermediary metabolism of fats, proteins, carbohydrates, and the rate of 
terminal oxidative metabolism. Thus the BMR will increase in cases of hyperthyroidism but 
decrease in hypothyroidism. Thyroid hormone effects the growth, development and function 
of most adult tissues including heart, muscle and brain. They have a role in maintaining 
metabolic energy balance, by increasing the number & size of mitochondria. Thyroid 
hormone increases bone turnover and osteopenia can occur in chronic hyperthyroidism [17]. 
Thyroid hormone stimulates hepatic gluconeogenesis and glycogenolysis as well as intestinal 
absorption of glucose, thus increases serum glucose (reviewed in [3, 18]).   
1.1.4 Thyroid Hormones Metabolism 
Although T3 is the active form of thyroid hormone, the thyroid gland produces more T4 
(80%), but deiodinase enzymes convert T4 to T3 intracellularly. The deiodination is 
performed by three types of the enzyme which are distributed in the body; DI-1, DI-2, and 
DI-3. DI-1 is expresses in the liver and kidney, stimulated by T3, has low affinity for T4 and 
can deiodinase either inner or outer ring (Figure ‎1.4). DI-2 is founds in the pituitary gland, 
brain, brown fat, and skeletal muscle, and is more active when T4 concentration is low and is 
an obligate outer ring deiodiniser [19]. DI-3 is expressed in placenta, brain, and skin, 
deiodinases inner ring only and is the major T3 and T4 inactivating enzyme. DI-3 and DI-1 
convert T4 to reverse T3 (rT3) by removing the outer ring iodine, which inactive the 
hormones, while rT3 and T3 can be further deiodinated to form Di-iodotyrosines in the liver 
(Figure ‎1.4). About 40% of the T4 and nearly all of theT3 that is produced each day is 
eventually deiodinated by inner ring deiodination, mostly via DI-3 (reviewed in [3, 20] ). 
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Figure ‎1.4; Cartoon showing the structure of thyroxine (T4) (blue) with inner ring and outer ring, and its 
conversion by deiodinase 1 or 2 (ID-1 or ID-2) (also known as Dio 1 or Dio 2) to T3 (active form), or by 
deiodinase 1 or 3 (ID-1 or ID-3) (also known as Dio 1 or Dio 3) to reverse tri-iodothyronine (rT3), 
(inactive form). The last structure is for di-iodotyrosines (DIT), (also called T2), which can be converted 
by ID-3 from tri-iodothyronine (T3) or by ID-1 & ID-2 from rT3.  
 
 
1.2 Thyroid Proliferation 
1.2.1 Development of the Thyroid 
The thyroid gland has a dual embryonic origin, with the most abundant thyroid follicular 
cells, arising from the embryonic endoderm (thyroid anlage), which emerges as a visible bud. 
The thyroid develops from the anterior foregut endoderm in which progenitor cells 
expressing four critical transcription factors, NKX2.1, PAX-8, FOXE-1, and Hhex, assemble 
to form the thyroid bud [21]. Thyroid C cells (which secrete calcitonin) arise from the 
ultimobranchial bodies (originating from pharyngeal pouch of the embryo). Thyroid cell 
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specification occurs in parallel to morphological and biochemical changes that make these 
cells clearly different from their neighbouring cells. Later the thyroid lobes expand and the 
gland obtains its definitive form, with a narrow isthmus connecting the two lateral lobes. 
Fully differentiated follicular cells express different thyroid-specific transcription factors. The 
beginning of thyroid development is on the floor of the primitive pharynx, which is followed 
by a migration to reach its final position at the pharynx, where the two lobes expand and the 
follicles formed (reviewed in [3]).  
After migration, thyroid cells express the essential proteins to start hormone biosynthesis. 
Expression of TG, TPO and TSHR starts first [22], then NIS, Duox1 & Duox2 [23, 24]. The 
biosynthesis of T4 starts before T3 [25]. Maturation of the hypothalamic–pituitary–thyroid 
system is also required for the hormone to be synthesised [26]. In addition to their function at 
the early embryonic stage, NKX2.1, PAX-8, FOXE-1, and Hhex have been shown to be 
playing an important role in the expression of these essential proteins of the gland. FOXE-1 
and PAX-8 have binding domains in the promoter regions of the TG, TPO, TSHR, and NIS 
genes, however NKX2.1 and PAX-8 have overlapping binding domains in TG and TPO genes 
promoters. In addition Hhex has been shown to play a fundamental role not only in the 
formation of the thyroid but also in the functional differentiation of the gland [21, 27-29]. 
Although these factors are present in other tissues, they are only expressed together in the 
thyroid. NKX2.1 and FOXE-1 are required for differentiation of both follicular and C cells of 
the thyroid, while PAX-8 is important only in differentiation of follicular cells. On the other 
hand lack of Hhex causes absence of the above three factors while absence of NKX2.1 and 
PAX-8 causes absence of Hhex [3, 29]. 
Mutations in FOXE-1, NKX2.1 or PAX-8 have been shown to be the cause of severe 
congenital hypothyroidism (CH) in humans, while germ line deletions of these transcription 
factors in animal models have provided important information on thyroid dysgenesis as a 
genetic disease [30-32]. A recent study [33] has reported that a transient overexpression of 
NKX2.1 and PAX-8 is sufficient to direct mouse embryonic stem-cell differentiation into 
thyroid follicular cells that are capable for iodide organification in vitro. The cells have 
shown an ability to rescue thyroid hormone deficits in athyroid animals. That has opened a 
new field for treating hypothyroid patients using stem-cell technologies. 
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In addition insulin like growth factor-1 (IGF-1) and epidermal growth factor (EGF) can 
promote thyroid cell proliferation in culture [34, 35]. They are expressed during embryonic 
life and could be the primary regulators of thyroid growth at that time [36, 37], (will describe 
more in ‎1.1.2).  
1.2.2 Physiological regulation of Thyroid growth 
Human thyroid cells divide about five times in adulthood, which reveals that there is a slow 
constant turnover (division and death) of these cells. Adult thyroids maintain their size with a 
slow cell turnover, but keep the capacity to grow by cell hypertrophy and proliferation when 
stimulated. During adulthood TSH enhances thyroid growth at several stages as TSH 
signalling has been shown to be the best growth stimulus for adult thyroid cells. However, 
this signalling is not a global regulator of thyroid function during the embryonic stage [25, 
27].  
On the other hand, some non-thyroidal factors act as thyroid proliferators, such as IGF-1 [38], 
transforming growth factor ß (TGF-ß)[39], and EGF [40]. Increased expression of these 
factors has been reported in proliferating thyroid tissue. Although IGF-1 plays a role in 
regulating growth in children generally and has anabolic effects in adults, it may also effect 
thyroid function and growth [41]. Cooperation between TSH, the major goitrogen, and IGF-1 
to regulate thyroid growth has been suggested, as studies showed both to be required for cell 
growth [42]. Moreover, enlarged thyroid and reduced TSH levels were also reported when 
IGF-1 and IGF-1 receptor (IGF-1R) were overexpressed in thyroid [43]. TGF-ß on the other 
hand, is a type of cytokine which has a role in the cell cycle (will be described in ‎1.6.2) and 
acts as an anti-proliferative factor [44]. In contrast, TGF-ß has been shown to down regulate 
NIS in BRAF
V600E
 mutant rat thyroid cells and its overexpression was observed in aggressive 
forms of human PTC in which absence of NIS was reported [45]. The growth factor, EGF 
binds to its receptor and stimulates cell growth, differentiation, proliferation and survival 
[46]. It has been reported to be increased in gene expression arrays of PTC tumours and 
shown to be a MAPK pathway activator [47].  
Thyroid gland was shown to be more active in children and adolescents than in young adults, 
while elderly thyroid is less active[48]. Several studies [48-50]on T4 and T3 levels during 
adulthood have pointed out that T4 secretion is reduced by age, which affects T3 levels, 
11 
 
because most circulating T3 derives from the deiodination of T4. However some studies have 
shown decrease in T3 but still in the normal range. Others have not found a decrease in T3 
even in very old individuals [51]. The fact that the mean calculated ratios of serum rT3, T4, 
free T3 and free T4 progressively increased with age suggest that the relative rate of T4 
conversion to rT3 increases with age during childhood and adolescence. In the thyroids of 
both adults and children, TSH plays the main role in thyrocyte growth (reviewed in [3]).  
 
1.3 Thyroid dysfunction 
Thyroid dysfunction can cause hyper production of the T3 & T4 hormones (hyperthyroidism) 
or hypo production (hypothyroidism). In both conditions goitre (will be described in ‎1.5.1) 
can be formed. Goitre can be caused by Auto Immune Thyroid Diseases (AITDs), which 
cause either of the above conditions, depending on the disease type. They often affect several 
members of the same family, often over many generations. These disorders are polygenic 
multifactorial with environment also playing a role. Some families with hyperthyroidism and 
cases of CH, (will be described in ‎1.3.2) are the result of single gene defects.  
1.3.1 Hyperthyroidism 
A ‘continuous increase in thyroid hormone biosynthesis and secretion by the thyroid gland’ is 
known as hyperthyroidism. This leads to an increase in the T3 & T4, accompanied by TSH 
suppression due to negative feedback. The thyroid gland in hyperthyroid patients produces 
more hormone than the body requirements, mainly as a consequence of TSHR activation. 
This can be due to two common conditions, either thyroid self-regulation (autonomy), or a 
presence of autoantibodies, which bind to, and activate the receptor. In thyroid autonomy, the 
receptor is activated without ligation of TSH, often due to gain-of-function- mutations in the 
TSHR.[52]. Toxic multinodular goitre (TMNG), diffuse thyroid autonomy or toxic thyroid 
nodule (TTN) are manifestations of the condition. In the case of antibodies, the TSHR is 
stimulated by Thyroid Stimulating antibodies (TSAB), in a condition known as Graves’ 
disease (GD), which is an AITD. It is the main cause of hyperthyroidism as it is responsible 
for about 60% to 90% of the hyperthyroidism cases across the world. Both conditions lead to 
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an increase of cAMP and start the cycle of thyroid hormone production and growth of the 
gland (reviewed in [3]). 
Toxic Multinodular Goitre (TMNG) is another form of Hyperthyroidism, in which 
autonomously functioning thyroid nodules (AFTNs) occur. These nodules also cause uni-
nodular goitre, which is known as Toxic Adenoma (TA). Both TMNG and TA are more 
common in women over 60, while TMNG is more common (~50%) in areas with iodine 
deficiency than TA (~10%)[53]. However enough supply of iodine decreases thyroid 
autonomy. TMNG prevalence showed 73% reduced after doubling iodine content of salt in 
Switzerland for 15 year[53]. TA is characterised by increased I- uptake of nodular cell with 
suppression of uptake in the surrounding extra-nodular tissue (hot nodule), while TMNG can 
be seen with or without additional nodules and with normal or decreased uptake (cold 
nodules) (reviewed in [3]).  
1.3.2 Hypothyroidism 
Hypothyroidism is the most common clinical disorder of thyroid function, with multiple 
etiologies. It is a condition in which the circulating T3 & T4 level is decreased accompanied 
by increased TSH and TRH released as a consequence of suppression of negative feedback. 
Nontoxic-Multinodular goitre (NT-MNG) is a form of hypothyroidism and is one of the most 
common endocrine diseases worldwide, affecting 500-600 million people in different areas of 
the globe [54]. It is related to iodine deficiency in many areas, which causes reduction in 
thyroid hormone synthesis. This reduction leads to an increase in TSH (by suppressing the 
negative feedback) and thus increase in both hormonal production and growth of the gland 
(endemic goitre) [54]. Nontoxic goitres can cause goitre in different types of thyroiditis 
(inflammation of the thyroid gland) such as Hashimoto’s thyroiditis (HT), which is the most 
common form of primary hypothyroidism. HT is autoimmune disease in which patient’s own 
immune system attacks the thyroid gland, making it unable to produce the hormones[55]. It is 
thought that Hashimoto’s is the end result of lymphocytes becoming sensitized to thyroidal 
antigens, to produce autoantibodies. All forms of AITD are associated with the presence of 
autoantibodies to thyroglobulin antibody (TG-Ab) and thyroid peroxidase (TPO-Ab) [56]. 
Gender distribution in AITD is four females to one male, older patients have a much higher 
incidence [54]. 
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Hypothyroidism can occur in childhood and is known as congenital hypothyroidism (CH). It 
is the commonest congenital endocrine disorder, affecting 1 in 3000 to 4000 newborns [57], 
which (if not treated on time) causes severe neurodevelopmental impairment, and has been 
shown to cause congenital heart disease as well [58]. CH is usually sporadic but up to 2% of 
thyroid dysgenesis, is familial [59]. The main causes of CH are genomic mutations in any 
genes related to thyroid function, development or growth and these mutations are often 
recessively inherited. These genes can be divided in two groups depending on their effect; 
those causing Thyroid gland Dysgenesis (TD), such as TSHR (causes non-syndromic CH), 
Gsα, NKX2.1, FOXE-1 and PAX-8 (cause syndromic CH)[60]. FOXE-1 Homozygous 
mutations, within the fork head domain (100 amino acids long domain), have been reported 
as a cause of CH (agenesis, dysgenesis or ectopic)[61], e.g. A65V was reported in two Welsh 
male siblings with the CH due to malfunctioning of the thyroid gland and thyroid dysgenesis 
[62]. On the other hand, variations within FOXE-1 poly-alanine tract may affect the 
susceptibility to TD. Studies on the poly-alanine tract suggested that FOXE-1 is more likely 
to be a TD susceptibility gene than a disease-causing gene[61]. Study of Italian subjects [63] 
reported 71% of the patients with 14 poly-alanine homozygous comparing with 85% healthy 
controls. Another Study of Italian subjects [64] showed that 14 poly-alanine homozygous 
present more in normal, while CH patient show more 16/16 and 14/16. Study on Japanese 
cohort[65] showed 14 poly-alanine homozygous in 96 normal and 43 TD cases. 
The second group of genes causing CH are those associated with defects in the organification 
of iodide, leading to dyshormonogenesis such as TPO, TG, NIS, PDS (Pendred 
syndrome), and DUOX2. Furthermore, genes involved in iodothyronine transporter defects 
such as MCT8, are shown to be a third group causing CH (reviewed in[60]).  
In 80 to 85 percent of CH cases, the thyroid gland is absent, abnormally located, or severely 
reduced in size (hypoplastic)[58].  
Radioactive iodine (RAI) therapy and surgical treatment for hyperthyroidism can cause 
hypothyroidism, as well as severe iodine deficiency[66].  
Secondary hypothyroidism occurs in cases of insufficiency of TRH secretion from the 
hypothalamus and/or insufficient secretion of TSH from the pituitary gland [67]. 
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Since thyroid hormone has important action on organs and tissues throughout the body, the 
symptoms and signs of thyroid hormone deficiency are multi-systemic and variable in 
expression. Subclinical hypothyroidism, the mildest form of thyroid failure, may be 
asymptomatic or have non-specific clinical features (reviewed in [3]). 
 
1.4 Nodular proliferation 
Enlargement in the thyroid gland (goitre) can occur without any disturbance of its function. It 
is more common at puberty or during pregnancy. Goitre can be toxic (in hyperthyroidism) or 
nontoxic (in euthyroid or hypothyroidism). Various types of familial goitre could be due to 
inherited thyroid disorders. They appear during childhood and are often associated with signs 
of hypothyroidism. 
Although many factors, such as age, gender, iodine intake and smoking are associated with 
nodularity of the thyroid, genetic factors also play a major role. A study has shown that 
children of parents with goitres have 2.7 fold higher risk of developing goitre [68, 69]. 
Thyroid nodules are very common, but few studies have been done to investigate their 
origins. One study [70], in iodine deficiency area was performed on a cohort with ages 
between 41 and 71 years and reported 46% of cold nodules (hypo functioning), 44% 
isofunction nodules (normal functioning) and 6% hot nodules (hyper functioning). In another 
two populations of 119 patients (from iodine deficient area) and 2537 controls (from iodine 
sufficient area), thyroid nodules were found in 5.1% of the patient and 1.9% of the control 
with cold nodules 2.5 times more frequent in patients [71]. On the other hand thyroid 
autonomy has been reported in 40% of 236 patients with euthyroid endemic goitres in an area 
of iodine deficiency[72]. 
Furthermore, DNA oxidation and damage can be caused by higher concentrations of H2O2, 
leading to mutagenesis and apoptosis [73]. In human thyrocytes this can cause frequent 
mutagenesis in the thyroid gland, which might provide the source for the frequent nodular 
transformation of endemic goitres [74]. In TSH receptor signalling, the cAMP cascade is 
shown to inhibit H2O2 generation, whereas the PLC and Ca
2+
/diacylglycerol cascade activates 
H2O2 production by DUOX2 stimulation and controlling TPO, which consequently control 
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thyroid hormone synthesis [75]. Furthermore, Iodine deficiency or autoimmunity cause 
diffuse thyroid hyperplasia [76], which increases proliferation and can lead to DNA damage 
due to elevated H2O2 levels.  
 
1.5 Benign thyroid diseases (adenoma) 
Benign diseases of the thyroid are quite common mainly in women with 5 times higher 
incidence than in men. There are three different types of benign thyroid disease; nontoxic, 
toxic and inflammatory [54]. A survey in northern England has reported goitres in 5.9% with 
a female/male ratio of 13:1 and 5.3% of women with single and multiple thyroid nodules 
comparing with 0.8% of men, with higher frequency in women over 45 years [77]. 
The most common forms of benign thyroid disease are Goitre (an enlargement of the entire 
thyroid gland), Graves’ disease (AITD) (described in‎1.3.1‎1.3) and Thyroid nodules (a result 
of clonal proliferation of a single thyroid cell). It has been proved that a history of benign 
thyroid disease is a high risk factor for the development of thyroid cancer [78, 79].  
1.5.1 Goitre 
The presence of goitre in the absence of autoimmune thyroid disease, malignancy, or 
inflammation, is known as MNG or diffuse goitre. Both genetic and environmental factors 
are involved in the goitrogenic process, but iodine deficiency is the most important risk 
factor. MNG is common even in areas without iodine deficiency [80], suggesting that other 
factors such as genetic, may play a role in the development. Both, thyroid mass and gland 
function increase due to MNG. Normal hormone secretion rate makes the condition as eu-
metabolic but goitrous. Usually the patient with MNG is unaware of any problem until the 
diagnosis is made during a routine physical exam or evaluation for another problem. 
Radiation is the clearest risk factor for thyroid carcinoma in humans, but a history of goitre or 
benign nodules also appears to significantly increase the risk for developing thyroid 
carcinoma. The roles of iodine, diet, reproductive and hormonal factors still remain unclear. 
The understanding of predisposing genetic factors is increasing (reviewed in [3]). 
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MNG is a significant risk factor for thyroid cancer[81] mainly Papillary Thyroid Cancer 
(PTC), (will be described in  1.6), whose incidence globally has increased in recent years [82]. 
The terms nontoxic nodular goitre, adenomatous goitre, and colloid nodular goitre are used as 
descriptive when a MNG is found. 
Familial thyroid cancers make up about 5% of cases, with earlier age of onset than sporadic 
disease. Several studies have reported candidate loci as factors causing nodular goitre, such 
as MNG1 locus on chromosome 14q13.3[83] and MNG2 locus on chromosome Xp22[84]. 
An association with 4 other susceptibility loci, three of which are associated with Familial 
Non Medullary Thyroid Cancer (FNMTC), has been reported on chromosomes 19p13.2, 
2q21, 1q21 and 10q23 [85-88]. In addition, loci on chromosomes 3q26, 2q, 3p, 7q, 8p and 
14q32, have been reported to be overlapping with familial goitre [89-91].  
Genes implicated in familial goitre and cancers generally differ from those in sporadic 
disease, with the exception of NKX2.1[92] and FOXE-1[93].  
Four genetic loci have been reported in genome-wide association studies, to be associated 
with thyroid volume: Two independent loci located upstream of and within capping protein, 
beta (CAPZB), one within fibroblast growth factor 7 (FGF7), and one on chromosome 16q23 
[94, 95]. 
1.5.2 Thyroid Nodules 
Nodules develop from a single cell having a growth advantage. They could be euthyroid, as 
in family #1 of this study, or hypo or hyper thyroid. Thyroid nodules may progress to 
neoplasia due to somatic mutation or over activated oncogenes (will be described in ‎1.6.1). 
Necrosis can lead to pseudocystic nodules due to an imbalance between angiogenesis and 
growth. Other mechanisms, including immune-toxicity and hyper-secretion of factors that 
increase permeability of the endothelium have been proposed in the pathogenesis of cyst 
formation (reviewed in [3, 96]). 
In addition, genetic factors have been demonstrated to play a role in familial nodular goitre 
presenting at a young age [97]. Many CH cases are due to mutations in genes regulating 
thyroid physiology. Elevated TSH, which is a compensation mechanism to try to increase 
thyroid hormone levels and often present in CH, may produce a euthyroid goitre [3, 97]. 
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1.6 Malignant Thyroid disease (Thyroid cancer)  
Thyroid cancer occurs when the normal equilibrium of regulatory pathways is disrupted. That 
could be through enhancement of stimulatory pathways (e.g. growth hormones and proto-
oncogenes) or deficiency in inhibitory pathways (e.g. tumour suppressors, normal cell-to-cell 
interactions, and cellular immortalization) [98]. Thyroid cancer is the commonest among all 
endocrine malignancies comprising 95% of such disorders [99, 100]. Its incidence is 
increasing with a global estimate of 0.5 million new cases in 2004[101]. 
Two main types of thyroid cancer are identified depending on the cellular origin of the cancer 
itself. The commonest type arises from Follicular thyrocytes (thyroxine producing cells) and 
is called Differentiated Thyroid Cancer (DTC). It can be either papillary carcinoma (the 
commonest, representing up to 80% of all thyroid malignancies), or follicular carcinoma (the 
most aggressive type, giving rise to metastases). Follicular carcinoma occurs in a slightly 
older age group than papillary (age is a very important factor in terms of prognosis), and is 
also less common in children. It occurs only rarely after radiation therapy in older people 
(Figure ‎1.5).  
Hurthle cell adenoma (HCA) (Figure ‎1.5) can be classified as a very rare type of thyroid 
tumour and could be sub-classified from PTC and FTC. The Hurthle cells are enlarged 
epithelial cells which can be found in several other thyroid abnormalities such as HT, toxic 
and non-toxic goitre[102]. There is general agreement in considering Hurthle cell neoplasms 
as a subset of all differentiated thyroid cancer, regardless of the papillary or follicular growth 
pattern. Hurthle cell carcinoma should be included in a subset of thyroid neoplasms different 
from true follicular cancers [103, 104] 
The second type is Medullary thyroid carcinoma (MTC) and is a neuro-endocrine tumour 
arising from calcitonin producing parafollicular thyroid cells (C-Cells)[105]. It is the third 
most common (5%) of all thyroid cancer, but more aggressive with high mortality rate if not 
treated. Approximately 25% of MTCs are classified as familial (FMTC) and are due to RET 
proto-oncogene mutation (will be described in ‎1.6.1) [106]. FMTC can occur alone or as part 
of Multiple Endocrine Neoplasia type 2 (MEN 2) and can be considered as a clinical variant 
of MEN 2A [107]. Clinically, MEN 2A can be characterized by MTC in combination with 
pheochromocytoma (neuroendocrine tumour of the medulla and the adrenal gland) and 
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hyperparathyroidism. MEN 2B can be characterised by MTC in combination with 
pheochromocytoma, Marfanoid habitus (changes in limbs, fingers & joints) and multiple 
mucosal neuromas [108].  
However, sporadic MTC can coexist with tumours of the parathyroid gland and can be 
classified as MEN2. It can be defined by absence of family history and lack of germline RET 
mutation and other MEN 2A related tumours [109]. Risks of metastases are high in both 
sporadic and hereditary MTC [110] 
Carcinoma cells in the above types can be identified under the microscope, but another type 
of thyroid carcinoma, Anaplastic Thyroid Cancer (ATC) is undifferentiated. This type has 
very poor prognosis and is resistant to cancer treatments and thus causes high mortality. ATC 
is very rare with prevalence of 1.3%. A personal history of a long-standing goitre, previous 
resection for PTC, and family history of other cancers were risk factors for ATC in a case–
control study[111].  
The early stages of thyroid tumour development appear to be due to an activation of several 
receptors, which are associated with the development of differentiated neoplasms [112]. 
Some cause benign toxic adenomas such as G-protein mutation (gsp) and TSHR, others, such 
as RAS, cause FTC or RET which causes PTC. PTC can also be caused due to gene 
rearrangements and chromosomal translocations such as RET/PTC, NTRK, and PAX-
8/PPARγ. Tumour suppressor gene (Tp53, RB) alternations, on the other hand, are associated 
with ATC (reviewed in [98]). The presumed stages of non-medullary thyroid tumourigenesis 
are summarised in (Figure ‎1.5). 
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Figure ‎1.5; Cartoon showing presumed stages of non-medullary thyroid tumourigenesis, starting from a 
defect in a normal thyroid which leads to either benign toxic adenoma, papillary thyroid cancer (PTC), 
follicular thyroid cancer  FTC, Follicular adenoma or Hurthle cell adenoma. These forms can be further 
developed to Follicular or Hurthle cell carcinomas. The later stage is anaplastic carcinoma. A full 
description is in the text. (adopted from[98]). 
 
 
One of the main concerns of any thyroid group is the accurate distinction between benign and 
malignant nodules. That can mostly be achieved in papillary cases, when using the common 
test for initial thyroid nodule diagnosis, which is histology of fine-needle aspirates 
(FNA)[113]. However, this test cannot differentiate between thyroid tumours with a follicular 
pattern. This challenge is creating problems in distinguishing between (FTA) follicular 
thyroid adenoma (benign) and (FTC) follicular thyroid carcinoma (malignant), accurately. 
Therefore most guideline recommendations for follicular pattern are to be surgically removed 
(partial thyroidectomy), and examined histopathologically, looking for invasion through the 
tumour capsule or the blood vessels[101]. A study on approximately 6,300 FNAs of the 
thyroid was reviewed [114], only 8–17% of these cytologically suspicious nodules were 
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definitely malignant on histology, leading to the conclusion that distinguishing follicular or 
Hurthle-cell adenomas from follicular or Hurthle-cell carcinomas is almost impossible in 
FNA. It is often necessary to remove healthy thyroid to rule out carcinoma. Attempts to 
identify markers to improve diagnosis have compared gene expression profiles in FTC and  
FTA, and have identified 4 genes of potential value although these are still not widely used 
[101].  
1.6.1 Proto-oncogenes & growth factors 
Most proto-oncogenes (e.g. RET, PPARγ, RAS & Met) are genes that code proteins 
responsible for regulation of cell growth and differentiation. These proteins are activated 
through their ligand binding region (by growth factor) and involved in signal transduction 
and execution of mitogenic signals. Abnormal activation of proto-oncogenes converts them to 
tumour inducing agents, which are then called oncogenes. Although oncogenes are involved 
in the normal programed cell death (apoptosis), activated oncogenes can cause those cells that 
should die to survive and proliferate instead[115]. Most oncogenes require an additional step, 
such as mutations in another gene, chromosomal changes (re arrangements, translocation), or 
environmental factors to cause cancer. Activated oncogenes have been indicated in several 
types of thyroid cancers and include mutation, overexpression (gene amplification), or 
chromosomal rearrangement (chromosomal translocations mainly). Several reports have 
shown that genetic cases of sporadic thyroid cancers could be RET chromosomal re-
arrangements [116], translocations between chromosome 2 and 3 generating a PPARγ-PAX-8 
fusion protein[117], mutations in Ras genes[118], and poly-alanine tract length variation in 
FOXE-1[91, 119]. Although BRAF mutations[120] causing constitutive activation, are the 
most frequent cause of PTC.       
RAS belongs to a protein family encoding small GTPase proteins that function as binary 
molecular switches, control intracellular signalling and are involved in cell growth, 
differentiation and survival. Activating mutations in the RAS proto-oncogenes, have been 
found in a wide spectrum of benign and malignant thyroid pathologies, including MNG, 
follicular adenomas, FTC and PTC, suggesting it is an early event in thyroid tumourigenesis. 
Overall, around 40% of benign and malignant thyroid neoplasms display RAS activation, and 
the frequency of RAS mutations is higher in FTC (80%) than in PTC (20%) [118]. RAS 
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mutations at amino acids 12, 13 and 61 cause constitutive activation of RAS proteins and 
convert them into active oncogenes, generating a continuous flow of growth signals. All three 
RAS genes (H-RAS, N-RAS and K-RAS4A and K-RAS4B) can be activated in thyroid cancer 
(reviewed in [3]).  
The RET proto-oncogene encodes a receptor tyrosine kinase (RTK), normally expressed in 
neuroendocrine cells, and the collecting duct of the kidney, but not normally present in 
thyroid follicular cells. Chromosomal re arrangements link the promoter and N-terminal 
domains of unrelated gene(s) to RET C-terminal, leading to an irregular expression of a 
chimeric form of the RTK in thyroid follicular cells which is constitutively active, without 
ligand binding requirement. This condition has been reported in PTC [116, 121]. There are at 
least 12 different types of RET rearrangements in PTC [122]. RET/PTC1 and RET/PTC3 are 
the most common, accounting for >90% of all rearrangements[121]. RET/PTC1 is formed by 
fusion with the CCDC6 (H4) gene (encodes coiled-coil domain-containing protein 6), and 
RET/PTC3 by fusion with the NCOA4 (ELE1) gene (encodes nuclear receptor co activator 
4). NCOA4 interacts with PPAR γ and Androgen receptor [123, 124]. A study [125] on 
human PTC specimens has reported (H4/PTEN) intra-chromosomal rearrangements between 
H4 and PTEN, a gene located on 10q22-23 (will be described in ‎1.6.2.1). In clinically 
detectable tumours, the presence of RET/PTC rearrangements varies widely, with frequencies 
between 0% and 59% reported in different series. The frequency is increased following 
exposure to radiation, and post-Chernobyl, the dramatic rise in paediatric PTC was associated 
with RET/PTC rearrangements. The mechanism is likely to be the increased incidence of 
chromosomal breaks following exposure of the thyroid gland to radiation [126].  
Absence of any significant increase of thyroid cancers after the Fukushima accident in spite 
of screening (until now), would certify the high level of health care in Japan especially 
among children and adolescents [127]. The estimation of iodine-131 (I
131
) release was 
770 PBq (1 Peta Becquerel = 10
15
 Bq), which is about 15% of the estimated Chernobyl 
release of 5200 PBq. Additionally, the release of contaminated cooling water from the 
damaged reactor buildings resulted in a direct discharge of about 4.7 PBq of radioactivity into 
the Pacific Ocean. The ocean discharge of radioactivity was estimated to be about 11 PBq 
of I131. The total amount of radioactive material released into the air during the event was 
22 
 
revised downwards to 130 PBq for 131I, which represents about 11% of estimated Chernobyl 
emissions (reviewed in [128]). 
Somatic rearrangements (on chromosome 1) of Neurotrophic tyrosine kinase, receptor type 1 
(NTRK1), the proto-oncogene that encodes the receptor for nerve growth factor (NGF), are 
seen in PTCs [129]. They arise from the fusion of the 3 terminal sequences of the 
NTRK1/NGF receptor gene with 5 terminal sequences of various activating genes, such as 
TPM3, TPR and TFG. TRK onco-proteins display constitutive tyrosine-kinase activity [130]. 
NTRK1 rearrangements have been found only in PTC, but with a lower prevalence than that 
reported for RET/PTC. Furthermore TRK receptors have been implicated in the onset and 
progression of MTC. Targeted over expression of one of the TRK family; TRK-T1 induces 
lesions resembling PTC in transgenic mice, suggesting its role in an alternative pathway for 
tumour initiation[131]. 
On the other hand germ-line RET mutations are shown to be more common in hereditary 
MTC (described in ‎1.6). These mutations are identified in more than 97% of cases of MEN 
2A and 95% of FMTC. Mutations of the cysteine at codon 634 account for around 80% of 
germ-line RET mutations MEN 2A is an example[132]. A review in 2012 [108] has reported 
a total of 39 different RET germline mutations identified in FMTC. The most affected codons 
were 609, 611, 618, 620 (exon 10) and 634 (exon 11) in the extracellular domain, and codons 
768 (exon 13) and 804 (exon 14) of the intracellular tyrosine kinase domain. On the other 
hand a high percentage (25-50%) of sporadic MTCs are caused by RET proto-oncogene 
activating mutations [133]. RET mutation met918thr is the most common somatic mutation, 
while met918thr germ-line mutation is less common and causes MEN 2B [134]. Mutations in 
codon 918 cause the most aggressive types of MTC[135]. Almost all patients with RET 
mutations will develop MTC. Although there is a clear genotype–phenotype relationship, 
aggressive disease can occur irrespective of the mutation involved. Somatic RET mutations 
that occur later in life and are limited to C cells are present in 40–50% of sporadic MTCs 
[136]. Although these tumours are heterogeneous, somatic RET mutations have been shown 
in up to 80% of sporadic MTCs, commonly 918ATG > ACG [137, 138], and less frequently 
at codon 634 and others (reviewed in [107]. 
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Peroxisome proliferator activated receptor gamma (PPAR-γ) is member of the nuclear 
receptor superfamily, in common with the receptors for thyroid hormone. PPAR-γ is a 
regulator of adipocyte differentiation and plays a role in fatty acid storage [139]. Although 
the receptors for thyroid hormone and PPAR-γ have diverse effects on developmental and 
metabolic processes and have their own cellular functions, recent studies[140] have indicated 
crosstalk between the nuclear receptor family with hormones affecting the activity of other 
receptors leading to alterations in various biological functions including carcinogenesis.  
Translocations between PAX-8 on chromosomes 2 and the member of the nuclear hormone 
receptor superfamily (PPAR-γ) on chromosome 3 have been detected in a series of mainly 
follicular cancers. The translocation causes an in-frame fusion of PAX-8 to PPAR-γ [117]. 
The predicted fusion protein has been detected in follicular cancer tissue by immune 
precipitation and has been postulated to have a role in the pathogenesis of thyroid follicular 
carcinogenesis. While PAX-8, a paired box containing transcription factor, is central to the 
expression of several thyroid-specific genes including TG and TPO, the precise role of 
PPAR- γ in this context has not been elucidated. PAX-8/PPAR-γ rearrangements have 
generally not been reported in PTC, follicular adenomas, or MNG [117]. Moreover, 
activation of PPAR-γ reduces plasma thyroid hormones and deiodination level [141]. 
Met, (c-Met) is a proto-oncogene which encodes c-met protein, a membrane spanning RTK 
that regulates cell growth, tissue repair and survival. Mutations in RTK have been implicated 
in the progression of many human cancers. c-Met is a receptor for Hepatic growth factor 
(HGF), a liver regeneration mediator which is also known as scatter factor (SF)[142]. These 
growth factors are multifunctional cytokines that bind to the c-Met receptors and activate 
tyrosine kinase signalling, which stimulate mitosis and cell motility and thus play a role in 
tumourigenesis and tissue regeneration [143].  c-Met has been shown to be overexpressed in 
approximately 90% of PTC and is significantly associated with an aggressive phenotype 
[144]. It was recently reported that the c-Met gene is overexpressed in 37% of PTCs in Saudi 
patients [145]. c-Met is a potent thyrocyte mitogen whose expression is thought to be induced 
by RAS and RET oncogene activation[146]. Dysregulation of c-Met signalling has been 
shown to contribute to tumourigenesis in a number of malignancies, including thyroid 
cancer[147]. 
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Growth factors IGF-1, TGF-ß & EGF play role in thyroid proliferators (as described in ‎1.2.2). 
In summary expression of any of the three factors has been increased in proliferating thyroid. 
TGF-ß overexpression was observed in aggressive forms of human PTC. EGF has been 
reported in gene expression array of PTC tumours and shown as a MAPK pathway activator. 
IGF-1 showed association with thyroid growth and goitrogenesis. It is known to be 
implicated in tumour cell apoptosis, invasion, transformation and metastasis, and to play a 
role in thyroid nodules. A study [148] on 62 thyroid tissues (blocks), including18 follicular 
adenomas (FA), 17 nodular goitres, 13 PTC, 2 FTC, and 12 normal controls, has reported that 
IGF-1 plays an important role in the genesis and development of certain solid cold thyroid 
nodules, including PTC, nodular goitres, and FA. 
On the other hand, these three growth factors (IGF-1, EGF & TGF-α) are reported to enhance 
both expression and phosphorylation of the Human Pituitary Tumour Transforming Gene 
(hPTTG). hPTTG is a proto-oncogene which encodes the PTTG protein and is overexpressed 
in pituitary, thyroid, breast, ovarian and other carcinomas [149]. Expression and 
phosphorylation of hPTTG in thyroid cells is associated with MAPK and PI3K activation. In 
addition hPTTG in thyroid carcinoma cells is reported to be activated independently of the 
original mediators by these growth factors [150]. Conversely, PTTG and its binding factor 
PBF are reported to supress expression of NIS mRNA, and this leads to inhibition of iodide 
uptake. This could have adverse effects on prognosis, by reducing the efficiency of 
radioiodine treatment of differentiated thyroid cancer, in which overexpression of PTTG and 
PBF has been reported [151].  
 BRAF  1.6.1.1
The BRAF oncogene is involved in the signalling pathway mediated by TSH, through Gβγ 
dimer which activates the PI3K pathway. It appears to be a signalling connector between 
PLC, DAG, PKC and ERK, in the MAPK pathway (Figure ‎1.3) [9]. TSH seems to be 
cooperating with BRAF to induce thyroid tumourigenesis. Thyroid hormone biosynthesis is 
suppressed by BRAF; the compensatory rise in TSH will then also contribute to increasing 
the proliferation of thyrocytes.  This may explain the major role for TSH as a tumour 
promoter in this disease [152]. Studies of BRAF-mutant PTCs have shown changes in the 
expression of NIS, the apical iodide transporter and or TPO [153].  
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BRAF is a member of RAF family which has three isoforms (ARAF, BRAF and CRAF) and 
activate extracellular signal-regulated kinase (ERK) through MAPK (Figure ‎1.3). Although 
RAS mediates the activation of the three isoforms, there is no evidence of overlapping 
between PTC with RET/PTC, BRAF or RAS mutations. It has been proposed that BRAF is 
the main isoform coupling RAS to MAPK/ERK (MEK), and that C-RAF and A-RAF signal 
to ERK to fine-tune cellular responses (reviewed in [154]). Point mutations of BRAF gene 
(the human oncoprotein) are found in about 45% of PTC and in 70% of melanomas. Most 
PTC (90%) are due to BRAF
V600E
 (valine to glutamine) mutation. The mutant amino acid is 
situated between residues T599 and/or S602, the phosphorylation either of which is sufficient 
for BRAF activity. The BRAF
V600E
 mutation is thought to mimic T599/S602 phosphorylation, 
rendering BRAF constitutively active.  BRAF
V600E
 probably functions in the early stages of 
tumour development by increasing growth, and promoting cell survival. On the other hand 
BRAF
V600E
 somatic mutations have been reported as a common genetic change in PTCs. 
Inducing BRAF
V600E
 mutation in mouse thyroid cells formed aggressive papillary thyroid 
cancers with short latency. A study [155] has observed that thyrocyte specific 
BRAF
V600E
 expression leads to hypothyroidism in mice which agrees with other reports about 
BRAF suppression of thyroid hormone biosynthesis. During the course of 1 year mice with 
the BRAF
V600E
 developed PTC. However, thyroid size and tumour development decreased 
and thyroid function was restored when MEK1/2 were inhibited. 
1.6.2 Tumour suppressor Genes 
Tumour suppressor genes normally inhibit the neoplastic process and if lost, promote tumour 
growth (e.g. p53 & RB Gene Product). Environmental factors such as ultraviolet light or 
various chemicals can damage DNA leading to mutations in these genes, which are believed 
to be the main reasons for activating the cell death program in the normal cell cycle. 
(reviewed in [156]).  
Cell cycle event is composed of two phases, interphase and mitotic phase (M phase). 
Interphase occurs in the cell nucleus as it is responsible for DNA copying. This phase 
proceeds in three stages, G1, S, and G2, during which the cell grows, copies its DNA, and 
prepares to divide. The second phase mitotic phase (M phase) comprises five stages or 
phases; Prophase, Metaphase, Anaphase, Telophase & Cytokinesis. In this phase Cell 
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division occurs and two daughter cells are formed. Progression through each phase of the cell 
cycle is monitored by sensor mechanisms known as checkpoints [157]. 
After mitosis or in new embryonic cells, the cell starts the cycle with G1 phase in which, 
more growth of the cell occurs and the cycle should pass pre-DNA synthesis checkpoint 
(G1/S) (Figure ‎1.6). In G1 phase the cell forms the required proteins and enzymes for DNA 
synthesis in the next phase and is under the control of the p53 gene (Tp53). Some cells stop 
growing (e.g. brain cells), and exit this process, and are described as being in G0 or rest 
phase. The next phase is for DNA replication (S phase, for synthesis), in which the amount of 
DNA in the cell doubles and all chromosomes replicate. Another cell growth phase (G2 
Phase or gap 2) then follows. G2 is the gap between DNA synthesis and mitosis, and has a 
checkpoint (G2/M) to ensure that everything is ready for entering the next phase, which is the 
M phase. In this phase, cell division occurs through mitosis, which comprises 5 phases as 
described earlier. After cell division each of the daughter cells begin at interphase of the new 
cycle (reviewed in [158]). The progression from one cell cycle phase to another is regulated 
by a family of proteins known as cyclins (A, B, D, E), which are degraded at specific points 
during each cell division (Figure ‎1.7). Cyclin binds with cyclin dependant kinase (CDK), via 
its unique binding site, creating cyclin-CDK complexes. These complexes determine the 
cell’s progress through different phases of the cell cycle, via chemical modification 
(phosphorylation) of other proteins, and are known as positive regulators [159]. Depending 
on the type of cyclin-CDK complex (Table ‎1.1), this phosphorylation can either activate or 
inactivate target proteins to arrange coordinated entry into the next phase of the cell cycle. 
For progression from G1 to S, phosphorylation of RB gene or its related proteins, p107 and 
p130 can play a role in the expression of genes required for entry into S phase [160]. The 
Nobel prize in Physiology or Medicine was won in 2001 for the discovery of the genes that 
control the cell cycle and checkpoints, CDK and cyclin molecules[161].  
During these cycles, detection and repair of any genetic damage occurs, in addition to the 
regulation of uncontrolled cell division. Different cyclin-CDK combinations decide which of 
the downstream proteins are targeted. CDKs are expressed all the time whereas cyclins are 
synthesised at different cell-cycle stages, depending on different molecular signals [162]. 
Cyclin-CDK complexes switch on cell cycles events at the correct time and in the correct 
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order to prevent any mistakes.G1/S checkpoint and G2/M checkpoint control these events. 
These two check points are controlled by different proteins (Figure ‎1.8). These proteins work 
by inhibiting cyclin or CDK or the complex of both. The cell cannot proceed to the next 
phase until checkpoint requirements have been met. They ensure that damaged or incomplete 
DNA has been repaired and thus not passed on to daughter cells (reviewed in [162]).  
Proteins controlling the checkpoint at G1 phase (also called restriction point), are p15INK4B, 
p16INK4A, p18INK4C, p19INK4D, p21CIP, p27Kip1 and p57Kip2, while P57, p27, P21 are regulating S 
phase [163]. These proteins have the ability to bind to several different classes of cyclin and 
CDK molecules. Some have the ability to bind and prevent the activity of cyclin-CDK 
complex, which prevent the addition of phosphate residues to its substrate protein. They are 
often referred to as cell cycle inhibitor proteins, because their main function is to stop or slow 
down cell division. Elevated expression of these proteins causes cells to arrest in the G1 
phase. Furthermore mutations of the genes encoding these proteins may lead to loss of 
control over the cell cycle and thus uncontrolled cell proliferation. These mutations have been 
observed in different tumour types [164], and shown to be associated with increased risk of 
cancers [165].  
As an example, p21 protein, which is regulated by p53, binds directly to cyclin-CDK 
complexes and inhibits their kinase activity, causing cell cycle arrest, to allow DNA repair to 
take place. The p21 (WAF1) gene contains several p53 response elements that mediate direct 
binding of the p53 protein and resulting in transcriptional activation of the gene encoding the 
p21protein[160]. 
Damaged DNA can be repaired by the tumour protein (p53), the transcription factor that 
causes cell cycle arrest. p53 helps to prevent cancer through its role in activating programmed 
cell death or apoptosis, one of the main pathophysiological changes governing a malignant 
cell. Cells have a built-in system of DNA repair, created by p53, which halts the cell cycle to 
allow such repairs to be made. There is increasing evidence that chemotherapy and radiation 
work by activating programmed cell death; tumours that contain normal p53 seem to respond 
well to therapy, while those that lack normal p53 generally have a poorer prognosis.  
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In cases of severe irrecoverable damage, it directs the cell to the programmed cell death 
pathway resulting in apoptosis. Cells with impaired tumour protein p53 function are more 
likely to permit the accumulation of altered genes, and mutations in Tp53 are the commonest 
genetic lesion in human cancer. Tp53 mutations are associated with poorly differentiated and 
anaplastic thyroid tumours in the majority of cases (but not in well-differentiated papillary or 
follicular carcinomas) [166, 167]. In contrast to RAS and RET, Tp53 mutations are not 
targeted to a discrete region of the gene. Loss of expression of TG, TPO and TSHR, as well 
as impairment of expression of PAX-8, have been observed when introducing mutant Tp53 
expression vectors into the well-differentiated thyroid cell line PCCL3 [168].  
 In addition, both copies of TP53 must be mutated for the phenotype to manifest. Mice with 
homozygous disruption of both TP53 alleles develop normally but get cancers at many sites 
after birth[169]. 
Proteins Types  
Cyclin A (A1, A2) B (B1, B2, B3) D (D1, D2, D3) E ( E1,E2) 
CDK 1 2 3 4 5 6 7 8 9 10 CDK-activating kinase 
CDK inhibitors INK4a/ARF (p14arf/p16, p15, p18, p19) cip/kip (p21, p27, p57) 
Tumour suppressor p53 p63 p73 
Table ‎1.1; List of types of cyclins, cyclin dependant kinases (CDK), CDK inhibitors and tumour 
suppressors. 
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Figure ‎1.6; Diagram showing phases of the cell cycle  starting with interphase which is itself comprised of 
three phases (G1 phase) for growth, (S phase) for DNA replication, then (G2 phase) for continued growth. 
This is followed by the mitotic phase (M phase), when cells divide by mitosis leading to cell duplication. 
G0 phase is when cells stop growing and exit the cell cycle.  A full description is in the text. Modified from 
http://ricochetscience.com/category/diseases/cancer/. 
 
 
 
Figure ‎1.7; Graph showing the concentration of members of the cyclin family (D, E, A & B) during 
different phases of the cell cycle. Cyclins bind with cyclin dependant kinases (CDK) to create cyclin-CDK 
complexes, which promote the progression of one phase of the cell, cycle to the next. Modified from: 
http://maptest.rutgers.edu/drupal/?q=node/224 
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Figure ‎1.8: Cartoon showing checks points at various stages of the cell cycle and the main regulatory 
proteins present.  These are p15
INK4B
, p16
INK4A
, p18
INK4C
, p19
INK4D
, p21
CIP
, p27
Kip1 and p57Kip2 in G1 phase, 
while P57, p27, P21 regulate S phase. Adopted from [163]. 
 
 
Retinoblastoma (RB), a tumour suppressor gene is inactivated when the cells complete the 
preparation to replicate their DNA. Inactivating mutations of both copies of RB gene, 
illegitimately release cell cycle block. Development of pituitary tumours was reported in 
heterozygous RB-null mice, which also develop MTC when crossed with P53-null 
heterozygotes [170]. Clonal loss of RB alleles has been reported in early stages of 
development of familial forms of MTC, while the role of RB in thyroid follicular tumours is 
controversial (reviewed in [144]). 
 PTEN and Cowden Syndrome 1.6.2.1
PTEN (Phosphatase and tensin homolog) is a tumour suppressor gene, coding for a protein 
phosphatase. Its absence (due to inactivating mutations) can cause Cowden Syndrome, which 
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is characterised by increased risk of developing thyroid and breast cancer. Approximately 
two-thirds of patients with Cowden’s syndrome have thyroid abnormalities[171], half of 
which are PTC and FTC carcinomas [172]. Studies report thyroid neoplasia (mostly FTC) in 
10% -  50% of affected individuals [173]. On the other hand, PTEN loss itself is unlikely to 
be playing a fundamental role early in PTC. PTEN low mRNA expression reported to occurs 
more in anaplastic thyroid cancers, but less so in FTC and PTC [174]. 
BRAF and ERK signalling have an important role in PTC tumourigenesis, while PTEN, 
which is also in the signal cascade with BRAF, may have indirect role. On the other hand loss 
of PTEN expression or function is assumed to be important both in the development of FTCs 
and more broadly in the progression and dedifferentiation of thyroid cancers[174]. 
PTEN requires loss of expression of both alleles to stop functioning as a tumour suppressor. 
However loss of one allele (LOH) can also occur in thyroid cancer, although LOH could not 
cause a complete loss of PTEN gene expression (reviewed in [174]). 
PTEN is a dual phosphatase that negatively regulates phosphatidylinositol-3 kinase (PI3K) 
signalling and prevents AKT (also known as Protein Kinase B) activation. PI3K consists of 
two subunits, one of which is coded by the PIK3 CA gene (Figure ‎1.9). In thyroid tumours, 
this pathway can be activated by gain-of-function mutations of RAS, PIK3 CA, and AKT and 
loss-of-function mutations of PTEN [175]. Many genetic alterations activating the PI3K/AKT 
pathway have been previously identified in thyroid cancer [176, 177].  
PTEN mutations have been reported in sporadic thyroid neoplasms, somatic mutations are 
found in 6% to 12% of follicular carcinomas and in 5% to 15% of anaplastic carcinomas[3].  
 
 
32 
 
 
Figure ‎1.9; Cartoon showing the signalling pathway of phosphatidylinositol-3 kinase / phosphatase and 
tensin homolog / protein kinase B (PI3K/PTEN/PKB(AKT)), in which transmission occurs from surface 
growth factor receptors, which are receptor tyrosine kinases (RTK). This may activate PI3K directly or 
through a member of the GTPase protein family RAS, while PI3K is negatively regulated by PTEN. 
Downstream activation of PI3K regulates multiple genes that oppose apoptosis and promote cell survival, 
proliferation, and migration/invasion. In thyroid tumours, this pathway can be activated by loss-of-
function mutations of PTEN, or by gain-of-function mutation of RAS or AKT. Adopted from [3]. 
 
 
 FOXE-1 1.6.2.2
Expression of (forkhead box E1) FOXE-1 also known as (TTF-2) has a potential role in 
follicular development (described in ‎1.2.1), as confirmed by genetic analysis. During 
embryonic development, FOXE-1 controls thyroid cell migration from the primitive origin to 
its normal position at both sites of the trachea; FOXE-1 expression is continued in adult life 
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(reviewed in [3]). Several studies as detailed below, reported FOXE-1 association with PTC 
and FTC. 
A study in 2009, investigating thyroid cancer risk in Icelandic population [91], has performed 
genome-wide association study on (192 cases, of histopathologically confirmed thyroid 
cancer and 37,196 control). The study detected a strong association of two variants (rs965513 
on 9q22.33 and rs944289 on 14q13.3), with high risk of PTC and FTC (5.7 fold greater than 
non- carrier). In the general European population, both risk alleles were shown to be 
associated with low concentrations of TSH, while allele on 9q22.33 was associated with low 
concentration of T4 and high concentration of T3. 
In a second genome-wide association study on data from PTC in children and/or adult 
exposed to Chernobyl radioactive iodine [178], four SNPs have been identified on 
chromosome 9q22.33 showing strong associations with the disease. One of these SNPs 
(rs965513) located 57-kb upstream from FOXE-1. Although the study reported FOXE-1 as 
the strongest genetic risk marker of sporadic PTC in European populations, it is unlikely to be 
the only key player in radiation-related thyroid carcinogenesis. It has been found that SNP 
showing the second strongest association with sporadic PTC in Europeans (rs944289 on 
14p13.3), is not associated with radiation-related PTC, that indicates how complex is the 
pathogenesis, suggesting a presence of other genetic factors in radiation-related PTC. 
Another study of GWAS on large Spanish cohort reported that FOXE-1 gene has the 
strongest association with PTC susceptibility. The functional assay of rs1867277 on 9q22, 
(the only functional variant associated with sporadic PTC) showed effect on FOXE-1 
transcription, while transfection studies showed an allele-dependent transcriptional regulation 
of FOXE-1. Furthermore, the risk allele (A) of this SNP increased FOXE-1 transcription by 
creation of a binding site for (Upstream Transcription Factor 1) USF1 and USF2 transcription 
factors [179]. rs1867277 was strongly associated with TC risk in Spanish and Italian 
cohorts[180]. 
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1.7 MPhil summary (study on Malignant Thyroid Dysfunction) 
I have studied a large family (Family #1) with euthyroid MNG of adolescent onset, 
progressing to PTC, affecting 7 individuals (at that time), in 4 generations (family tree is in 
Figure ‎2.1). In addition to MNG and PTC, individual (III-2) developed breast cancer in her 
fourth decade and individual (IV-3) had polycystic kidney disease in infancy. I have 
investigated the genes indicated on the basis of the accompanying breast cancer, (NIS) and 
kidney disorder, (PAX-8). Both genes were eliminated by Sanger sequencing [181]. PTEN 
gene has also been sequenced and eliminated. Furthermore I have investigated the known 
MNG loci on chromosomes 14q, Xp and 3q [84, 89, 182] and the known Familial Non-
Medullary Thyroid Cancer (FNMTC) on chromosomes 19p, 2q and 1q [85-87], on 17 
individuals of the family. That was performed by using microsatellite markers followed by 
linkage analysis, which have excluded all loci. Thus I hypothesize that this family represents 
a new form of inherited MNG with a significant risk of progression to papillary carcinoma. 
 
1.8 Aims & Objectives 
The aim of this study was to increase the understanding of the genetic defects causing 
MNG/PTC in family #1. 
 Primary objective was performing whole genome scan using SNP markers on 
microarray chip, (chapter 2).  
 The secondary objective was to perform the statistical analyses GWLA, to find the 
region(s) on chromosome(s) which has/have shown significant linkage with the 
disease allele, (shared common SNPs by the affected individual only), (chapter 3).  
 The third objective was to perform GWLA on the second family (family #2), to seek 
any shared predisposing genetic factors (chapter 4)  
 The fourth objective was to further investigate regions showing linkage and identify 
candidate gene(s) implicated in the thyroid defects and causing MNG/PTC, by any 
analyses indicated ,such as copy number variation (CNV) (chapter 5). 
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Chapter 2 GeneChip® Mapping Assay 
In this chapter I will describe the first family studied and the Microarray used for the whole 
gene scan. 
 
2.1 Case report and family history of family #1 
2.1.1 Index patient 
The family tree of family #1 is shown in (Figure ‎2.1).  
The index patient (IV-6), a girl (DOB; 17/12/90) was referred (at age 12) to the Paediatric 
Endocrine service based at the University Hospital of Wales, Cardiff, with multinodular goitre.  
She had been born at 39 week gestation by spontaneous vaginal delivery. The prenatal history 
was uneventful and the neurodevelopment had been within normal limits. The girl was of 
average height for her age. 
Ultra-sound scan showed multiple hyper echoic thyroid nodules (three in the left and one in 
the right lobe). Fine needle aspirate (FNA) histology showed multiple papilloid adenomata with 
no features of papillary carcinoma. The kidney scan was normal. 
Thyroid function tests (at age 12) showed normal TSH (1.4 mU/l; normal range 0.35-5.5 
mU/l) and normal free T4 (16.2 pmol/l; normal range 9.8 - 23.1pmol/l), confirming a euthyroid 
condition. TSHR antibodies "TSAB" were negative and TPO antibodies were within the normal 
range (8.6 kU/l; normal range <32.0 kU/l). In addition, the TG antibodies were 22 kU/l (normal < 
46.0 kU/l).  
Since the girl had a large compressive goitre, with concerns for coexisting thyroid cancer, she 
underwent total thyroidectomy. Histopathological examination of the removed gland showed 
papillary hyperplasia, but no morphological evidence of malignancy. The nodules were multiple 
papilloid adenomata and resembled the histology of her mother's thyroid at age 17. Areas with 
ectopic thymus tissue were also observed.  
The "photographs of mitotic chromosomes arranged in homologous pairs" showed a normal 
karyotype; 46 XX. 
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The girl is currently euthyroid, receiving daily replacement with thyroxine, 125mcgs. 
2.1.2 Family History 
There is a strong family history of MNG progressing to papillary thyroid cancer in some 
members of the family, accompanied by cystic kidney disease (in one male) and breast cancer (in 
a female). 
Although physical examination of the thyroid of the girl's older brother (IV-3), (DOB; 
31/01/84) was normal (at age 18), thyroid scan revealed 8 or 9 hyperechoic cysts. Furthermore, 
his FNA showed changes suggestive of papillary thyroid cancer. He also underwent total 
thyroidectomy. In infancy (5 months) he had undergone nephrectomy for polycystic kidney 
disease. 
Her oldest sister (IV-1) (DOB; 30/8/80) has MNG but thyroid scan revealed small hypo-
echoic cysts. She did not undergo thyroidectomy but will be investigated regularly for changes. 
In addition one of her 2 sons has been refereed for thyroid scan in 2011. 
The girl's mother (III-2) (DOB; 9/12/61) underwent partial thyroidectomy at age 17 for 
MNG. The thyroid contained many benign lesions; some cystic, some follicular, and some 
papillary. 
At the age of 27 she underwent a second partial thyroidectomy. The histology revealed 
multiple, mostly benign, papilloid adenomas. Some lesions again had a mixed follicular/papillary 
appearance. Papillary regions displayed very pale nuclei and other changes suggestive of 
papillary cancer and at age 28 she had a total thyroidectomy.  She has developed breast 
carcinoma at age 41 which recurred at 47.  
The girl's one brother (IV-5) (DOB 30/9/89) and one sister (IV-4) (DOB14/8/86), have no 
sign of thyroid or kidney lesions. The sister (IV-4) has undergone thyroidectomy for Graves’ 
disease in 2011.  
The girl’s oldest brother (IV-2) (DOB 9/12/82), was not tested in the microsatellite analysis 
performed during my MPhil. However he attended UHW in 2008 and was confirmed to have a 
normal thyroid and kidneys and his blood sample was taken then. Her youngest sister (IV-7) 
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(DOB 27/6/94) has also been refereed for thyroidectomy at age 18 (in 2012). This has increased 
the affected individuals in the family to 8.  
Her maternal uncle (III-3) and his family, have no sign of thyroid or kidney lesions. By 
contrast, her maternal grandmother (II-2) and great-grandmother (I-2) underwent surgery for 
presumed benign thyroid disease, which has not been possible to confirm. 
Her mother's first cousin (III-5) underwent thyroid surgery for benign disease.  
2.1.3 LREC 
Cardiff University research ethics governance falls to the South East Wales Local Research 
Ethics Committee (LREC) which provided approval for the study. Informed consent was 
obtained from all family members and all samples were stored in accordance with Human 
Tissue Act (HTA) policy and procedure (under the guidance and direction of Cardiff 
University Human Tissue Act Compliance Team). 
 
 
 
Figure ‎2.1: Tree of family #1. Affected members are in black boxes. The Index patient IV-6 was referred 
with multinodular goitre (MNG), her kidney scan was normal. Thyroid FNA of her 18 year old brother 
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IV-3 showed changes suggesting papillary thyroid cancer (PTC). In infancy he had a nephrectomy for 
polycystic kidney disease. Her sister IV-1 had MNG but thyroid scan revealed small hypo-echoic cysts, 
and her son V-1 recently developed MNG at age 5 (not genotyped). Her sister IV-7 was pre-pubertal in 
2002 but has since developed MNG at age 18 whilst IV-4‎developed‎Graves’‎disease. The brothers IV-2 
and IV-8 had no thyroid or kidney lesions. The mother of the index patient III-2 underwent partial 
thyroidectomies at age 17 and 27 for MNG and a total thyroidectomy at 28 when PTC was present.  She 
developed breast carcinoma, at 41. The maternal uncle III-3 and his family have no thyroid or kidney 
lesions but the maternal grandmother II-2, great-grandmother I-2 and mother's first cousin III-5 
underwent surgery for presumed benign thyroid disease. The 2 boys in the last generation V-1 & V-2 
have not been tested.   
 
 
2.2 Introduction 
2.2.1 Whole Genome Scan (WGS) 
The traditional method of discovering disease genes begins with family based linkage gene-
scans, looking for regions of the genome that are transmitted in parallel with the transmission 
of a trait [183]. WGS can be performed by using known markers across all chromosomes. 
Two different types of markers have been broadly used, microsatellite markers (will be 
described in ‎2.2.3) and single nucleotide polymorphisms (SNPs) markers (will be described 
in‎2.2.4 ).  
WGS depends on the genetic differences between individuals and populations, or different 
individuals among the same family. This population differentiation can be ascertained by 
comparing (1) target individual vs. the entire population, (2) target individual vs. the 
subpopulation (to which that individual belongs) and (3) randomly chosen individual vs. the 
entire population[184]. Method (2) has been used in this study as there are specific 
individuals in the family known as affected (targets) and these have been compared with the 
rest of the family members (subpopulation). The best markers are those which show high 
levels of population differentiation (heterogeneous distribution).  
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2.2.2 Genetic Markers 
The first genetic markers, measuring variations at the DNA sequencing level, were restriction 
fragment length polymorphisms (RFLP’s), and were first used as a tool for genetic analysis in 
1974. RFLP is a sequence of DNA that has a restriction site on each end with a "target" 
sequence in between. The target sequence binds to a probe labelled with radioactivity or an 
enzyme. The combination of restriction enzyme and probe sequence produces a series of 
bands in Southern blot, with lengths complementary to the probe. An RFLP occurs when the 
length of a detected fragment varies between individuals. Each fragment length is considered 
an allele, and can be used in genetic analysis (reviewed in [191]). 
Microsatellites and SNPs (will be described in ‎2.2.4 respectively in more detail) are the most 
common markers to be used for genetic linkage mapping (will be described in 3.2.1). This 
mapping will estimate the distance between the disease locus and the genotyped markers and 
thus can be used to help identify the location of a disease gene [185].  
Until recently it was common practice to use a panel of about 400 microsatellites at 10 cM 
average inter-marker distance from the well-defined human genetic map for linkage analysis 
(will be described in 3.2.1) [186-188]. However, recent progress in SNP discovery and 
genotyping provides the opportunity to use this marker type for linkage analysis as well [189, 
190]. 
The 1000 Genomes project [192] examined a wider variety of populations to the original 
HapMap dataset [193]. One thousand genomes discovered additional SNPs and broadened 
the understanding of genetic diversity; it was started in 2008 and finished in 2010. It is an 
international effort in which at least 1000 unnamed members of different population have 
their genome sequenced using about 15 million SNPs. The project described the location, 
allele frequency and local haplotype structure of those SNPs, the majority of which were 
previously un-described [194]. This project aims to understand the genotype/phenotype 
relationship describing 1,092 individuals from 14 ethnic groups, showing that individuals 
from different populations carry different profiles of rare and common variants, and that low-
frequency variants show substantial geographic differentiation, which is further increased by 
the action of purifying selection. It refined the human genome map and provided the data 
online in 2012 [194]. However, this study is about to be at least partially replaced by the 
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UK10K project [195], which aims to study the genetic code of 10,000 people in much finer 
detail than ever before.  
One of the important challenges in the human genome scan is gaps in the centromeres and 
telomeres (Figure ‎2.4) [196].    
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Figure ‎2.2; Comparing genome coverage when mapping using arrays containing 10,000 (A) or 100,000 
(B) single nucleotide polymorphism (SNP) markers or 400 short tandem repeat (STR) markers, also 
known as microsatellites (C). Gaps (black dots) at centromeres and telomeres are shown, e.g. 
chromosomes 1, 9, 13, 14, 15, 21 & 22 have bigger gaps than others. Adopted from; 
http://www.docstoc.com/docs/119871841/AFFYMETRIX-SNP-chips   
 
 
2.2.3 Microsatellite Markers 
Microsatellites are a special class of tandem repeat loci (di-, tri-, or tetra nucleotide) of the 
DNA, which can be repeated up to 100 times. They can be distinguished by different 
numbers of repeats of these short sequences of nucleotides, and are widely distributed 
throughout the genomes of eukaryotes. The number of repeats is variable in populations of 
DNA and within the alleles of an individual (Figure ‎2.3). These alleles have been reported to 
have quite high mutation rates (10
-3
 per generation) [197].  
If microsatellites are flanked with fluorescent PCR primers then amplification will give a pair 
of fluorescent allelic products, varying in size according to their repeat length (Figure ‎2.3). 
According to the type of repeat sequence, microsatellites are classified as perfect 
(e.g. CACACACACACACACA), imperfect (e.g. CACACACATACACACACA), 
interrupted (e.g. CACACACTGCTACACACACA) or composite 
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(e.g. CACACACACACTCTCTCT) [198]. As an example, G to A mutation has changed the 
sequence ATGTGTGT to ATGTATGT, which creates “tetra” microsatellites (ATGT), with 
two repeats. These microsatellite were reported in African monkeys (ATGT), with 4 
repeats and in human (ATGT) with 5 repeats[199]. 
A study [200] reported two hypotheses for the origin of the short DNA repeats; commonly 
substitutions, which is the main source for 2 nucleotides repeats and insertions (less 
common), but is the mean source of more than 70% of 2 to 4 nucleotide repeats. Both 
generate new repeats and thus new microsatellites originating from random mutations 
(Figure ‎2.4).  
Microsatellite can be used in DNA fingerprinting[201]. Its application in linkage analysis can 
involve the examination of a large number of families or one large pedigree to observe the 
difference in the repeat-score of the same markers (allele) among each individual. If similar 
alleles were inherited together with a particular phenotype, then it could be assumed that this 
allele is linked to that particular phenotype. After PCR amplification, the alleles from each 
individual in a family are separated by size. Then linkage analysis can be performed between 
all markers [202].  
Microsatellite markers generally are about 10Mbp (~10cM) apart, which is close enough to 
detect marker - marker linkage, and thus be capable of identifying the genetic regions 
associated or linked with the phenotype. Since microsatellites are spaced at approximately 
10cM intervals, 300 or more microsatellites can be used to screen the entire genome[203]. 
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Figure ‎2.3; Microsatellite marker containing 20 dinucleotide repeats of CA (40bp), shown in bold (A). 
PCR products (labelled using fluorescent primers), vary in size according to their repeat length. (B) The 
example shows 5 different repeat lengths in a population. Adopted from; 
http://www.lifesciences.sourcebioscience.com 
 
 
 
Figure ‎2.4; Cartoon showing point mutation Guanine  Cytosine (GC), which has created a 
microsatellite. Modified from [200]. 
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2.2.4  SNPs  
A single nucleotide polymorphism (SNP) as its name suggests, is a small genetic variation in 
the DNA sequence in which a single nucleotide e.g. Adenine (A) is replaced by one of the 
other three nucleotides (T, G, C) (Figure ‎2.5). This creates 2 alleles at the same region (two 
sequences). These variations are more likely to occur in the non-coding region, and can only 
be called SNPs, when both sequences are present in at least 1% of the population. The term 
"polymorphism" is commonly used to refer to a normal variation, or to changes that do not 
directly cause disease. Furthermore, variation with lower than 1% frequency can be called 
mutation, even though, the 1% cut-off is not accurate enough [204].  Thus SNPs (or variants 
in general) can be classified depending on their allele frequency in genes (or population), 
which can be defined by Minor Allele Frequencies (MAFs); the frequency at which the less 
abundant (or minor) allele of a SNP is present in a population. There are three types of 
variants; rare with a frequency of less than 1%, uncommon with a frequency between 1-5%) 
and common SNPs with a frequency greater than 5% [205]. 
The main point behind using SNPs in linkage analysis is the frequency variation between 
minor and major alleles of the same SNP, across the population [206]. Population 
susceptibility to disease can be assessed by testing for any correlation between disease status 
and the SNP genetic variations. The simplest such study design used to test for association is 
the case–control study, in which cases affected with the disease of interest are compared with 
controls who are free of disease. The power of these studies is improved when the cases are 
related to the controls, as in family #1 [207], which will be described in more detail in 
Chapter 3. 
Two areas of study commonly focus on; detection of rare mutations in highly selected cases, 
and common SNPs and haplotype of the general population. In WGS with rare variants, weak 
association between common tag SNPs (show linkage disequilibrium, will be described in 
3.2.1) and rare causal variants has been reported [208]. In order for variants to be highly 
associated they must have similar allele frequencies and the two loci have equal minor allele 
frequencies. Therefore for associations with rare variants it is necessary to perform direct 
mapping and rare variants within a sample must first be identified [209]. Sequencing of 
candidate genes or entire genomes is the optimal way to identify rare variants. A number of 
studies have successfully used the approach of sequencing candidate genes [210, 211].  
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The main challenge in WGS is to develop statistical procedures that minimize false positives 
without greatly sacrificing true positives. That can be approached by selecting the SNPs with 
the right MAF, as the power to detect genetic effects mainly depends on the MAF of the risk 
allele tested. Loci with a low MAF (<10%) have significantly lower power to detect weak 
genotypic risk ratios than loci with a high MAF (>40%) [212]. Furthermore, rare genotypes 
are more likely to result in false findings and thus, many WGS remove SNPs with 
MAF<10% [213]. Many studies use common filter for SNPs which is based on MAF, with 
typical thresholds of 3, 5 or 10%. The latter approach (10%) is not sensitive enough to detect 
SNPs with a small genotype class because rare homozygous genotypes can be observed with 
minor alleles of moderate frequency [214]. 
 
 
 
 
 
Figure ‎2.5; Example of a single nucleotide polymorphism (SNP) variant, in which a single nucleotide 
cytosine (C) is replaced by thymine (T) and thus the reverse sequence changes from guanine (G) to 
adenine (A). Adopted from; http://blog.biosyn.com/2012/09/genes-that-define-shape-of-our-face.html 
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2.2.5 The International HapMap Project 
This project is the result of collaboration between researchers and companies in several 
countries, aiming to develop a haplotype map (HapMap) of the human genome. The Project 
describes the common patterns of human genetic variation. Samples from normal individuals 
of four populations were used for genotyping and Copy Number Variation Analysis as 
follow; 30 adult (and both their parents) from Nigeria (YRI), 30 adult (and both their parents) 
from U.S., residents of northern and western European ancestry, Caucasian (CEU), 44 
unrelated individuals from Japan (JPT) and 45 unrelated individuals from China (CHB). The 
information produced by the project is made freely available to researchers around the world.  
The goal of this project was to “create a public, genome-wide database of common human 
sequence variation, providing information needed as a guide to genetic studies of clinical 
phenotypes” [215]. The project has become a very good source of information about human 
genome sequence and used as databases of common SNPs genotypes of several populations 
(will be described in 3.1.6.2). In particular it also provides insights into human Linkage 
Disequilibrium (will be described in 3.2.1 in more detail) and has led to the development of 
inexpensive, accurate technologies for high-throughput SNP genotyping with imputation. The 
output of the project is made available online with web-based tools for storing and sharing 
data, and provides frameworks to address associated ethical and cultural issues[216].  
In Phase I of the HapMap project, more than one million SNPs were genotyped, one SNP 
every 5,000 bases, using five different genotyping technologies. By 2006 the database 
included more than ten million SNPs; over 40% of them common (MAF >5%). During Phase 
II, more than 2.5 million additional SNPs have been genotyped. In phase I and phase II, the 
project has collected and studied 1,184 samples from 11 populations [217]. 
Although microsatellites were more frequently used in the past, SNPs are more popular 
nowadays because of their higher number “roughly 10 million” across the genome and thus 
the distance between is narrower than microsatellites (Figure ‎2.5). Avoiding bigger gaps 
between markers is important to avoid any inaccuracy due to the possibility of multiple 
recombination events (described in 3.1.4) therefore microsatellites are no longer the first 
choice of genetic marker.  The greater number of alleles of microsatellite markers, along with 
a less automated method of genotyping leads to a higher error rate relative to SNPs [203].   
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2.2.6  DNA Microarrays 
Microarray analyses are of two types, both uses reference nucleic acid on a solid surface 
(chip), which is known as the probe and hybridises to the target nucleic acid. One type of 
microarray is used for gene expression profiling, these usually involve the binding of cDNA 
(generated from RNA extracted from cells or tissues) to the probe sequence but as they have 
not been used in my work will not be described further. The second type of microarray is 
used for genotyping and will be summarised in the following sections. 
DNA microarrays take advantage of the ability of complementary base pairs of nucleic acid 
strands to bind each other. For example, GCGCATAATT will bind to its complement 
(AATTATGCGC). On this basis the whole genome can be scanned (WGS). A DNA 
microarray is a collection of microscopic DNA spots attached to a solid surface (a silicon 
chip, e.g. Affy chip in case of Affymetrix Chip), and can be used in genotyping multiple 
regions of a genome. Each DNA spot (feature) contains specific sequences known as probes. 
These can be short sections of a gene that are used to hybridize target (the DNA sample), 
which is prepared in multiple copies (PCR amplified). Probe-target hybridization occurs and 
is detected and quantified using fluorescence-labelled targets which generate signals and thus 
the identity of the feature can be known [219]. 
In this study, DNA microarrays will be used to perform WGS, using SNP markers across the 
genome as features (probes) attached to affy chip. 
2.2.7 Affymetrix 10K chip DNA Microarray 
GeneChip® Human Mapping 10K 2.0 Array (HMA10K) is one of the arrays, (provided by 
Affymetrix), which utilizes SNPs to increase understanding of the genetics of complex 
human diseases.  
The Gene Chip ® Mapping Assay performs genotyping of more than 10,000 human SNPs, 
distributed throughout the human genome at a median inter-marker distance of 210 kb [220]. 
It uses a single array and single PCR primer and allele-specific hybridization (will be 
described in‎2.2.8). The selection of SNPs is based on those which demonstrate 99.9% 
reproducibility, and average call rate of >95%. In addition to heterozygosity average of 0.37 
and genome scan resolution of 0.31 cM (centi Morgan), (will be described in 3.1.5). The SNP 
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array is a viable alternative to panels of microsatellites [221]. It is a mapping tool for 
identifying regions of the genome that are linked to, or associated with, disease or a particular 
phenotype. Allele frequency in different populations can also be determined by this tool. 
Some studies have used it for mapping regions with chromosomal copy number variation 
(CNV), but others consider the 10K chip inadequate for CNV analyses, especially since the 
availability of arrays with substantially more SNPs, 100K as in [222], 500K and 1.5M (as 
will be described in chapter 3). Linkage studies can be conducted more quickly than 
microsatellite markers with higher accuracy and better results with 10,000 SNPs [223-227]. 
One study [225] indicated (on the basis  of a direct comparison between the linkage peaks 
obtained using microsatellite markers and the HMA10K assay), that generally there is a high 
degree of correspondence between the two approaches but traditional microsatellite 
approaches are largely insufficient to detect (even) highly significant linkage peaks. The 
HMA10K assay provides a high level of accuracy due to the greater information content and 
coverage and the ability to rapidly perform and analyse the data obtained from genome wide 
scans with MERLIN and other software (will describe in 3.3.2 & 3.3.3).  
2.2.8 Principles of Allele-Specific Hybridization on GeneChip® Probe 
Arrays 
Allele-specific hybridization (ASH) is the method of studying allele variations in genotyping 
[228]. The Gene Chip® Mapping Assay contains probes corresponding to both of the two 
possible alleles at each SNP and labelled as A & B. the probes are labelled with fluorescent 
dyes and contain 25 bp with the single SNP at the central position (Figure ‎2.7 A). After 
adding the target DNA, hybridization to the array probe occurs. There are two types of 
probes: reference probes that match a target sequence exactly, called the perfect match (PM), 
and partner probes which differ from the reference probes only by a single base in the centre 
of the sequence. These are called the mismatch (MM) probes. Analysing the resulting signals 
from the allele-specific probes determines whether a SNP is AA, AB, or BB, depending on 
PM or MM with A allele, or B allele (Figure ‎2.6).To determine specificity in binding, for 
each SNP there are up to 40 different 25 bp oligonucleotides, each with a slight variation in 
perfect matches, mismatches, and flanking sequence around the SNP (Figure ‎2.7).  
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Figure ‎2.6; Cartoon showing the four probe sequences (probe quartet) for a target SNP (genomic 
sequence).  Mismatch (MM) and perfect match (PM) for allele A and allele B is also shown. Adapted 
from: http://www.docstoc.com/docs/119871841/AFFYMETRIX-SNP-chips 
 
 
 
Figure ‎2.7; Cartoon showing (A) single probe with 25 nucleotides, (B) set of probes, (C) Probe-target 
Hybridization, (D) Fluorescence signals, (E) Hybridization image and (F) actual size of the chip. Adopted 
from; http://esd.lbl.gov/research/facilities/andersenlab/phylochip.html 
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2.2.9 GTYPE software and allele calls 
GeneChip® Genotyping Analysis Software (GTYPE) from Affymetrix analyses the data 
from GeneChip Mapping 10K array, to determine the alleles of the SNPs represented in the 
DNA sample. 
The fluorescence signals (from microarray probes, representing each SNP), which are known 
as Relative Allele Signal (RAS), can be detected and calculated, by a clustering process, on 
forward and reverse strands across many DNA samples. RAS is the ratio of the signal of the 
A allele to the sum of the A and B alleles A/(A+B). Depending on MM and PM of DNA 
samples and the probes (described in ‎2.2.8), two independent RAS values are derived for 
each SNP, from the forward (sense) strand (RAS1) and the reverse (anti-sense) strand 
(RAS2). Affymetrix GTYPE software plots RAS1 scores against RAS2 scores and 
tracheotomise (divide into 3 elements) these RAS scores, which forms the genotypes for 
DNA of an individual. RAS values near 0.0 are identified as a BB homozygote, 0.5 as an AB 
heterozygote, and 1.0 as an AA homozygote.  
The call zone (known as the Distance to Radius ratio), for each allele type of the SNP can be 
calculated. GTYPE calculates the distance between “tested allele call” clusters and the RAS 
value (default 0.8). Adjustable call zones increase the stringency of the genotype assignment 
by filtering the data to mitigate nonspecific hybridization. RAS points that fall outside call 
zones are assigned as “No Calls (Figure ‎2.8) [221, 229]. For SNPs with sufficient minor 
allele frequencies, all three possible genotypes should be observed (AA, AB & BB). Only 
SNPs with all three observed clusters could be considered informative. Quantitative measure 
of clustering quality can be derived by the silhouette score (s), whose value ranges from 0 to 
1. SNPs with s values closer to 1 show clusters that are tight and well separated, while poorly 
clustering SNPs show lower s values (Figure ‎2.8).  
SNPs on the Chromosome X are first called using general model. Then the calls are evaluated 
to determine the gender of the sample (if has been specified by the operator). The SNPs are 
then called again using the appropriate gender-specific model. The call for Chromosome X 
SNPs displayed in the Scatter Plot are made using the gender-specific  model; however, the 
gender model clusters and call zones are displayed in the Scatter Plot [221, 230].  By 
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following the genotyping calls of these SNPs markers, it would be known if they are identical 
by descent or only identical by state (will be described in 3.1.7).  
 
 
Figure ‎2.8; Screen shot showing clusters of genotypes obtained by comparing the ratio of the relative 
allele signal (RAS) of the A allele to the sum of the RAS for A and B alleles A/(A+B).  
 
 
2.2.10 Protocol Summary  
In summary genomic DNA from each family member was digested with restriction enzyme 
(Xba1), (will be described in ‎2.2.11) and ligated to adaptors recognizing the cohesive four 
base overhangs (Figure ‎2.10), (all fragments resulting from restriction enzyme digest are 
substrates for adaptor ligation). A generic primer, which recognizes the adaptor sequence, 
was used to amplify the ligated DNA fragments and PCR conditions were optimized to 
amplify fragments in the 250-1000 bp size range. The amplified DNA was further fragmented 
to smaller size (100-25 bp), then labelled and hybridized to GeneChip array. All arrays were 
washed and stained on a GeneChip fluidics station, then scanned on a GeneChip Scanner 
3000 (Figure ‎2.9). 
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Figure ‎2.9; Protocol summary which starts with genomic DNA digestion to 250-1000 bp, then adapter 
ligation and single primer PCR amplification. This is followed by further fragmentation of the PCR 
amplicons to 100-25bp, then labelling and hybridization to GeneChip arrays. The arrays were washed 
and stained using GeneChip fluidics, then scanned on a GeneChip Scanner 3000. Modified from: 
GeneChip Mapping 10k 2.0 Assay Manual. 
 
 
The genome-wide distribution of SNPs in the GeneChip Mapping 10K 2.0 Array is well 
distributed across the genome, but coverage is not absolutely uniform, as some regions 
contain less markers than others.  
2.2.11 Xba1 enzyme 
DNA can be reduced to smaller fragments by restriction endocnucleases such as Xba1, which 
can recognise specific sequence in the genome (T: CTAG A) and cut the DNA at that 
sequence. Since this sequence is repeated every 250-1000 bp, restriction by Xba1 enzyme 
breaks the DNA in small fragments ranging from 250 bp to 1000 bp, all with similar start of 
five base (CTAGA) in forward and (TGATC) in reverse sequence (Figure ‎2.10). These 
consistent four bases can be recognised by specific adaptors which ligate and overhang all 
53 
 
fragments. The sequence of these adaptors can be recognised by the generic primer which is 
used to amplify the ligated DNA fragments by PCR. 
 
 
 
Figure ‎2.10: Cartoon showing the recognition site of Xba1 enzyme and the sequence of the 
complementary tails after restriction. A full description is in the text. Modified from; Klug & Cummings 
1997.  
 
 
2.2.12 Fragmentation 
DNA can also be fragmented by DNAse enzymes which cut anywhere in the sequence. For 
DNA fragmentation, Affymetrix 10K GeneChip® procedure has used DNase I enzyme, 
which is thought to be responsible for fragmentation during apoptosis[231].  
2.2.13 Hybridization 
The main principle of this protocol is ASH (described in ‎2.2.8) in which Probe-target 
hybridization occurs and the fluorescence on the probes generates signals that identify the 
genotypes of the SNPs on the target sample (described in ‎2.2.6-‎2.2.9). 
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2.2.14 Image analysis 
The strength of signals generated from probe-target hybridization (intensity of the features), 
(described in ‎2.2.6), can be measured by the GeneChip Scanner 3000, which creates (yields) 
a specific file (CEL file) that stores the result of the intensity calculated from the image of 
“probe-target hybridization” in the Affymetrix GeneChip® (Figure ‎2.7 E). Image analysis 
identifies markers with poor-quality and low-intensity features, which can be removed.  
2.2.15 Software for data receiving 
GeneChip® Operating Software (GCOS) can be used to acquire the data after scanning in the 
GeneChip® Scanner 3000. The software creates images and cell intensity files, by extracting 
the measured intensity of raw signal then prepares the file to be suitable for processing by 
GTYPE (described in ‎2.2.9). 
 
2.3 Aim 
To genotype 10,000 SNPs covering the entire genome in the single large family, for 
identifying the region(s) of the genome that harbour disease susceptibility loci. 
 
2.4 Materials & Methods 
2.4.1 DNA Extraction from peripheral lymphocytes 
Approximately 5 ml of blood was collected into EDTA vacutainers (Beckton Dickenson). 
DNA was extracted from whole blood with the QIAamp Blood Kit (Qiagen), using the “large 
sample volume blood and body fluid protocol”.  
EDTA blood (1 ml) was incubated for 10 min at 70 C with 1 ml of lysis buffer (AL) and 125 
l of proteinase K, after which 1050 l of 100% ethanol was added. The sample was then 
passed through a Qiagen spin column by centrifugation (at 8000 rpm for 1 min) in a Mikro 20 
Patterson Scientific centrifuge. The column was washed twice with washing buffer (AW), 
prior to the elution of DNA by centrifugation (at 8000rpm for 1 min), with 200 l of elution 
buffer (AE) preheated to 70 C. 
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2.4.2 DNA quantification by spectrophotometer  
DNA was quantified by measurement of absorbance at 260 nm wavelength () using a Gene 
Quant pro spectrophotometer (Amersham Pharmacia Biotech). DNA concentration was 
calculated based on a solution of 50 g/ml having an optical density of 1 at 260 nm, and with a 
light path of 1cm. An absorbance ratio 260/280 of greater than 1.8 is indicative of a pure DNA 
sample. 
2.4.3 Genomic DNA Preparation  
Working stocks of all DNA samples were prepared to be 50ng/μl, as this concentration is 
required by the protocol for DNA digestion step, for high throughput assay, TE buffer (0.1 
mM EDTA, 10 mM Tris HCl, pH 8.0) was used for the dilution process when required. Five 
μl (50ng/μl) of each diluted genomic DNA has been aliquoted into each well of the 96-well 
plate. 
2.4.4 DNA control 
The Affymetrix kit has provided DNA reference control (reference genomic DNA 103), to be 
processed with the samples as part of quality control check. Thus that DNA was also 
processed with DNA of family member. 
2.4.5 DNA digestion with Xba1 restriction enzymes 
A master mix of 10.5 μl H2O, 2 μl of NE buffer 2 (10X), 2 μl of bovine serum albumin 
(BSA) (10X (1mg/ml)) and 0.5μl of Xba1 (20 u/μl) was prepared on ice. Fifteen μl of the 
master mix was then added to the 5 μl (50ng/μl) of the diluted genomic DNA in the 96-well 
plate. The plate has been covered with a plate cover and sealed tightly, mixed by vortex, and 
centrifuged briefly at 2,000 rpm for 1 minute. The plate was then placed in a thermal cycler 
for 120 minutes at 37 C and hold at 4 C. 
2.4.6 DNA Ligation  
A master mix of 1.25 µ of (5μM) Adaptor Xba and 2.5µ T4 DNA Ligase buffer (10X) was 
prepared. In each digested DNA sample, 3.75 μl of the Ligation Master Mix has been added 
followed by 1.25 μl of T4 DNA Ligase making the final reaction volume 25µl. The plate was 
then covered with a plate cover and sealed tightly, vortexed at medium speed for 2 seconds, 
and spun briefly at 2,000 rpm, for 1 minute. The plate was then placed in a thermal cycler (at 
16 C for 120 minutes then 70 C for 20 minutes). Each DNA ligation reaction has been diluted 
56 
 
by adding 75 μl of molecular biology-grade H2O to make the final volume of ligated DNA to 
be 100µl. 
2.4.7 PCR  
  PCR Master Mix  2.4.7.1
A master mix was prepared in the pre-PCR clean room; it comprised 10 μl of PCR buffer 
(10X), 10µl of dNTP (2.5 mM each), 10µl of MgCl2 (25 mM), 7.5µl of PCR Primer Xba (10 
μM), 2 μl AmpliTaq Gold® (5 U/μl) and 50.5µl of H2O making the total of 90µl.  
  PCR staging  2.4.7.2
PCR master mix (90 μl) was added to each well of a new PCR plate, followed by diluted, 
ligated DNA (10 μl) with 4 wells being used per sample. The plate was then sealed with plate 
cover, vortexed at medium speed for 2 seconds and spun at 2,000 rpm for 1 minute. The plate 
was then put in a thermal cycler using specific programme for MJ DNA Engine machines (as 
shown in Table ‎2.1).  
 
Temperature  Time Cycles 
95C 3 minutes 1X 
95C 
59C 
72C 
20 seconds 
15 seconds 
15 seconds 
35X 
 
72C 7 minutes 1X 
4C Hold  
Table  2.1; The PCR programme used described in terms of temperature (column 1), time of incubation (column 
2) and the number of cycles performed (column 3). The programme is specific for MJ DNA Engine PCR 
machines as stated in the protocol manual. 
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  PCR Quality Control (agarose gel) 2.4.7.3
Each PCR product was run on a 2% agarose gel, as a part of quality control. A 2% agarose 
(Gibco® BRL) gel containing 400 ng/ml ethidium bromide was prepared in TAE buffer, (2 
M Tris base, 50 mM EDTA (pH 8) and 1 M glacial acetic acid); the same concentration of 
ethidium bromide was maintained in the TAE running buffer. Three µl of each PCR product 
mixed with 3µl 2X gel loading buffer (Promega) were loaded per well. Each PCR product 
was compared against a 1kb bp DNA ladder (Promega) to confirm the size of the amplicon. 
The gel then was run at 120V for 1 hour.  
2.4.8 PCR purification and elution with QIAGEN Min-Elute 96 UF PCR 
purification plate 
 All 4 PCR products of each sample (400µl) were consolidated into a single well of a Min-
Elute 96 UF PCR Purification Plate. After preparing a vacuum manifold and adjustment to 
create a vacuum source able to maintain ~800 mbar, the Min-Elute 96 UF PCR Purification 
Plate was placed on top of the manifold. Unused wells were covered with PCR plate cover 
and the used well left uncovered. Vacuum applied and the ~800 mbar vacuum maintained 
until the wells were completely dry. That has taken around 2 hours to dry 400 μl PCR 
samples. 
The PCR products were washed by adding 50 μl molecular biology water and drying the 
wells completely (approximately 50 minutes). The washing steps were performed 3 times. 
Then the Min-Elute plate was removed from the vacuum manifold and gently tapped on a 
stack of clean absorbent paper to remove any liquid that might remain on the bottom of the 
plate. To elute the PCR product, 40 μl elution buffer (EB) (10mM Tris-HCl, pH 8.5) was 
added to each well, the plate covered with PCR plate cover film and been moderately shaken 
on a plate shaker at 960 rpm for 4 minutes. The purified PCR product was recovered by 
pipetting the eluate out of each well. 
2.4.9 Purified‎PCR‎product’s‎concentration‎adjustment 
Purified PCR product needed to be at a concentration of 20µg per 45µl solution to be 
prepared for the next step (Fragmentation). EB (10mM Tris-HCl, pH 8.5) was used for any 
required dilutions. 
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 Quantification of purified PCR product 2.4.9.1
Purified PCR products were measured (quantified) by Nano Drop (from Thermo Fisher 
Scientific Inc), and 20µg per 45µl of each Purified PCR product was prepared for 
Fragmentation.  
2.4.10 Fragmentation 
Fragmentation Buffer (5 μl 10X) was added, (using fragmentation plate), to each 45µl of 
purified PCR products on ice and vortexed at medium speed for 2 seconds. Fragmentation 
reagent was diluted (0.048 U/µl) on ice, by adding 5µl buffer to 1µl fragmentation reagent 
and the volume completed to 50µl by molecular biology water. Then 5µl of the mixture was 
added to the previous 50µl. The fragmentation plate was covered with a plate cover and 
sealed tightly. The fragmentation plate was vortexed at medium speed for 2 seconds, and 
briefly spun at 2,000 rpm for 1 minute. The plate was then placed in pre-heated thermal 
cycler (37 C) immediately for 30 minutes then at 95 C for 15 minutes and then cooled at 4 C.  
 Fragmentation Quality Control (agarose gel) 2.4.10.1
The fragmented PCR products (4µl) were mixed with 4µl 2X gel loading dye and run on a 
4% agarose gel at 120V for 30 minutes (as quality control check), the 100 bp ladder was used 
as a size standard. After confirming the success of fragmentation reaction by analysing the 
gel picture, the samples then were handled to a third party, the Central Biotechnology 
Services (CBS) department, for labelling, hybridization, washing, staining and scanning. 
2.4.11 Labelling 
Master mix for labelling reaction was prepared (in ice) by mixing 14µl of  5X TdT buffer 
with 2 μl GeneChip DNA labelling reagent (5 mM) and 3.4 μl of TdT (30 U/μl). A total 
volume of 19.4 µl of this mixture was added to 50.6 fragmented PCR products making the 
total reaction of 70µl. (The remaining fragmented DNA was used in the agarose gel). The 
plate was then sealed tightly with a plate cover, vortexed at medium speed for 2 seconds, and 
briefly spun at 2,000 rpm for 1 minute. The plate was then placed in pre-heated thermal 
cycler (37 C) for 2 hours then at 95 C for 15 minutes and cooled down at 4 C. The plate was 
briefly spun at 2,000 rpm for 1 minute after the labelling reaction. 
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2.4.12 Target Hybridization 
Hybridization mix was prepared according to manufacturer's instructions. Each labelled 
sample was transferred from the plate to a 1.5 ml Eppendorf tube and 190μl of the 
hybridization Cocktail Master aliquoted. The 260 μl of hybridization mix and the labelled 
DNA were heated at 95 C in a heat block for 10 minutes to denature, and then cooled down 
on crushed ice for 10 seconds. That was followed by a brief spin at 2,000 rpm for 1 minute in 
a microfuge to collect any condensate. The tubes were then placed at 48 C for 2 minutes and 
80 μl of the denatured hybridization mix injected into the array. It was then hybridized at 48 
C for 16 to 18 hours at 60 rpm. 
2.4.13 Washing, Staining, and Scanning 
Fluidics Station 450/250 automatic washing and staining probe arrays were used according to 
manufacturer's instructions for GeneChip® mapping. That was followed by scanning of the 
probe arrays using the GeneChip® Scanner 3000, according to manufacturer's instructions. 
2.4.14 Data acquiring  
GCOS software (described in ‎2.2.15) was used to acquire the data from the GeneChip® 
Scanner 3000. The software creates images and cell intensity files, by extracting the 
measured intensity of raw signal. Thus special files were created for analysis; “Data Transfer 
Tool (.DTT) Archive files”. These files contain the genotyping data from all members of 
family #1. Such files are not compatible with Microarray Suite (MAS) and thus GCOS 
restores these files and made them suitable to be processed by GTYPE software (described 
in ‎2.2.9). GTYPE has then been used to expose the raw image data of cell fluorescence 
intensity (.CEL files), which contain information about the expression levels of the individual 
probes. GTYPE then generates CHP files (from CEL files), for each sample to display a 
Relative Allele Signal (described in ‎2.2.9) and thus the genotype of each DNA sample across 
the ~ 10,200 markers (Figure ‎2.15). All data have been saved in Excel format which will be 
analysed in chapter 3. 
2.4.15 Data Check per Individual, per SNPs and per Batches 
The data imported into an Excel worksheet has undergone a range of quality control steps. 
The first step was to check call rate for each SNP across the 19 DNA samples (18 family 
members and 1 duplicate, as described in the next section), and remove any SNP showing ‘no 
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call’ for more than 4 individuals. The second step was to check call rate for each individual 
across the 10208 SNPs and remove any individuals showing ‘no call’ for more than 10% of 
SNPs. The third step was to check for any common error in data from the same batch.  
 
2.5 GeneChip Mapping Assay RESULT 
2.5.1 DNA Extraction from peripheral lymphocytes 
Genomic DNA samples from all family members (except IV-2), were available from my 
MPhil microsatellite studies. However, as these were several years old, even though they 
were stored at -20C they might not have been suitable for micro-array. I was able to obtain 
new samples from 6 family members which were extracted and quantified. The new DNA 
was extracted and quantified by measurement of absorbance at 260 nm wavelength () using 
a Gene Quant pro spectrophotometer (Amersham Pharmacia Biotech). DNA concentrations 
were between 50 and 80 ng/μl and the ration was good enough to confirm purity. 
2.5.2 Comparing microarray results from New and Old Genomic DNA  
Samples of the same individual (IV-7) were used, new (N) and old (O), to perform all steps, 
then compare the output as quality control check of old DNA samples.  
2.5.3 Genomic DNA Preparation  
Working stocks of DNA samples need to be adjusted to 50ng/μl, if required. Concentrations 
of both new and old DNA were close to the recommended value and thus no adjustment was 
required. Reference DNA from Affymetrix was ready to use thus has been processed directly. 
2.5.4 DNA digestion with Xba1 restriction enzymes 
Three digestion runs have been performed for each sample to have enough quantity for 
subsequent steps  
2.5.5 PCR Quality Control (agarose gel) 
Two percent ethidium bromide stained agarose gel electrophoresis was prepared, which 
showed a smear of PCR products (Figure ‎2.11). This is expected since the PCR generates 
many products of differing lengths and is similar to the example provided in the 
manufacturer’s protocol.  
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Figure ‎2.11; PCR products from individual IV-7 analysed by agarose gel electrophoresis and ethidium 
bromide staining. The first lane (Lad) contains the 100bp ladder, the second lane (-ve) contains the 
negative control (master mix without DNA template), lanes 3-7 (N) show the PCR products obtained 
using new DNA samples and lanes 8-12 (O) with old DNA sample. Lanes 13 & 14 (C) show the amplicons 
obtained using “reference‎genomic‎DNA control 103” provided with the kit. Gel picture shows a smear of 
PCR product similar to the example provided in the manufacturer’s‎protocol 
 
 
2.5.6 Quantification of purified PCR product 
PCR products were purified and the DNA concentration was measured using Nano Drop, 
aiming to adjust the concentration for the following step (fragmentation), in which requires 
20µg/45µl. Sample N shows concentration of 385.7 µg/µl = 17µg/45µl and sample O shows 
266.8 µg/µl = 12µg/45µl, while reference control shows 233.9 µg/µl = 10.5/45µl. As the 
concentrations were less than the recommended value, more PCR products have been 
purified using an additional 400µl of PCR product for each sample. In this purification, 
previously purified PCR product was used at elution instead of EB, which increased DNA 
concentration when measured. Purified PCR product of N showed 490.5 µg/µl = 22µg/45µl, 
 
 Lad  -ve  N   N    N   N    N   O   O   O    O   O   C   C 
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which has reached to the recommended concentration, but O showed 400.3 µg/µl= 
18µg/45µl, which is still below the recommended concentration. Therefore more PCR 
product of O was purified as above to yield a concentration of 466.3 µg/µl = 20.9 µg/45µl, 
same done with reference control. 
2.5.7 Fragmentation quality control (agarose gel) 
Agarose gel (after fragmentation) was performed as quality control step. Four µl of each 
fragmented DNA was mixed with 4µl 2X gel loading dye and run on 4% agarose gel at 120V 
for 30 minutes. One hundred bp DNA ladder was used as size standard. (Figure ‎2.12) shows 
the gel picture with a smear of PCR products, similar to the example in the manufacturer’s 
protocol.  
 
 
 
Figure ‎2.12; Fragmentation products of DNA for individual IV-7 analysed by agarose gel electrophoresis 
and ethidium bromide staining. The first lane (Lad) contains the 100bp ladder, the second lane (N) new 
sample,‎ the‎ third‎ lane‎ (O)‎ old‎ sample‎ and‎ fourth‎ lane‎ (C)‎ for‎ “reference‎ genomic‎ DNA‎ control‎ 103”‎
provided with the kit. A smear of PCR products between 100-25 bp is shown, similar to the example in 
the‎manufacturer’s‎protocol.‎ 
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2.5.8 Processing DNA of the remaining family #1 members (in 5 batches) 
All DNA samples underwent quantification, digestion with Xba1 enzyme, PCR 
amplification, purification of PCR products, fragmentation, labelling, staining, and scanning, (as 
described in ‎2.5.1‎2.5.7). The DNA concentration of all samples was measured and found to vary 
from 32 to 160ng/μl. Different dilutions were performed to keep the concentration closer to 
50ng/μl, for high DNA concentration sample. At lower DNA concentrations (less than 50ng/μl) 
calculated increases in DNA volume were used in the PCR master mix (instead of water) to 
increase the concentration to 50ng/μl. Figure ‎2.13 is showing PCR product for all family 
members, after DNA digestion and amplification.   
 
 
 
Figure ‎2.13; PCR products from all individuals of family #1, analysed by agarose gel electrophoresis and 
ethidium bromide staining. The first and last lanes (Lad) contain the 100bp ladder, lanes 2-18 (I 1, II 1, II 
2, II 3…..etc.) show the PCR products of DNA samples from all members labelled as in the family tree. 
Gel‎ picture‎ shows‎ a‎ smear‎ of‎ PCR‎ product‎ similar‎ to‎ the‎ example‎ provided‎ in‎ the‎ manufacturer’s‎
protocol.  
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Figure ‎2.14 Fragmentation products of DNA for some members from family #1 analysed by agarose gel 
electrophoresis and ethidium bromide staining. The first and last lanes (Lad) contain the 100bp ladder, 
lanes 2-14 (I 1, II 1…..etc.) show fragmented PCR products of DNA samples from some members of the 
family, labelled as in the family tree. A smear of PCR products between 100-25 bp is shown, similar to the 
example‎in‎the‎manufacturer’s‎protocol.‎ 
 
 
2.5.9 The reference genomic DNA control 103 
Following fragmentation, labelling, target hybridization, washing, staining and scanning, the 
DNA control showed a call rate of > 92%. That is within the manufacturer's recommended 
specification, which indicates that the assay was performed correctly.   
2.5.10 Scanned Data reception 
Following fragmentation, labelling, target hybridization, washing, staining and scanning, the 
data of the 10K GeneChip® Arrays for the 19 DNA samples (of family #1) were imported 
into GeneChip Operating Software (GCOS), which made it possible to be processed by 
GeneChip® Genotyping Analysis Software (GTYPE). Using GTYPE software, the 
genotypes of each DNA sample have been called (as described in in ‎2.2.9), across 10,208 
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markers (Figure ‎2.15). The table containing the genotype data was exported into a Microsoft 
Excel worksheet (Figure ‎2.16). The standard allele format for data output from GTYPE is A 
B representing the genetic calls for each SNP, (described in ‎2.2.9). 
2.5.11 Check Data Drop Rates per Individual, SNPs and Batches 
The three steps of data quality control (individual, SNPs and batches) were performed and all 
SNPs giving “no calls” for more than 4 individuals (5 or more) were removed. Since 19 DNA 
samples were processed, this rate (4 out of 19) is equivalent to 21%. In the second step, each 
individual was checked for “no call” rate across the 10208 SNPs and the rate was varying 
from 900 SNPs and 286 SNPs. That is equivalent to 8.8% and 2.8% respectively. This means 
none of the samples has a “no call” rate below the threshold of 10%, and thus all individuals 
remain included (Figure ‎2.16). In contrast the new and old DNA of (IV-7) demonstrated a 
“no call” rate of 286 SNPs and 410 SNPs respectively. In the third step, no common error 
was found in data coming from the same batch.  
Following all quality control analyses, data from all individuals and 9,527 SNPs (93%) were 
retained, for further preparation and then analysis (as will be seen in chapter 3).     
 
 
 
Figure ‎2.15; Screen shot of Genotyping Analysis Software (GTYPE) output, showing clusters of 
genotypes obtained by comparing the ratio of the relative allele signal (RAS) of the A allele to the sum of 
the RAS for A and B alleles A/(A+B). The table below shows a portion of the calls for single nucleotide 
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polymorphisms (SNP) with the SNP  identity (SNP ID) followed by the chromosomal location of each SNP 
marker (chromosome) and then 19 columns with the genotypes of the 19 DNA samples (18 family 
members, 1 in duplicate). Allele calls are highlighted in orange for AA, Green for AB, Blue for BB and 
gray for No Call. Row 6 shows SNP with monomorphic calls of AA for all individuals. A full description is 
provided in the text. 
 
 
 
Figure ‎2.16; Excel worksheet showing a portion of the calls for single nucleotide polymorphisms (SNP), 
imported from the Genotyping Analysis Software (GTYPE). It encloses the SNP identity (SNP ID) 
(column A), followed by the chromosomal location (column B), and the physical distance (column C) of 
each SNP marker. That is followed by the (national centre for biotechnology information)‎“NCBI”‎SNP‎
ID (dbSNP RS ID) [232] (column D), and then the genotyping of all family individuals (18 family 
members, 1 in duplicate), in A & B format (columns E-W). No call rate counts and percentages for each 
individual (across all SNPs) are shown in rows 1 and 2 respectively. A full description is provided in the 
text. 
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2.6 Conclusion 
There are several conclusions to be drawn from the results in this chapter. At the time of 
performing the analysis using the Affymetrix GeneChip mapping 10K array, with mean 
distance between SNPs of 210Kb and the average heterozygosity 0.37, it  was very popular 
and was validated in over 250 publications by the end of 2007, with a growing number of 
researchers getting better results for several applications including linkage analysis, whole-
genome association, population genetics and chromosomal copy number changes [233]. 
Although 100K and 500K mapping arrays were starting to be available, with mean distance 
between SNPs of 23.6Kb and 5.8Kb respectively and an average heterozygosity of 0.30 for 
both [234], these mapping arrays use more than one chip (e.g. 2 chip of 250K in case of 
500K), and more than one restriction enzyme (e.g. Xba1 and Hind III in case of 100K chip) 
[235]. Therefore, the 10K chip was the cheapest and least time consuming option and thus 
was the best choice at this stage as further investigation after Genome Wide Linkage Analysis 
(GWLA) was planned, to identify any region of interest and undertake more analyses if 
required.  
As mentioned earlier, blood samples from various family members have been obtained at 
different times. To ensure that results obtained with ‘old’ and ‘new’ samples were identical, I 
have performed the WGS with 10K chip on an old and a new sample from family member 
(IV-7). After obtaining the genotyping data on Excel file, I have compared the genotype of 
both samples among 9266 SNPs; data from both samples were identical in all SNPs except 4. 
The similarity indicates that old samples can be used in the chip analysis when new samples 
are not available. 
Since DNA quantity is one of the main affecting factors in this protocol, DNA quantification 
and concentration adjustment was required twice in the protocol; once at the start for 
preparation of Xba1 restriction process, second after PCR purification and before 
fragmentation. As a result, call rate of the DNA control and sample was within the 
manufacturer's recommended specification > 92%. That confirmed the accuracy of the assay 
which means the samples were prepared well and the DNA quality was good enough to 
perform this Genome scan. In addition, the three quality control steps on the data obtained 
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has also removed any SNPs not up to the standard and have confirmed that all DNA sample 
are good enough to proceed to further steps of data analysis . 
Processing DNA samples of all family members and obtaining the genotyping data of all 
SNPs for each individual will enable us to compare the data of affected vs. un affected, and 
search for the region on the genome which contains common SNPs inherited by all affected 
individuals but not all unaffected, using GWLA. That region could be linked with the disease 
allele and one or more of the genes in that region could be playing a role in the pathology of 
family #1. 
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Chapter 3 Genome Wide Linkage Analysis of family #1 
In chapter 2, I described the hybridization of DNA from all family members to the 
Affymetrix GeneChip 10K array, which was followed by scanning, to obtain the genotyping 
of 10,208 SNPs from 19 DNA samples (of family #1) and importing the data in Excel format, 
in addition to some quality control checks. In this chapter, I will perform further quality 
control steps on the data, followed by genome-wide linkage analysis (GWLA), (will describe 
in ‎3.2.1) with the aim of identifying loci implicated in the thyroid defects affecting the 
family. 
 
3.1 Introduction 
GWLA of a particular family detects the genetic differences between specific individuals in 
the family known as affected (targets) and the rest of the family members (subpopulation). 
These differences occur due to crossing over (will describe is ‎3.1.2) during cell division and 
meiosis across several generations. 
3.1.1 Cells division and meiosis: 
When cells in the human body divide the new cell carries a complete set of chromosomes 
(n=46) which is two copies of each (23), containing an identical copy of DNA (mitosis). 
However the reproductive cells carry (haploid) only one copy of the chromosome (23) after 
division (meiosis). Paternal and maternal reproductive cells (gametes) will each carry a single 
copy of chromosomes. When the gametes combine, that creates  a new genetically variable 
offspring or zygote with 46 chromosomes (23 from father and 23 from mother) (reviewed in 
[236]). During meiosis chromosome pairs are in close proximity and in homologous regions 
meet at a point called a chiasma (Figure ‎3.1) and their genetic material can be exchanged in a 
process known as crossing over.  Consequently, the gamete forms with any combination of 
paternal or maternal chromosomes. 
3.1.2 Crossing over & recombination 
Chromosomal crossing over is the exchange of genetic material between homologous 
chromosomes (carrying the same type of information) leading to a recombination (the 
outcome of recombinant chromosomes), (Figure ‎3.1 A & B). It occurs when correspondent 
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regions on homologous chromosomes break and then reconnect to the other homologous 
chromosome at meeting point known as chiasma (Figure ‎3.1 A). The number of chiasma 
across the chromosome could be non-random and multiple chiasmas can increase the 
probability of multiple crossovers. This phenomenon provides the basis for a whole genome 
scan (described in 2.2.1), using SNP markers (Figure ‎3.1 C). The new regions, due to 
multiple crossovers in any chromosome, provide a powerful and realistic means of 
accounting for genetic interference when applied to the problems of gene localization 
(reviewed in [237]). On the other hand if two crossing-overs occur between mapped loci A 
and B then recombination between them may be missed. That is why closer markers give 
stronger output as they can detect every single crossover[183]. 
Crossing over was first described, in theory by Thomas Hunt Morgan in 1916 who proposed 
that the crossover frequency might indicate the distance separating genes on the chromosome. 
Thus the unit of measurement for linkage is known as the Morgan [238].   
 
 
 
 
 
 
Figure ‎3.1; Cartoon showing; (A) crossing over between maternal and paternal homologous chromosomes 
during meiosis, at chiasma. (B) The new chromosome shows a recombination in three genes J, K & L which 
are replaced by j, k & l. (C) Example of single nucleotide polymorphism (SNP) marker and their transfer 
during crossover. Modified from; http://online.santarosa.edu 
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3.1.3 Mendel’s‎law‎of‎independent‎assortment 
It is also known as "Inheritance Law" and it states that; “alleles of different genes assort 
(separate) independently of one another during gamete formation”, concluding that different 
characters (traits) are inherited independently of each other, when genes of these traits are not 
linked to each other. Along with crossing over, independent assortment increases genetic 
diversity by producing novel genetic combinations. Thus the possible combinations of 
gametes formed from maternal and paternal chromosomes will occur with equal frequency 
(reviewed in [236]). 
3.1.4 Linkage 
Genes (or loci) on the same chromosome are physically connected or linked. If they are 
closer they are more likely to segregate together non-randomly. On the other hand loci on 
different chromosomes are predicted to segregate independently during meiosis, following 
Mendel’s law of independent assortment. Gene pairs that segregate independently have 
recombination frequency of 50%.  
During meiosis, independent segregation occurs when genes are on different chromosomes. 
Genes on the same chromosome, but wide apart, can also segregate independently since the 
probability of being inherited together is low. The recombination frequencies of pairs of 
genes indicate how often 2 genes are transmitted together. For linked genes, the frequency is 
less than 50%. The greater the distance between linked genes, the higher the recombination 
frequency. Since crossing over can occur with approximately equal frequency at any point on 
a chromosome then the probability of any two loci lying on the same chromosome (syntenic)  
being inherited together will also be 0.5 (reviewed in [239]).  
3.1.5 Recombination Fraction  
The recombination fraction (θ) (also called recombination frequency) is a statistical measure 
calculating the probabilities of crossover occurrence between two loci along a chromosome. 
It ranges between 0 (no recombination) and 0.5 (unlinked loci). The recombination fraction is 
an indicator of the distance between the loci and thus the zero value of θ gives a clue of tight 
linkage while a value of 0.5 indicates independent assortment. That is because non-linked 
alleles have a 50% chance of recombination, due to independent assortment. Thus 
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recombinant fraction is equal to [R/(NR+R)]. When NR denotes the number of non-
recombinant offspring, and R denotes the number of recombinant offspring. Recombination 
fractions define genetic distance rather than physical distance. To find markers near the 
disease locus, we should look for a recombination fraction of < 0.5 between them [239].  
3.1.6 Physical & Genetic Distance 
The length of DNA can be measured in two different ways, by counting the nucleotides 
between two locations in any DNA, which is known as physical distance and is measured in 
base pairs (bp). The second method counts the number of recombination events between two 
loci (on a single chromatid) per meiosis. This is known as genetic distance and is measured in 
Morgan or centiMorgans (cM), also known as the genetic map unit (m.u.). A centiMorgan is 
defined as the distance between genes for which one product of meiosis in 100 is 
recombinant. The correlation between physical and genetic distance can be summarised as 
one centiMorgan corresponds to about 1 million base pairs in humans on average. 
3.1.7 Identity By Descent (IBD) & Identity By State (IBS) 
SNPs are described as having identity by type (IBT) when they have the same DNA sequence 
(calls). SNPs that are identical by type either are identical by descent (IBD) because they 
inherited from the same member in an earlier generation or are non-identical by 
descent (NIBD).  IBD is often used in genetic linkage and association analyses (will be 
described in ‎3.2.1), to identify alleles which are potential candidates for genetic disease 
[240]. NIBD can also be identical by state (IBS), if they share the same DNA sequence, but 
are not from the same member in an earlier generation (not origin). Parent-offspring pairs 
share 50% of their genes IBD, and monozygotic twins share 100% IBD [254].  
 
3.2 Method for Genetic Mapping 
3.2.1 Linkage Analysis 
Linkage analysis is a strategy that aims to identify genes responsible for certain inherited 
diseases solely through their chromosomal location within the genome. In the case of 
scanning the whole genome, a more general approach can be used which is GWLA. Linkage 
Analysis is a statistical method based on the fact that if two loci are close enough to each 
73 
 
other on the same chromosome, they tend to be inherited together since the chance of 
recombination between them will be reduced. This analysis tests linkage between genetic loci 
and any human trait. By investigating the genetic loci it counts the number of recombinants 
and nonrecombinants, estimates the recombination fraction and tests this fraction to see if it is 
significantly smaller than 0.5. Linkage studies have been shown to have high power to detect 
loci that have alleles (or variants) with a large effect size, i.e. alleles that make large 
contributions to the risk of a disease or to the variation of a quantitative trait [254].  
Although linkage studies have been  known since 1955[241], the advent of low-cost 
genotyping platforms for interrogation of several hundred thousand to one million SNPs, 
coupled with the completion of the second generation haplotype map of the human genome 
(HapMap2) by the mid-2000s, made genome-wide association and linkage studies feasible. 
However, identifying the actual sequence variant(s) responsible for these linkage signals is 
challenging because of difficulties in sequencing the large regions implicated by 
each linkage peak [242]. This challenge could to be solved by “next generation” DNA 
sequencing techniques [243], which will be described in chapter 6 of this thesis.  
3.2.2 LOD Score 
When performing linkage analysis on extended multigenerational families, with known 
clinically characterized members (affected or unaffected), the parametric logarithm of odds 
(LOD) score is one of the most popular statistical tools. The LOD score method  compares 
the probability of observing the data if two loci (the sites of genes) are close to each other on 
a chromosome and are therefore likely to be inherited together, to the probability of 
observing the same data purely by chance [239]. In this method the likelihood of linkage at 
different values of θ is tested against the null hypothesis of no linkage (i.e. θ=0.5).  
LOD score = log 10      (Likelihood if the loci are linked θ)      . 
                   Likelihood if the loci are unlinked θ=0.5 
 
If the LOD score between markers is positive, it means that these markers may be close to 
each other. A LOD score of 3 or more is generally taken to indicate that two gene loci are 
linked [244]. A LOD score of 3 means the odds are a 1000 to 1 in favour of genetic linkage, 
(conventional p=0.05 threshold of significance). Negative LOD score, (mainly LOD <-2), on 
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the other hand, indicates the opposite i.e. rejects the hypothesis of linkage. furthermore, no 
conclusion can be made when LOD value is above -2 and less than 3 (-2 < LOD < 3) [245].  
However, this is based on the LOD score being maximised over only a single parameter 
(recombination fraction), if the maximisation is over more than one parameter (such as 
recombination fraction and penetrance) then a more stringent threshold of significance is 
required as evidence for linkage, i.e. LOD score of 3 is no longer significant and it is 
necessarily to be larger [246].   
It is less common to find a single family large enough (2 offspring at least) to reach statistical 
significance. However, it is recommended to use data of more than one independent family 
(with related phenotype), so LOD score can be added up across families. That was my 
intention in this thesis, to add family #1 data to family #2 data (as described in chapter 4). 
3.2.3 Non Parametric Linkage Analysis (npl) 
This is the approach by which examination of the pattern of allele-sharing by relatives, (such 
as siblings, parents and offspring) and transmission from parent to offspring can be made. 
Methods for this analysis do not make any assumptions about the disease model, such as 
mode of inheritance, penetrance or disease allele frequency (the parameters). This analysis 
makes use of the information for alleles identical by descent (IBD) between affected sib-pairs 
(or discordant sib-pairs) to conclude the location of genes that are linked to the trait of 
interest [245].  
 Linear and exponential npl 3.2.3.1
As described above, a popular tool in genetic mapping of complex traits is model free (also 
call non parametric). That is because no assumption about the underlying mode of inheritance 
is required. Accurate p-values and LOD scores calculation is very important in linkage 
analysis between a genomic region and a trait. Depending on the segregation of marker 
alleles at a genomic region linked to the trait, specification of a model for the trait-dependent 
segregation could be required. With several families and large number of member in each, the 
p value can be well approximated by applying normal approximation to the test statistics, 
which is used in traditional npl studies and known as npl linear model [247]. However, 
normal approximation may not work well when the data are for one single family, which 
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usually has a very high number of shared common alleles. In such cases, applying normal 
approximation can give a very conservative p value due to excessive sharing and thus normal 
approximation may not be reliable. An exponential model can provide more reliable output in 
such data and thus is recommended. The two models are much closer and the score statistic 
corresponding to the exponential model is exactly the same as that of the linear model 
(reviewed in [248]).  
3.2.4 Parametric Analysis 
After aggregation and/or segregation studies established a genetic component for a phenotype 
of interest, parametric linkage analysis has been the traditional approach used for Mendelian 
disease gene mapping since the 1970's [241]. It is the approach by which examination of the 
pattern of allele-transmission from parent to offspring can be made. In this analysis a genetic 
model for the disease must be specified including allele frequency and penetrance 
parameters. These parameters will be assumed as known without error in order to estimate 
recombination fractions for testing linkage [249]. The parametric analysis is more powerful 
than nonparametric if the genetic model specified for analysis is sufficiently close to the true 
mode of inheritance (MOI) that governs the defect. Thus the key issue in parametric linkage 
analysis is the specification of the correct genetic model [250].  
3.2.5 Multipoint & Single point Linkage Analyses 
Linkage analysis used to be described with respect to two loci; however it is now performed 
in multipoint form (multiple markers per chromosomal region) as this provides much better 
information on the origin of each chromosomal segment segregating through a family, and 
much better estimates of IBD sharing [251]. Multipoint analysis is commonly used to 
evaluate linkage of a disease to multiple markers in a small region and is highly powerful in 
the studies when the IBD between family members at the trait locus are not very clear, as it 
uses haplotype information from several markers to infer the IBD.  
Single-point (also known as two-point) linkage analyses indicate the mapping using two loci, 
a single known genetic marker locus and one unmeasured disease loci (or another genetic 
marker), and that is why it is known as single point and two point. In single-point analysis 
each marker is analysed separately (reviewed in [252]).  
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The power of single-point is also decreased by the lack of using haplotype, thus Multipoint 
analysis is more accurate than (and preferable to) single-point analysis [239]. On the other 
hand Multipoint linkage analysis is quite sensitive to the correctness of the map on which it is 
based (due to misspecification of inter marker distances). Such misspecification has more 
effect when dealing with closely spaced markers. In addition single marker analyses may 
provide more reliable measures of the strength of support for linkage than multipoint 
statistics. Therefore comparing the output of both is highly recommended especially when the 
inter marker distances are misspecified or if there are doubts about the accuracy of the map 
(reviewed in[239]). 
3.2.6 Allele Frequency 
During linkage analysis and likelihood estimation, the population frequency of each marker 
and disease allele is required. It is important to choose the markers which are more frequent 
in the population, as the uniquely known genotype at a locus in any pedigree indicates that, 
the gene frequencies for that locus have no effect on the value of the LOD score [253].It 
should be noted that common variants will be non-informative as well as the monomorphic 
genotypes (reviewed in [254]). 
3.2.7 Haplotype Analysis 
A haplotype in SNP analysis refers to a group of SNPs statistically associated and located on 
a single chromosome of a chromosome pair. Analysing these associations can identify alleles 
of a haplotype sequence, which can clearly identify all other polymorphic sites in its region. 
This is able to provide information about gene flow in a pedigree which can be used to 
reconstruct likely haplotypes for families and individuals. Most of the knowledge of SNP 
haplotype comes from the international HapMap and 1000 genome projects [255].  
With the advanced method of genome-wide SNP microarrays for whole-genome scan, a vast 
amount of information can be obtained through phased haplotypes, which identify the alleles 
that are co-located on the same chromosome. Determination of haplotype phase (which is 
maternal and which paternal), is becoming increasingly important when dealing with large-
scale genotyping such as the 10K chip used in this study (reviewed in [256]). In general 
haplotypes have no defined size and can refer to anything from a few closely linked loci up to 
an entire chromosome.  
77 
 
3.2.8 Multidimensional scaling (MDS)  
Multidimensional scaling (MDS) is a data analysis technique that reduces data into more 
manageable pieces of information from which conclusions can be drawn. MDS condenses 
large amounts of data into a relatively simple spatial map that transmits important 
relationships in the most economical manner [257]. Performing MDS analysis on the 
genome-wide IBS pair wise distances creates a file containing columns with largest variants 
across the X-axis (horizontal) in the MDS plot (C1), second largest variant across the Y-axis 
(vertical) in the MDS plot (C2), third largest variant across the Z-axis (C3) and the fourth 
largest variant across T-axis (C4). Using Excel scatter graphs, pair wise comparisons for each 
dimension (C1 to C4) can be performed. For example scatter graph for C1 against C2 will 
create clusters in which each point is an individual. The distance between these clusters 
demonstrates the ethnic background of an individual (which population he/she belongs to) 
[258]. 
 
3.3 Data Analysis “Methods” 
A wide range of software can be downloaded online and used to check data and perform 
linkage analysis. Depending on the data and the aim of the study, particular software can be 
chosen depending on the function of that software and its enhanced performance. In the 
below section I will explain the software used in data streamlining and quality control.  
3.3.1 Software for streamlining and Quality control 
PLINK software is an “open-source toolset for whole genome association analysis, designed 
to perform a range of basic, large-scale analyses in a computationally efficient manner”[258]. 
“PLINK (one syllable) was developed by Shaun Purcell at the Centre for Human Genetic 
Research (CHGR), Massachusetts General Hospital (MGH), and the Broad Institute of 
Harvard & MIT” [258]. It is used regularly in the scientific community for data management, 
summary statistics, population stratification, association analysis, and identity-by-descent 
estimation. PLINK is an analysis package and as such supports steps for genotype/phenotype 
data analysis; it does not provide support for study design, planning, generating genotype or 
CNV calls from raw data.  
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PedCheck software reads the pedigree file and checks for any errors (mainly Mendelian) by 
analysing the entire family in one step [259]. It analyses Mendelian errors in 4 levels, each 
leads to the next. These levels are: - nuclear-family algorithm (level 1), genotype-elimination 
algorithm (level 2), critical-genotype algorithm (level 3) and odds-ratio algorithm (level 4). 
Thus PedCheck can indicate that the data do not have any errors on basis of nuclear family, 
by level 1 analysis. In level 2, PedCheck creates a new nuclear family, by eliminating 
founders and checks for errors. This step can identify any errors that have not been detected 
by level 1. However level 2 checks cannot identify errors created by an individual with 
genotypes causing LD (critical genotype), when treated as unknown the inconsistency will be 
eliminated. These errors can be identified by level 3 analysis in which individuals with 
critical genotypes will be un-typed (one at time), then re checked for consistency. In level 4 
PedCheck will identify the valid typings of critical genotypes that eliminate the inconsistency 
and provide a list of the best genotypes (reviewed in [259]). 
Graphical Representation of Relationships (GRR) software investigates the genotype of each 
marker for every individual and compares them to see how many allele are shared [identity 
by state (IBS)] at each locus. GRR estimates the mean and standard deviation (stDev) of 
these IBS counts for each pair of individuals across all markers. The highest percentage of 
alleles shared by IBS will be in identical twins. First-degree relationships such as full siblings 
or parent-offspring pairs will show the second highest percentage, followed by half siblings 
and finally unrelated individuals. The software then generates a graph with X axis (the mean) 
and Y axis (stDev). Different types of relationship pairs will have different overall mean and 
stDev IBS values, in first degree related, the value will be much higher than unrelated. If the 
software shows clear variation in the IBS mean within a category that could be an indication 
of labelling error or relationship errors (not real parent). GRR is able to show five 
relationships provided in the PedFile, in different colours (Figure ‎3.3). Pairs with the same 
relationship should cluster together. If not then that would be the second indication of 
labelling error or relationship errors (not real parent) [260]. 
3.3.2 Software available for linkage Analysis 
LOD score calculation has been implemented using different algorithms in several public 
domain software packages. The first generally available computer program for linkage 
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analysis was introduced in 1974 [261]. The commonly used programs that perform linkage 
analysis (but have not been used in this study) are explained in this section. Only Merlin 
software was used in this study, and will be described in the next section (‎3.3.3).  
FASTLINK software is flexible for the linkage analysis of a large pedigree with a small 
number of family members with a strongly Mendelian mode of inheritance [262]. 
FASTLINK is competent for pedigrees containing inbreeding loops [262]. It is more common 
to be used for parametric analysis than non-parametric [253]. 
VITESSE Software was shown to be faster (than FASTLINK) to run single- or multi-point 
analysis for most pedigree structures [262]. Thus it is more common to be used for parametric 
analysis than non-parametric as is FASTLINK [253].  
GENEHUNTER [263] offers a wide package of linkage and association tests and has been 
used a lot for statistical genetics analysis. It has the advantage of analysing a considerable 
number of markers although the number of individuals it can handle is limited 
(approximately 12 non-founders). When the pedigree exceeds the maximum allowed number 
of individuals, the program discards individuals starting with the unaffected. Splitting the 
kindred into smaller pedigrees could sort this issue (reviewed in [264]).  GENEHUNTER 
underwent several developmental processes when it was renamed as GENEHUNTER-PLUS 
(version 1.3) and GENEHUNTER-IMPRINTING. By the later version, Strauch and the team 
obtained a LOD score of 4.76 for a study on sensitization to mite allergen in an English 
population [262, 265]. 
ALLEGRO is a faster version of GENEHUNTER (20-100 fold faster), and has been designed 
to perform multipoint linkage analyses. It can be used with most pedigree structures, 
providing more accurate significance levels for non-parametric statistics. It allows 20−30% 
larger pedigrees and reduces memory requirements by a factor of 20−60 in comparison with 
GENEHUNTER. It offers more parameters such as family weighting schemes. It provides 
linear-model LOD score option [261].  
3.3.3 Software used in this study for linkage Analysis (MERLIN)  
Merlin software is efficient software that provides fast solutions to common problems such as 
allele-sharing analyses and haplotyping. It provides fast pedigree analyses, including non-
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parametric linkage and error detection [266]. It offers a faster algorithm that is particularly 
useful in dense marker maps, for which the number of recombinations allowed between 
markers can be constrained [262]. It also provides the linear-model LOD score option as in 
ALLEGRO. Thus it is considered as a competitor to GENEHUNTER and the fastest 
programme mainly for non-parametric analysis [261]. The standard non-parametric linkage 
analysis in Merlin uses the Kong and Cox linear model to evaluate the evidence for linkage 
[248]. However Kong and Cox “Exponential” model (an alternative likelihood-based non-
parametric linkage test), has been shown to be more powerful in samples which include large 
pedigrees [266], such as family #1 in this study, (--exp command). Merlin provides swap-file 
support for handling very large numbers of markers [266].  
 Haplotype Analysis (by Merlin) 3.3.3.1
Merlin software represents haplotypes estimation in three modes; haplotypes corresponding 
to the most likely form of gene flow (--best command), sample gene flow forms according to 
their likelihood (--sample) or all non-recombinant haplotypes (--zero, --all). For this study 
the first model was used (--best). The output file (Merlin.chr), lists the two haplotypes for 
each individual, maternal haplotype first then paternal, for non-founders. Between the parents 
haplotypes several signs gave specific indications (a | indicates no recombination event 
between the current locus and the previous informative locus, a / indicates a recombination 
event in the maternal haplotype, a \ indicates a recombination event in the paternal haplotype, 
a + indicates a recombination event in both the maternal and paternal chromosomes, and 
a : indicates information about recombination between the current marker and the previous 
marker is not available), (Table ‎3.5, page 104). 
 
3.4 Aim 
The Aim of this chapter was to analyse the SNP genotyping data obtained by Microarray 
Chip processed in chapter 2, to identify alleles in regions linked to disease. In other words, to 
identify linkage between the SNP genotypes and “thyroid growth & neoplasia” in the family, 
and find the region on the genome where all affected members are carrying the same SNPs 
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but not the unaffected. That would be achieved by performing linkage analysis, after several 
quality control steps and data streamlining, followed by Haplotype analysis.  
 
3.5 Data Analysis  
The SNPs data was acquired (as described in 2.5.10) with standard allele format for data 
output from GTYPE as (A & B) genetic calls for each SNP, (as described in 2.2.8). The data 
were imported into an Excel worksheet and some data quality checks were performed (as 
described in ‎2.5.11). Following those quality control steps, data from all individuals and 
9,527 SNPs (93%) were retained. 
3.5.1 Preparation of PedFile (Pedigree File): 
The Excel file, imported from the 10K chip, was used to prepare the Pedigree File; a file with 
details of all family members (father ID, mother ID, sex) together with their genotype as 
described in (Zhao, J. H.) [267]. The genotype information was in the alphabetical format (A 
& B) and (No Call), (as described in2.2.8), while the “No Calls” have been converted to 0 0. 
Since individuals #II-2 and #II-3 have maternal but not paternal SNPs data, a dummy father 
(I-1) has been created with all details as other members, and a genotype of 0 0 for all SNP 
markers. The Excel file has then been transposed and saved as a text file (tab delimited). That 
was followed by separating the genotypes of each SNP with space (to be as; A B or 0 0). The 
file now can be called PedFile (Figure ‎3.2). 
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Figure ‎3.2; Example of pedigree file showing the first six columns containing information about each 
individual (family identity (ID), individual ID, father ID, mother ID, sex, disease status). That is followed 
by the genotype information of single nucleotide polymorphism (SNP) for that individual as A A, A B or 
B B. The SNP markers are shown (in green) above their calls. The first line shows the data of individual 
III-2 (marked as 1) and the second line that for individual II-2 (marked as 2). 
3.5.2 Streamlining the data before analysis (Appendix A1a) 
Some SNP markers are not informative and thus will not be analysed, such as 96 SNPs with 
unknown chromosomal location. Therefore these SNPs have been removed from the data, 
using PLINK (described in ‎3.3.1). That reduced the number of returned SNPs to 9,431 SNPs 
which is equivalent to 92% of the total SNPs at the start. Although monomorphic SNPs are 
non-informative in linkage analysis, they can be used in allele frequency estimation. Thus 
they have been conserved within the data.  
3.5.3 Mendelian Error Analysis 
 Mendelian error analysis by PedCheck software (Appendix A1b) 3.5.3.1
PedCheck software (described in ‎3.3.1), has been used to check the accuracy of family 
members relationship and mainly to analyse Mendelian errors. Mendelian errors analysis was 
performed in 4 levels (as described in ‎3.3.1). PedCheck has found 459 inconsistencies, across 
200 SNPs. These SNPs have been excluded from the family data using PLINK software. That 
reduced the number of returned SNPs to 9,231 SNPs which is equivalent to 91% of the total 
SNPs at the start. PedCheck was run again and no inconsistencies have been found. 
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 Mendelian error analysis by PLINK software. (Appendix A1c) 3.5.3.2
The remaining 9,231 SNPs were then investigated (using PLINK) for Mendelian errors and 
no further error was detected. However 5 SNPs (on chromosome 1) have been detected in 
PLINK “HH” file indicating invalid genotypes and thus were removed. That has reduced the 
number of returned SNPs to 9,226 SNPs which is equivalent to 90% of the total SNPs at the 
start.  
 Mendelian error analysis for chromosome X 3.5.3.3
Of the 200 SNPs showing Mendelian error by PedCheck, 118 were on chromosome X. The 
data of the remaining SNPs on chromosome X with no Mendelian errors (122 SNPs), have 
been extracted (by PLINK) and Mendelian error was re analysed by both PedCheck and 
PLINK software; none were detected.  
3.5.4 IBS Mean check by GRR among the family members 
GRR software (described in 3.3.3) was used to confirm the assumed relationships between 
family members by analysing their genetic data. The three main within family relationships 
have been seen in this family (Figure ‎3.3). The 3 common relationship pairs have been shown 
in this family and the IBS Mean was predominantly more than 1.6 in the sib-pairs and parent-
offspring, and less than 1.6 in the unrelated. In addition the duplicated samples in the family 
have shown an output similar to the monozygotic twins with very high IBS Mean (2.0), 
providing an indication of good data quality.  
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Figure ‎3.3; Screen shot of graphical representation of relationship (GRR) software’s output for family #1. 
Three clusters were obtained by studying the inheritance of the single nucleotide polymorphisms (SNPs) 
between the relatives.  The software calculates the mean on (x-axis) and the standard deviation (stDev) on 
(Y-axis) for all SNPs calls to create these clusters. Blue clusters indicate unrelated, red indicate sib-pairs 
and yellow for parent-offspring. IBS mean value for sib-pairs and parent-offspring is higher (more than 
1.6) indicating inheritance of the same SNPs more than the unrelated who shows IBS mean (<1.6). The 
highest IBS mean value (of 2.0) was shown with the duplicate sample, which provides an indication of 
good quality of old and new DNA samples.  
3.5.5 Data preparation for LINKAGE Analysis 
  Change 1 2 to A C G T. (Appendix A1d) 3.5.5.1
The data (in 1 & 2 genotype format) have been converted to A, C, G or T. To perform this 
conversion by PLINK, data (provided by Affymetrix Technical support), showing the allele 
codes of A, C, G or T for each SNP, have been used.  
  Change all negative strand SNPs to positive. (Appendix A1e) 3.5.5.2
All data of negative strand SNPs have been converted to positive using PLINK and data 
(provided by Affymetrix Technical support), showing all negative and positive strand SNPs.  
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  Merging the data with HapMap data. (Appendix A1f) 3.5.5.3
To obtain allele frequency data for each SNP and to investigate the ethnic background of 
family #1, family data have been merged (using PLINK) with 4 files of HapMap data 
(founders only), one file for each population, 60 Europeans individuals (CEU), 90 Chinese 
(CHB) & Japanese (JPT) & 60 Yoruba (YRI). A further 22 SNPs show errors in terms of 
strand and have been removed, leaving 9,204 SNPs (90%) of the total SNPs to be merged 
with HapMap data. 
 Multidimensional scaling (MDS)  3.5.5.4
The aim of using MDS (described in ‎3.2.8 ) was to study to which population family #1 data 
are most similar. The MDS analysis has been performed on the merged data of family #1 and 
HapMap. The ethnicity of family #1 then was determined by importing the data in Excel. 
Pair-wise comparisons for each dimension (C1 to C4) were plotted against each other for 
each two dimensions. Family data have been shown to be closer to the European cluster 
(when plotting C1 against C2), as shown in Figure ‎3.4). That indicates the family members 
are belonging to European population and thus European allele frequencies (for all SNPs) 
will be used for linkage analysis of family #1.   
 Removing all HapMap data except European 3.5.5.5
Since European allele frequency will be used in the Linkage Analysis, HapMap data of other 
populations have been removed from the PedFile. Thus the new PedFile contains family data 
and European data only and will direct linkage analysis software to use European allele 
frequencies. Thus the study will be more precise but loses generalizability.  
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 Changing the chromosomal position (of all markers) from base pair 3.5.5.6
to centiMorgan (cM) in the Map file (Appendix A1g) 
The positions of the SNPs analysed were originally provided in physical distance in base 
pairs (as described in ‎3.1.6). Since linkage analysis will be performed using Merlin software, 
genetic distance will be measured in cM (as described in ‎3.1.6). Marshfield map, and 
deCODE map [188] were used to change bp into cM by using Excel sheet and commands. 
The cM positions of 9111 SNPs (out of the total 9,204 SNPs) were found in the Marshfield 
map while no position of the remaining 93 SNPs has found in Decode map either. Thus these 
93 SNPs have been removed from the data leaving 9,111 SNPs (89%) for further studies. 
Figure ‎3.4; Screen shot of multidimensional scaling (MDS) output showing dimension1 (Y axis) 
plotted against dimension 2 (X-axis) for data from family #1 and HapMap. The scatter plot shows 
three clusters one for Chinese (CHB) & Japanese (JPT) population (red), one for Yoruba (YRI) 
population (yellow) and one for Caucasian (CEU) population (black). Family #1 data (blue) are 
shown to be closest to the cluster of the Caucasian (European) population. 
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3.5.6 Data preparation for Merlin software: 
 Changing SNPs genotyping format from A C G T to 1 2 3 4 in 3.5.6.1
PedFile 
Merlin software, (described in ‎3.3.3), was used for performing Linkage analysis. This 
software requires the genotype format to be in numbers rather than letters. Therefore the 
PedFile data have been changed from A C G T to 1 2 3 4 respectively by using --allele1234 
command in PLINK.‎3.5.6.2 ‎3.5.6.1 
 Adding age in PedFile 3.5.6.2
The age of individuals is one of the parameters required in the parametric linkage analysis 
(described in ‎3.2.4). Therefore age has been added in the Pedigree file for each individual, 
after his or her allele calls. For affected individuals, age at onset (AAO) has been added, 
while current age (on 2013) was added to others. Since no information is available for the age 
of European founders of HapMap, age of 55 year was added to each assuming they are old 
founders. Two different age ranges (44 & 50 years) were tried and no difference was 
observed in linkage analyses, giving an indication that this age has no effect on the 
analyses.  ‎3.5.6 
 Creating Data File 3.5.6.3
In addition to the Map and Pedigree files, Merlin requires a third file known as the Data file. 
This file starts with disease title and it is (Thyroid Cancer) for this study, followed by a list of 
all SNPs markers (M) and ends with one line for AGE (Figure ‎3.5). The data file interprets 
what is in the PedFile. It says that the first 6 columns in the PedFile are for patients of 
(Thyroid Cancer), followed by genotypes of markers as listed in the data file (under title M) 
and after the genotypes of all markers there is the age of that patient.  
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Figure ‎3.5; Type of files required to perform linkage analyses by Merlin software are shown above. Panel 
(A) shows the Pedigrees file, in numerical format. Panel (B) shows the map file which includes the list of 
chromosomes (chrom), single nucleotide polymorphism (SNP) on each chromosome (SNPs) and positions 
of each SNP in centiMorgans (position in cM). Panel (C) shows the data file which includes a title of the 
disease (A Thyroid Cancer) at the top, list of markers (M) and Age at the bottom. A full description is 
provided in the text. 
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3.6 LINKAGE Analysis by Merlin 
When deciding which type of analysis to perform, several factors were taken into 
consideration; these included the lack of clarity regarding age of disease onset in some family 
members and the variable penetrance. Therefore non-parametric linkage analysis was 
selected as the primary analysis and parametric ‘dominant model’ was chosen for the 
secondary analysis.  
3.6.1 Non -Parametric Linkage Analysis (Appendix A1h) 
The first analysis performed was the (model free) Non-Parametric (Multipoint) Linkage 
analysis (as described in ‎3.2.5). The Kong and Cox “Exponential” npl analysis has been 
chosen (as described in ‎3.3.3).  That was followed by performing Single point npl analysis 
(described in ‎3.2.5). 
3.6.2 Parametric Linkage Analysis  
The traditional (model based) Parametric Linkage Analysis (described in ‎3.2.4) was 
performed as a secondary analysis. Dominant model of inheritance was the main model to be 
run and Recessive model was the secondary choice as described above (in ‎3.6).  
 Defining Disease Model (Dominant) 3.6.2.1
A specific disease model was defined in which ‘Thyroid cancer’ was selected as disease title 
and Dominant as mode of inheritance. Since the index patient has been referred for MNG at 
age 13, thus the age of onset (of MNG for all affected members) was chosen to be above 12 
years. Based on the disease history in the family described in (1.18.3), disease penetrance was 
chosen to be 90% in females (0.001, 0.9, 0.9 for aa Aa AA) and 50% in males (0.001, 0.5, 0.5 
for aa Aa AA). SNP allele frequencies will be estimated based on the European population 
data, disease allele frequency was stated to be 0.01 (Table  3.1).  
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Table ‎3.1: The inputs file specifying the disease model and other input parameters for Merlin software. 
First line shows the disease name, allele frequency and mode of inheritance (dominant in this case). 
Second line shows the disease penetrance before age 12 years (for the three types of inheritance; aa, aA & 
AA). Third line shows the penetrance in the female above or equal to 12 years. Fourth line shows the 
penetrance in the male above or equal to 12 years. Fifth line shows the penetrance in any other cases. A 
full description is in the text. 
 
 
 Parametric Linkage Analysis (Dominant) (Appendix A1i) 3.6.2.2
Multipoint linkage analysis, using Dominant mode, was performed by Merlin with the 
commands described in the appendix. That was followed by Single point Dominant analysis. 
Both “multi and single” point analyses (described in ‎3.2.5) have been performed. 
 Defining Disease Model (Recessive) 3.6.2.3
The disease model for both Dominant and Recessive were the same except for the mode of 
inheritance. Thus with disease penetrance of 90% in females, the mode was defined as 
(0.001, 0.001, 0.9 for aa Aa AA) and 50% in males as (0.001, 0.001, 0.5 for aa Aa AA), 
(Table ‎3.2). The age at onset has been adjusted to be over 12 years as all affected individuals 
are affected after that age. The reason behind adjusting disease penetrance in female to be 
90% is that out of 8 females in the family, 7 were affected. The reason behind adjusting 
disease penetrance in male to be 50% is that only one male in the family is affected and one 
male is obligate carrier as he transferred the disease to his daughter.  
ThyroidCancer 0.01 * DOMINANT_DISEASE_MODEL
AGE < 12 0.001,0.0001,0.0001
SEX = 1 0.001,0.5,0.5
SEX = 2 0.001,0.9,0.9
OTHERWISE 0.001,0.0001,0.0001
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 Parametric Linkage Analysis (Recessive) (Appendix A1j) 3.6.2.4
Multipoint linkage analysis, using Recessive mode, was performed by Merlin with the 
commands described in the appendix. That was followed by Single point Recessive analysis. 
Both “multi and single” point analyses (described in ‎3.2.5) have been performed. 
 
 
Table ‎3.2: The inputs file specifying the disease model and other input parameters for Merlin software. 
First line shows the disease name, allele frequency and mode of inheritance (recessive in this case). Second 
line shows the disease penetrance before age 12 years (for the three types of inheritance; aa, aA & AA). 
Third line shows the penetrance in the female above or equal to 12 years. Fourth line shows the 
penetrance in the male above or equal to 12 years. Fifth line shows the penetrance in any other cases. A 
full description is in the text. 
 
 
 
 
 
 
ThyroidCancer 0.01 * RECESSIVE_DISEASE_MODEL
AGE < 12 0.001,0.0001,0.0001
SEX = 1 0.001,0.001,0.5
SEX = 2 0.001,0.001,0.9
OTHERWISE 0.001,0.0001,0.0001
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3.7 RESULTS 
3.7.1 Non Parametric Linkage Analysis 
The output of nonparametric multipoint linkage analysis on chromosomes 1 to 19 has shown 
that maximum LOD score values vary from -0.11 (on chromosome 8) and 1.00 (on 
chromosome 17) and minimum values varys from -0.2 (on chromosome 14) and -0.8 (on 
chromosomes 8 & 12) . A summary of all chromosomes is shown in (Figure ‎3.6) & 
(Table ‎3.3). Chromosome 20 showed the maximum LOD score of 3.01, while the minimum 
LOD score was -2.4.  
Chromosomes 21, 22 and X showed a maximum values of 0, 0.01 and 0.67 respectively, 
while the minimum scores were -0.19, -0.06 and -0.03 respectively. Thus the LODs on 
chromosome 20 were the only score indicating significant evidence for linkage and were 
located between (20p12.3-20p11.23). In this region 52 SNPs showed LOD scores of 3.01. 
That was at position between 23.7 cM and 43.2 cM of chromosome 20, over a region of 19.5 
cM, and was shown to contain 46 genes, (Figure ‎3.7).  
The output of nonparametric single point analysis has supported the findings of multipoint in 
all chromosomes including chromosome 20, in which 33 SNPs (out of 53), have single point 
LODs > 1 in the region identified by multipoint analysis LODs, (over 19.5 cM), (Table ‎3.4 ) 
and (Figure ‎3.7). That has supported the region identified in multipoint Analysis. 
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Figure ‎3.7; Graph showing a regional plot of chromosome 20 comparing LOD scores obtained using 
multi-point non-parametric linkage analysis (npl) (blue solid line) and single point npl (red dots). The 
region (20p
12.3
-p
11.23
) displayed the maximum npl LOD score of 3.01 and was supported by single-point 
npl in which the maximum npl LOD score was 2.41.  
Figure ‎3.6; Graph showing the maximum and minimum LOD scores (of all chromosomes), obtained by non-
parametric linkage analysis. All chromosomes showed maximum LOD score <1.00, except chromosome 20 
which showed the maximum LOD score of 3.01, while the minimum LOD score was -2.4.  
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3.7.2 Parametric Linkage Analysis (Dominant) 
The output of Parametric Dominant multipoint linkage analysis on chromosomes 1 to 19 has 
shown that maximum LOD score values vary from 0.96 (on chromosome 3) and -2.10 (on 
chromosome 8) and minimum values vary from -2.2 (on chromosome 10) and -4.1 (on 
chromosomes 8, 12 & 19) . A summary of all chromosomes is shown in (Figure ‎3.8) & 
(Table ‎3.3). Chromosome 20 showed the maximum LOD score of 2.03, while the minimum 
LOD score was -2.1. Chromosomes 21, 22 and X showed a maximum value of -2.03, 0 and 
0.56 respectively, while the minimum score was -2.39, -2.6 and -1.4 respectively. Thus the 
LODs on chromosome 20 were the only scores that suggested linkage and were located 
between (20p
13
-20p
11.23
). In this region 69 SNPs showed LOD scores of 2.03. That was at 
position (11.69.7- 43.2 cM) over a region of 31.51 cM (Figure ‎3.9). This region is larger than 
the one which occurred in the npl, but both shared a common region (Figure ‎3.10). 
The output of Dominant single point analysis supported the findings of multipoint in all 
chromosomes including chromosome 20, in which 21 SNPs (out of 69), have single point 
LODs > 1 in the region identified by multipoint, (over 1.51 cM), (Table ‎3.4) and (Figure ‎3.9).  
 
 
 
Figure ‎3.8; Graph showing the maximum and minimum LOD scores (of all chromosomes), obtained by 
parametric linkage analysis (dominant). All chromosomes showed maximum LOD score <1.00, except 
chromosome 20 which showed the maximum LOD score of 2.03, while the minimum LOD score was -2.1. 
Many chromosomes show very low minimum LODs (-4.00_ which is normal in parametric analyses 
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Figure ‎3.9; Graph showing a regional plot of chromosome 20, comparing LOD scores obtained using 
multi-point dominant (blue solid line) and single point dominant (red dots). The region (20p
13
-p
11.23
) 
displayed the maximum dominant LOD score of 2.03 and was supported by single-point dominant in 
which the maximum LOD score was > 1 
 
 
 
 
 
 
Figure ‎3.10; Schematic of chromosome 20 showing the region with the maximum LOD value in 
parametric dominant (20P
13
-P
11.23
, in red) with 57 genes, and non-parametric (20p
12.3
-P
11.23
 in green) 
with 46 genes. The over lapping region is shown (within the green and the red brackets). 
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3.7.3 Parametric Linkage Analysis (Recessive) 
The maximum recessive multipoint LOD score obtained was less than 1.1 among all 
chromosomes, except chromosomes 2, 8, 9, 13, 15 & 19 which had no LOD scores above 0 
and chromosome 20, on which the maximum LOD was 1.08 (over 149 SNPs). Part of this 
region was identified in Dominant (Figure ‎3.11).  
The output of Recessive single point analysis has supported the findings of multipoint in all 
chromosomes including chromosome 20, in which 41 SNPs (out of 149), have single point 
LODs > 0.6 in the region of multipoint maximum LOD (Table ‎3.4 ). That has supported the 
region identified in multipoint analysis. 
 
 
 
Figure ‎3.11; Graph showing  a regional plot of chromosome 20 comparing LOD scores obtained using 
multi-point dominant (blue solid line) and recessive (red dots). The region (20p
13
-p
11.23
) displayed the 
maximum dominant LOD score of 2.03, while recessive LOD score is 1.09. 
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Chromosome Maximum 
LODs, npl  
Maximum LODs, 
Dominant  
Minimum 
LODs, npl  
Minimum LODs, 
Dominant   
1 0.22 0.06 -0.7 -3.8 
2 0.02 -0.26 -0.7 -4.0 
3 0.27 0.96 -0.7 -4.0 
4 0.01 0.039 -0.6 -3.9 
5 0.02 -0.26 -0.7 -4.0 
6 0.03 0 -0.7 -4.0 
7 0.22 0.14 -0.5 -2.5 
8 -0.11 -2.10 -0.8 -4.1 
9 -0.02 -1.60 -0.3 -2.4 
10 0.27 0.08 -0.4 -2.2 
11 -0.03 -1.51 -0.5 -3.8 
12 0.04 0.03 -0.8 -4.1 
13 0.02 0.01 -0.6 -3.9 
14 0 -1.2 -0.2 -2.4 
15 0.04 0.03 -0.5 -3.7 
16 0.03 0.04 -0.6 -4.0 
17 1.00 0.36 -0.7 -3.8 
18 0.04 0.07 -0.3 -4.0 
19 0 -1.52 -0.7 -4.1 
20 3.01 2.03 -2.4 -2.1 
21 0 -2.03 -0.19 -2.39 
22 0.01 0 -0.6 -2.6 
X 0.67 0.56 -0.3 -1.4 
Table ‎3.3: A summary of maximum and minimum LODs of nonparametric linkage analysis (npl) and 
dominant analyses for all chromosomes. The first column shows the chromosome number, the second the 
maximum npl LOD, the third the maximum dominant LOD, fourth the minimum npl LOD and sixth the 
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minimum dominant LOD. The maximum npl LOD varies from -0.11 and 1.00 (on chromosomes 8 and 17 
respectively) and minimum LOD varies from -0.2 (on chromosome 14) and -0.8 (on chromosomes 8 & 12). 
Chromosome 20 showed the only significant npl LOD (of 3.01). Maximum dominant LOD vary from 0.96 
and -2.10 (on chromosomes 3 and 8 respectively) and minimum LOD vary from -2.2 (on chromosome 10) 
and -4.1 (on chromosomes 8, 12 & 19). Chromosome 20 has showed the only significant dominant LOD 
(of 2.03). 
 
 
SNPs ID Position 
Mb 
Position 
cM 
npl 
Multipoint 
LOD 
npl  
Single 
point 
LOD 
Dominant 
Multipoint 
LOD 
Dominant 
Single point 
LOD 
Chromosomal 
location 
rs2250711 8.20 22.19 2.840 1.200 2.034 1.152  
rs771943 8.36 23.02 2.940 0.210 2.035 0.196 20p12.3 
rs2223539 8.49 23.69 3.010 1.200 2.035 0.303  
rs2327088 8.71 23.93 3.010 0.000 2.035 0.001  
rs2143267 8.76 23.96 3.010 1.200 2.035 0.303  
rs3848831 8.80 23.98 3.010 1.200 2.035 0.302  
rs756374 8.89 24.04 3.010 1.460 2.035 0.553  
rs724089 9.00 24.11 3.010 1.200 2.035 0.302  
rs953021 9.90 24.65 3.010 1.200 2.035 1.142  
rs725565 9.95 24.68 3.010 1.810 2.035 1.739  
rs2327282 10.38 27.42 3.010 0.900 2.034 0.014  
rs973542 10.64 28.17 3.010 1.030 2.035 0.135  
rs2327302 10.66 28.23 3.010 1.590 2.035 0.686  
rs763383 10.85 28.71 3.010 0.900 2.035 0.015  
rs1028846 10.96 29.01 3.010 2.110 2.034 1.146  
rs726867 11.18 30.67 3.010 1.200 2.034 1.154  
rs3887413 11.75 31.90 3.010 1.640 2.035 1.574  
rs2206798 11.85 32.09 3.010 1.200 2.035 1.153  
rs720489 11.90 32.20 3.010 0.000 2.035 0.001  
rs729552 12.13 32.42 3.010 1.500 2.035 0.598  
rs1099620 12.74 32.80 3.010 1.770 2.035 1.704  
rs2327450 12.93 32.91 3.010 0.190 2.035 0.179  
rs721243 13.17 33.06 3.010 1.610 2.035 0.704  
rs2327790 13.46 33.25 3.010 2.410 2.035 1.444  
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rs1358766 13.86 33.50 3.010 1.200 2.035 0.303  
rs724820 15.02 34.23 3.010 0.500 2.034 0.482  
rs763659 15.74 37.09 3.010 0.000 2.033 0.000  
rs726207 15.96 37.41 3.010 0.600 2.034 0.585  
rs718610 16.21 37.82 3.010 0.000 2.034 0.000  
rs2144883 16.27 37.97 3.010 1.500 2.034 0.598  
rs1080954 16.45 38.38 3.010 1.200 2.035 1.153  
rs720592 16.45 38.38 3.010 1.500 2.035 0.598  
rs720593 16.45 38.38 3.010 1.500 2.035 0.598  
rs2328024 16.60 38.72 3.010 1.510 2.035 1.441  
rs724053 16.93 39.08 3.010 0.000 2.035 0.000  
rs956110 17.02 39.18 3.010 0.900 2.035 0.013  
rs2010316 17.08 39.24 3.010 1.510 2.035 1.441  
rs2010307 17.08 39.24 3.010 0.000 2.035 0.000  
rs1078530 17.08 39.24 3.010 1.510 2.035 1.441  
rs726256 17.40 39.60 3.010 1.200 2.035 0.304  
rs16823 17.74 39.96 3.010 0.300 2.035 0.289  
rs1073052 17.79 40.02 3.010 0.600 2.035 0.585  
rs2024673 18.12 40.37 3.010 0.600 2.035 0.585  
rs2328245 18.14 40.40 3.010 2.110 2.035 1.153  
rs2328293 18.31 40.61 3.010 0.000 2.035 0.000  
rs1535487 18.94 41.86 3.010 2.410 2.035 1.442  
rs2328361 19.03 42.05 3.010 1.800 2.035 1.734  
rs1074615 19.13 42.25 3.010 0.300 2.035 0.289  
rs2328384 19.37 42.72 3.010 1.510 2.035 1.441  
rs2328410 19.49 42.98 3.010 0.300 2.035 0.289  
rs2328411 19.50 42.98 3.010 0.300 2.035 0.289  
rs2328412 19.50 42.98 3.010 1.420 2.035 1.353  
rs725862 19.58 43.14 3.010 1.200 2.035 0.304  
rs720436 19.60 43.19 3.010 1.280 2.035 0.376 P11.23 
Table ‎3.4; The output data of the linkage analyses on chromosome 20 (at the region with over lapping 
maximum LODs of both, non-parametric linkage (npl) and dominant). First column shows single 
nucleotide polymorphisms (SNPs) ID, second the position in mega base (Mb), and third the position in 
centiMorgan (cM). Fourth column for npl multipoint LOD scores, fifth for npl single point LOD, sixth for 
dominant multipoint LOD, seventh for dominant single point LOD and eighth for chromosomal location. 
The first and last markers showing maximum LODs (in the table) are highlighted in yellow. A full output 
data of chromosome 20 are in the Appendix C1a).  
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3.8 Haplotype Analysis (Appendix A1k) 
A Haplotype Study (described in ‎3.2.7) was then undertaken among all individuals in the 
region of maximum LOD score on chromosome 20. The aim of the analysis was to identify 
any significant evidence for biased transmission of one of the haplotypes linked to the 
disease. The study has been performed using Merlin (--best) as described in (‎3.3.3.1). The 
haplotypes of each founder have been labelled in alphabetical formats; A & B for individual 
(II-4), C & D for individual (I-2), E & F for individual (II-1), G & H for individual (III-1), I 
& J for individual (I-12) and K & L for individual (III-4) (Figure ‎3.12).  
Using the (Merlin.chr) output file (described in ‎3.3.3.1), a comparison between the 
haplotypes of affected and unaffected individuals was carried out by following the 
transmission of the (alphabetically labelled) haplotypes across generations (manually on 
Excel worksheet). To identify the disease haplotype, the inheritance of each alphabetic label 
was looked for, seeking for what has only been inherited by the affected individuals and 
assuming it as a disease haplotype. The study has shown several crossings over (defined 
in ‎3.1.2 ), between paternal and maternal haplotypes among the siblings and that have 
increased and/or decreased the LOD score in several regions (Table ‎3.5). 
The genotype of affected individual (I-1) has been labelled as C D; the same C haplotype has 
been inherited by her affected daughter (II-2) and her (disease carrier) son (II-3) (who 
transferred it to his daughter (III-5). The same C haplotype was inherited by the next 
generation female, (III-2) who has transferred it to all her affected children (IV-3, IV-6, IV-1 
and IV-7). Some of her unaffected children have also inherited this haplotype (IV-4 and IV-
5), and are assumed to be carriers. Only individual (IV-2) of this nuclear family has not 
inherited the C haplotype (as well as his maternal uncle (III-3) and his son (IV-8). Therefore 
the data of these three individuals (IV-2, III-3& IV-8) have been used for any comparison 
between family members to identify linkage to the disease haplotype. Since C haplotype was 
shown to be inherited by the affected individuals (and carriers) only at a specific region (from 
2.27Mb to 12.13Mb) which is about 10 mega bases (with 53 genes), it could be assumed that 
the disease haplotype is linked to this region[83]. 
101 
 
3.8.1 Haplotype vs. Linkage Data 
The haplotype analysis demonstrated that the assumed disease region began at position 
2.27Mb on chromosome 20, and ends at 12.13 Mb. Since npl maximum LODs started at 
position 8.49 Mb, the region above will be ignored. In addition the maximum LODs in both 
Dominant and npl analyses were maintained until 19.60 Mb, but the second crossing over 
was at 12.13Mb, thus the region below will be ignored. That will make the region of interest 
to be “between 8.49Mb and 12.13Mb” because it is the region where the overlapping between 
haplotype and npl maximum LODs occurs. That region is 3.64 Mb long (20p
12.1
 – 20p12.3) 
and comprises 10 genes. These genes are PLCβ1, PLCβ4, LAMP5, PAK7, ANKRD5, 
SNAP25, MKKS, C20orf94 (later known as LOC128710 or SLX4IP), JAG1 and BTBD3, 
(Figure ‎3.12) and (Table ‎3.5). 
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Figure ‎3.12; Family tree, showing a portion of the output of the haplotype study using Merlin software. 
The software has labelled the haplotypes of each founder in alphabetical format. A & B for individual II-
4, C & D for individual I-2, E & F for individual III-4, G & H for individual II-1, I & J for individual III-
1 and K & L for individual I-1 (estimated). The assumed disease allele C in (I-2) has been inherited by her 
daughter (II-2) and her son (II-3). Both children have transferred the same allele to their daughters (III-2 
& III-5 respectively). Individual (III-2) has transferred the same allele to her 6 out of her 7 children (IV-
1, IV-3, IV-4, IV-5, IV-6 and IV-7). Only (IV-2) has not inherited the assumed disease allele C, and has 
shown‎a‎ clear‎ “maternal”‎ crossing‎ over‎ at‎ third‎haplotype. Thus the region after this crossing over is 
assumed to be linked with the disease. More details are in (Table ‎3.5) below. 
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Table ‎3.5: Haplotype study of some members of family #1 (across part of chromosome 20). First column 
(position Mb) shows position in mega base (Mb), second (linkage analyses npl), non-parametric linkage 
position Linkage Analyses Individuals haplotypes 
Mb npl  Dom  II-4 (F) I-1 (F) II-2 
(10,20) 
III-2 
(2,16) 
IV-2 
(1,19) 
III-3 
(2,16) 
0.12 1.57 1.611 A:B C:D C:K C:G C:I K:H 
0.69 1.64 1.69 A:B C:D C|K C|G C|I K|H 
1.18 1.91 1.803 A:B C:D C:K C:G C:I K:H 
2.27 2.25 1.881 A:B C:D C|K C|G G/I K\G 
3.68 2.33 1.958 A:B C:D C|K C|G G|I K|G 
4.25 2.36 2.022 A:B C:D C|K C|G G|I K|G 
4.26 2.36 2.022 A:B C:D C|K C|G G|I K|G 
4.33 2.36 2.027 A:B C:D C|K C|G G|I K|G 
6.44 2.07 2.024 A:B C:D C|K C|G G|I K|G 
6.53 2.07 2.024 A:B C:D C|K C|G G|I K|G 
6.79 2.07 2.025 A:B C:D C|K C|G G|I K|G 
6.92 2.07 2.025 A:B C:D C|K C|G G|I K|G 
6.96 2.07 2.025 A:B C:D C|K C|G G|I K|G 
7.12 2.07 2.026 A:B C:D C|K C|G G|I K|G 
7.17 2.07 2.026 A:B C:D C|K C|G G|I K|G 
7.22 2.08 2.026 A:B C:D C|K C|G G|I K|G 
7.25 2.09 2.026 A:B C:D C|K C|G G|I K|G 
8.20 2.84 2.032 A:B C:D C|K C|G G|I K|G 
8.36 2.94 2.035 A:B C:D C|K C|G G|I K|G 
8.49 3.01 2.035 A:B C:D C|K C|G G|I K|G 
8.71 3.01 2.035 A:B C:D C|K C|G G|I K|G 
8.76 3.01 2.035 A:B C:D C|K C|G G|I K|G 
8.80 3.01 2.035 A:B C:D C|K C|G G|I K|G 
8.89 3.01 2.035 A:B C:D C|K C|G G|I K|G 
9.00 3.01 2.035 A:B C:D C|K C|G G|I K|G 
9.90 3.01 2.035 A:B C:D C|K C|G G|I K|G 
9.95 3.01 2.035 A:B C:D C|K C|G G|I K|G 
10.38 3.01 2.034 A:B C:D C|K C|G G|I K|G 
10.64 3.01 2.035 A:B C:D C|K C|G G|I K|G 
10.66 3.01 2.035 A:B C:D C|K C|G G|I K|G 
10.85 3.01 2.035 A:B C:D C|K C|G G|I K|G 
10.96 3.01 2.034 A:B C:D C|K C|G G|I K|G 
11.18 3.01 2.034 A:B C:D C|K C|G G|I K|G 
11.75 3.01 2.035 A:B C:D C|K C|G G|I K|G 
11.85 3.01 2.035 A:B C:D C|K C|G G|I K|G 
12.13 3.01 2.035 A:B C:D C|K C|G G|I K|G 
12.74 3.01 2.035 A:B C:D C|K C|G G|I C/G 
12.93 3.01 2.035 A:B C:D C|K C|G G|I C|G 
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analysis (npl) LODs & third (linkage analyses dominant) dominant LODs. The next columns show the 
haplotypes of the individuals. Column four is for II-4 haplotypes, five II-2 haplotypes, six III-2 haplotypes 
and seven III-3 haplotype. Merlin software has marked founders with (F). For non-founders, parents ID 
added in brackets (instead of F). Haplotype pairs are separated by a | for no recombination, : for no 
information on recombination and /, \, + for recombination (in the maternal, paternal & both haplotype 
respectively). At position 8.49 Mb the npl showed maximum value (highlighted in yellow) and thus the 
region after that assumed as significant. Crossing over in individual III-3 occurred at 12.74 Mb 
(highlighted in blue), led him inherit C haplotype again and thus the region below was counted as 
unlinked. A full haplotype data of chromosome 20 are in the Appendix C1b) 
 
 
 
Figure ‎3.13: Summary of the regions of interest identified by non-parametric linkage analysis (npl) and 
Haplotype studies and number of genes located in each region. (A) Region of 11.1 Mega base (Mb) 
showed maximum LODs obtained by npl and contains 46 genes. (B) Region of 10.4 Mb showed linkage 
with disease haplotype and includes 51 genes. (C) Region of 3.6 Mb showed overlapping of both npl and 
Haplotype analyses and includes 10 genes. 
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3.9 Conclusion 
There are several conclusions to be drawn from the results in this chapter. As mentioned in 
chapter 2, blood samples from various family members have been obtained at different times. 
Although the similarity of old and new sample has been indicated after obtaining the 
genotyping data of SNPs, further data check steps also have confirmed that finding. In GRR 
output the relationship detected by the software showed the IBS between old and new DNA 
to be 2.00, as if they are identical twins. Furthermore, after performing all quality control 
steps the quality of the data was good enough to be considerable for using in GWLA.  
Although only one old DNA sample has been directly compared to a new one the finding that 
the output was identical for both indicates that reliable data can be obtained from old DNA 
samples, although it does not confirm that all old DNA samples will provide reliable data. 
Further direct comparisons of old and new samples would be needed to provide a good 
indication as to the reliability of data from old DNA samples. 
In the linkage analyses, the half of 20p closest to the telomere has shown significant LOD 
score in npl from the beginning of the chromosome. Although the first 8 mega bases have not 
given the highest score, the next 19 mega bases showed the highest score of 3.01 (from 
8.49Mb). After a complete study of the output all three linkage analyses (npl, dominant & 
 
Figure ‎3.14: The 10 genes in the region of 3.6 Mega base (Mb) where non-parametric linkage analysis (npl) 
maximum LOD and Haplotype analyses overlapped. These‎ genes‎ are‎ PLCβ1,‎ PLCβ4,‎ LAMP5,‎ PAK7,‎
ANKRD5, SNAP25, MKKS, C20orf94 (later known as LOC128710 or SLX4IP), JAG1 and BTBD3 
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recessive), and performing haplotype analysis, I came to a conclusion that the linkage region 
between disease locus and markers could be the overlapping region between haplotype and 
npl highest LODs which is 3.64Mb long (between 8.49Mb and 12.13Mb) and comprised 10 
genes at 20p
13.3
-P
12.1
 (Figure ‎3.13) and (Table ‎3.5). 
In contrast, the big region (34.7Mb) with a significant LOD (8.49Mb to 43.19Mb) could 
suggest more than just a single mutation in a candidate gene. This could indicate a major 
chromosomal re-arrangement rather than a point mutation in a single gene. However, the 
Karyotyping of the index patient reveal 46 chromosomes of normal shape and size; although 
such analyses would not detect small deletions, which might also explain the high LOD score 
observed over the long distance in chromosome 20p. 
To conclude on the LOD score across all chromosomes (other than chromosome 20), the 
maximum npl was 1.0 on chromosome 17 and maximum dominant was 0.96 on chromosome 
3. Minimum npl was -0.8 on chromosomes 8 and 12 and minimum dominant was -4.1 on 
chromosomes 8, 12 and 19. However npl LOD score on chromosome 20 showed the 
maximum (3.01) and minimum (-2.4), which are the highest and the lowest value across all 
chromosomes (Table ‎3.3).  This could add more to our understanding of what exactly 
occurred in that region. 
  
 
 
 
 
 
 
 
 
107 
 
Chapter 4 Microarray and GWLA of Family #2 
This chapter analyses the data of a second family (family #2) which has been introduced to 
my department after publishing the data obtained during my MPhil study [181]. Several members 
of this new family have shown similar signs and symptoms to that of family #1 (Euthyroid MNG 
of adolescent onset) and same histopathology picture in some members of both families.  
Linkage analyses will be performed on this family as in chapter 4. Then both families will be 
merged and linkage analyses will be run on the merged data. 
   
4.1 Family #2 History 
4.1.1 Index patient 
The family tree of family #2 is shown in (Figure ‎4.1). The index patient (III-1, in the family 
tree), a boy (D.O.B 4/8/90) has been refereed (at age 18 years) to the Paediatric Endocrine 
service based at the University Hospital of Wales, Cardiff, with clinical evidence of MNG 
(bilateral thyroid nodules), which were noted previously at age 16 years, he was found to be 
euthyroid when his thyroid function was tested.  
The boy had been born at 39 weeks gestation by normal vaginal delivery, weighing 8lb 8ozs. 
The prenatal history was uneventful and the neurodevelopment had been within normal limits. 
The boy was of average size at birth. 
Ultrasound scan of the neck was used to identify thyroid nodules. The scan indicated that 
although cystic, the nodules were complex. Previous ultrasound reports (03/2007, 10/2007 & 
03/2008) show similar findings with thyroid lobe (cystic containing solid elements), measuring 
4.1 cm on the left and 3.4 cm on the right. 
At age 18 he underwent thyroidectomy and the histopathological picture showed multiple 
papillary adenomatosis. Since that age he is euthyroid, receiving daily replacement of thyroxine. 
4.1.2  Family history 
The Index patient’s sister (III-2) (D.O.B 1/7/97) has been referred (at age 11 years) to the 
Paediatric Endocrine service based at the University Hospital of Wales, Cardiff, with a thyroid 
swelling.  Ultrasound scan (at age 8 years) confirmed the presence of a Multi-nodular thyroid 
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gland. Thyroid peroxidase antibodies were negative at that age. Subsequent follow up thyroid 
ultrasound scan at age 11 years continued to show heterogeneous nodularity of the thyroid gland, 
particularly in the right lobe. Some of the previous nodules have changed in appearance and 
reduced in size. There was no evidence of microcalcification (associated with PTC). She 
appeared to be clinically and biochemically euthyroid. At age 14 years a dramatic expansion in 
the right lobe of her thyroid recommended thyroidectomy be performed with some urgency.  
The father (II-2) (DOB; 18/5/69) was found to have sudden onset of goitre at age 22 years. 
The thyroid histopathology revealed Multi-nodular goitre with numerous hypoplastic nodules. 
One of the nodules had infarcted either spontaneously, or following a Fine Needle Aspirate 
(FNA). The other nodules 10 to 20 in number, were well circumscribed, and are composed of 
follicles of varying size, with papillary infolding. Some were more cellular, with crowded oval 
nuclei, but none show the nuclear features of papillary carcinoma. The histopathological picture 
(multiple papilloid adenomas) strongly resembles that seen in family #1. He underwent 
thyroidectomy and is currently euthyroid, receiving daily replacement with thyroxine. 
The boy’s paternal grandmother (I-2), (DOB; 17/12/45) had non-toxic nodular goitre at age 
10 and underwent thyroidectomy at age 17 years. Her niece (II-5), (DOB 5/2/53) underwent total 
thyroidectomy at age 27 years. Her 2 sisters (I-4 & I-6) underwent thyroidectomy for undefined 
reason. The boy’s paternal uncle (II-4) is also affected (MNG) as well as his daughter (III-4), 
(DOB 2000) who had thyroid swelling (MNG) at age 5 years. His mother (II-1), (DOB 1/1/69) is 
unaffected. 
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4.2 Aim 
To determine whether the genes predisposing to goitre and thyroid cancer have any similarity 
in these two families, displaying similar clinical and histological features.  
 
 
Figure ‎4.1; Tree of Family #2. Affected members are in black boxes. The Index patient III-1 was 
referred with multinodular goitre (MNG). Thyroid ultrasound of his 11 year old sister III-2 confirms 
MNG, but no evidence of PTC. His father II-2 has sudden goitre at age 22 years, with 
histopathological picture resembles to what seen in one member in family #1 (III-2). His paternal 
grandmother (I-2) had non-toxic MNG, her niece and 2 sisters underwent thyroidectomy. The‎boy’s 
paternal uncle (II-4) is also affected (MNG) as well as his daughter (III-4), (MNG). The‎boy’s‎ mother 
(II-1) is unaffected. 
110 
 
4.3 GeneChip® Mapping Assay Materials, Methods & Results 
4.3.1 DNA Extraction from peripheral lymphocytes 
Blood samples from 6 members of family #2 (green box in family tree (Figure  4.1)), were collected 
with informed consent (EDTA vacutainers Beckton Dickenson). DNA was extracted, quantified, digested 
with Xba1 restriction enzymes, the linkers then were ligated (as described in sections 2.3.3 to 2.3.7). The 
same steps were performed in parallel on the reference genomic DNA 103 (described in 2.2.4). 
4.3.2 PCR  
Eight PCR reactions have been performed for each DNA sample, all were quality checked 
using 2% agarose gel electrophoresis (Figure ‎4.2), prior to purification and adjustment of the 
concentration of the purified PCR product (all as described in sections 2.3.8 - 2.3.10). 
4.3.3 Fragmentation 
Subsequent fragmentation of all samples was performed as previously described (sections 
2.3. 12) and analysed by 4% agarose gel electrophoresis (Figure ‎4.3).  
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Figure ‎4.2; PCR products from individuals III-1 and III-2 analysed by agarose gel electrophoresis and 
ethidium bromide staining. The first lane (Lad) contains the 100bp ladder, the second lane (-ve) contains 
the negative control (master mix without DNA template), lanes 3-7 (III 1) show the PCR products of 
individual III-1 and lanes 8-12 (III 2) with DNA sample of individual III-2. Lanes 13 & 14 (C) show the 
amplicons‎obtained‎using‎“reference‎genomic‎DNA‎control‎103”‎provided‎with‎the‎kit.‎Gel‎picture‎shows‎
a‎smear‎of‎PCR‎product‎similar‎to‎the‎example‎provided‎in‎the‎manufacturer’s‎protocol 
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Figure ‎4.3; Fragmentation products of DNA for individuals III-1 and III-2 analysed by agarose gel 
electrophoresis and ethidium bromide staining. The first lane (Lad) contains the 100bp ladder, the second 
lane (X) empty, lanes 2 & 3 (III 1) for sample of individual III-1, lanes 5 & 6 (III 2) for sample of 
individual III-2‎and‎lanes‎7‎&‎8‎(C)‎for‎“reference‎genomic‎DNA‎control‎103”‎provided‎with‎the‎kit.‎A‎
smear of PCR products between 100-25 bp is shown, similar to the example in the manufacturer’s‎
protocol.  
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4.4 Genome Wide Linkage Analysis, Family #2  
4.4.1 Data Reception 
The hybridization quality has been checked and then genotyping data was imported to Excel 
worksheet (as described in section 3.3.1, for family #1). 
 Check Data Drop Rates per Individual, SNPs and Batches 4.4.1.1
The quality control checks were performed as in section 3.3.2. The standard for family #1 
regarding omitting SNPs was; “any SNP giving No Call for more than 4 individuals (out of 
19) was omitted (i.e. SNPs show 21% No Call, have been omitted). To keep the same 
standard for family #2, any SNP was giving No Call for more than 1 individual, out of 6 was 
omitted, (i.e. SNPs show 17% No Call, have been omitted). Total number of SNPs after 
omission was 9,803 (96%). A further 100 SNPs with unknown chromosomal location were 
removed. Following all quality control analyses, all individuals were included and 9,703 
SNPs (95%) remained for further study.  
 Data Streamlining and Errors check 4.4.1.2
The data then were prepared to be in PedFile format as described in section (‎3.5.1). That was 
followed by streamlining as described in (‎3.5.2).  
Mendelian errors have been analysed using PedCheck software and 156 inconsistencies have 
been detected, among 122 SNPs, 105 of which were on chromosome X. These SNPs have 
been removed from the data (as in ‎3.5.2 & ‎3.5.3.1). That reduced the number of returned 
SNPs to 9,581 SNPs which is equivalent to 94% of the total SNPs at the start. 
Mendelian errors have also been analysed on the remaining 9581 SNPs, no error was 
detected. However a further 2 SNPs (on chromosome 2) have shown invalid genotypes (in 
PLINK .hh file) and thus have been removed. That has reduced the number of returned SNPs 
to 9,579 SNPs which is equivalent to 94% of the total SNPs at the start. 
The data of the remaining SNPs on chromosome X have been analysed for Mendelian error 
by both PedCheck and PLINK. No further errors were detected. 
IBS Mean was checked using GRR software among the family members as described in 
section (‎3.5.4), no variation was obtained in the output indicating no labelling or relationship 
errors (Figure ‎4.4).  
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Figure ‎4.4; Screen shot of graphical representation of relationship (GRR) software output for family #2. 
Three clusters were obtained by studying the inheritance of the single nucleotide polymorphism (SNP) 
between the relatives.  The software calculates the mean on (x-axis) and the standard deviation (stDev) on 
(Y-axis) for all SNP calls to create these clusters. Blue clusters indicate unrelated, red indicate sib-pairs and 
yellow for parent-offspring. IBS mean value for sib-pairs and parent-offspring is higher (more than 1.7) 
indicating inheritance of the same SNPs more than the unrelated who shows IBS mean (<1.6).  
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 Data preparation for LINKAGE Analysis 4.4.1.3
PedFile format has been changed from numerical allele code to A C G T, as in family #1 
(‎3.5.5).  The data of all negative strand SNPs have been flipped (as in ‎3.5.5.2). Family #2 
PedFile was then merged with HapMap data and a further 21 SNPs have been removed from 
the data due to merge error, leaving 9,558 SNPs, (equivalent to 94% of the total SNPs), to be 
merged with HapMap data. MDS analysis was then run on the merged data (as described in 
sections ‎3.5.5.4). Plotting the first two dimensions suggested that the family #2 belongs to 
European (CEU) population as does family #1 (Figure ‎4.5). Thus the data of other 
populations have been removed (as in 3.5.7.5), leaving the PedFile with family and CEU data 
only. 
Chromosomal bp position has been changed to cM (as in 3.5.7.6), which has led to the loss of 
further 93 SNPs as no cM position was found. That has returned 9,465 SNPs, (equivalent to 
93% of the total SNPs). 
 Data preparation (for Merlin software) 4.4.1.4
Further changes have been made to suit the data for Merlin software (as described in 
section ‎3.5.6). The allele calls in PedFile have been changed from A C G T to 1 2 3 4 
respectively (as in 3.5.8.1). In addition ages for all individuals have been added in the PED 
file (as in 3.5.8.2) .Data file has been also created (as in 3.5.8.3). The files were then ready 
for Linkage analysis with 9,465 SNPs, (equivalent to 93% of the total SNPs).   
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4.5 LINKAGE Analysis by Merlin (Family #2, only) 
As in family #1, some parameters in family #2 (described in family history,‎4.1) are not clear 
such as the age at onset, the mode of transmission and disease penetrance as described in 
family #1 (in 3.6). Thus non-parametric linkage analysis has been chosen to be the primary 
analysis in this study. Parametric linkage analysis “Dominant model” was chosen to be the 
secondary analysis and recessive model has also been performed (as described in ‎3.6). 
Both non-parametric and parametric analyses have been performed in multi and single point 
(as described in sections ‎3.6.1 &‎3.6.2). 
Figure ‎4.5; Screen shot of multidimensional scaling (MDS) output showing dimension1 (Y axis) plotted 
against dimension 2 (X-axis) for data from family #2 and HapMap. The scatter plot shows three clusters 
one for Chinese (CHB) & Japanese (JPT) population (red), one for Yoruba (YRI) population (yellow) and 
one for Caucasian (CEU) population (black). Family #2 data (blue) are shown to be closest to the cluster of 
the Caucasian (European) population. 
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4.6 GWLA of merged data of (family #1 and family #2) 
To confirm that no any information has been missed during examining the two GWLA data 
sets (of family #1 and family #2), both families have been analysed as one set. The data of 
both families have been merged and GWLA has been performed on them in one go. That will 
increase the power of the analysis by having larger number of individuals to be analysed.  
4.6.1 Different between the SNPs in the data of family #1 and family #2 
The data of family #1 contain 9,111 SNPs and of family #2 contain 9,465 SNPs with 8,935 
SNPs common to both. One hundred and seventy six SNPs are in family #1 but not family #2 
data, while 530 SNPs are in Family #2 but not in family #1 data. 
4.6.2 Merge the data of family #1 with data of family #2 
The data for all members of family #1 and family #2 have been merged after the step of 
preparing for Merlin software as seen in section (‎3.5.6). Thus both data have passed the steps 
of quality check and streamlining. A data of 9,641 SNPs have been merged in both family by 
PLINK. That is the data of all SNPs in family #2 plus the data of 176 SNPs in family #1 only. 
Positions have been changed to cM (as described in ‎3.5.5.6 ), and data file has been created 
(as described in 3.5.8.3) 
4.6.3 Linkage Analysis by Merlin (on merged data of both families) 
Both parametric and non-parametric analyses have been performed in multi and single point 
(as described in sections 3.4.1 & 3.4.2).  
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4.7 RESULTS (Family #2 only) 
4.7.1 Non- Parametric Linkage Analysis 
I have viewed the npl on chromosome 20 and all other chromosomes in general then focused 
on the region of interest in family #1 (described in ‎4.7.1.2).   
 Npl for chromosome 20 and others 4.7.1.1
The maximum (multipoint) npl LOD score for chromosome 20 is 0.41, at a region close to 
the P-Telomere of the chromosome, but upstream from the region of the interest in family #1 
(described in ‎4.7.1.2).  
Two SNPs have single point LODs of 0.6 & 0.15 at the same region of multipoint maximum 
LOD (Table ‎4.1) and (Figure ‎4.6). That has supported the region identified in multipoint 
Analysis. 
In addition the maximum LOD scores on other chromosomes were 0.90 among chromosomes 
2, 3, 4, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 21 & 22, while maximum LOD scores on 
chromosomes 1, 19 & X were 0.03, 0.57 & 0.29 respectively. In contrast no LOD score > 0.0 
value was obtained for chromosomes 5, 6, 7 & 12. (Figure ‎4.7) showed the maximum and 
minimum LODs on each chromosome. 
4.7.1.1.1 Comment on result 
The small number of individuals analysed in family #2 (only 6 individuals) decreases the 
strength of any independent study of this family, as seen above with maximum LOD score of 
below 1 in all chromosomes (Figure ‎4.7). Therefore analysing family #2 data was only 
expected to add more to what has been found in family #1. Thus I aimed to focus more on the 
results of the analyses at the region of interest in family #1. 
 The region of interest in Family #1 4.7.1.2
The region in family #1 which has shown overlapping between haplotype and npl maximum 
LODs is between 8.49Mb and 12.13Mb and is 3.64 Mb long (20p
12.1–p12.3) and comprises 10 
genes (as described in ‎3.7.1‎3.8.1).  
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 Npl of family #2 at the region of interest in family #1 4.7.1.3
The region of interest in family #1 (described in ‎4.7.1.2) was focused on and the npl 
Multipoint analysis of family #2 at that region showed LOD score of -0.03 among the whole 
region (Figure ‎4.6).  
 
 
 
 
 
 
 
 
 
Figure ‎4.6; Graph showing a regional plot of chromosome 20 comparing LOD scores obtained using multi-point 
non-parametric linkage analysis (npl) (blue solid line) and single point npl (red dots). The maximum LOD score 
was 0.41, at a region close to the P-Telomere of the chromosome, but upstream from (20p
12.3
-p
11.23
, where 
maximum LOD obtained in family #1), and was supported by single-point npl in which the maximum npl LOD 
score was 0.6.  
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Figure ‎4.7; Graph showing the maximum and minimum LOD scores (of all chromosomes), 
obtained by non-parametric linkage analysis on family #2 data. All chromosomes showed 
maximum LOD score <1.00, including chromosome 20 where the maximum LOD score in family 
#1 was obtained 
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SNPs Position 
cM 
Multipoint Single 
Point 
rs1858597 0.40 0.41 0.15 
rs722829 0.49 0.41 0.6 
rs1342841 0.68 0.4 0 
rs2317024 3.52 0.28 -0.29 
rs1923876 6.69 -0.16 0 
rs2013961 8.55 -0.27 0 
rs1109010 8.71 -0.28 0 
rs3848810 9.84 -0.33 0 
rs910652 10.28 -0.35 -0.29 
rs674110 10.28 -0.35 0 
rs910952 11.47 -0.4 0 
rs2422925 11.69 -0.41 -0.29 
rs3904872 11.71 -0.41 -0.29 
rs3904864 11.84 -0.42 -0.12 
rs1411296 17.96 -0.42 -0.12 
Table ‎4.1; LOD scores of part of chromosome 20 of multi vs. Single point non-parametric analyses (npl). 
First column with a list of single nucleotide polymorphism (SNPs), second (position cM), their position in 
centiMorgan (cM), third (multipoint), multipoint npl LOD score and fourth (single point), single point 
npl LOD scores. Two peaks of single point LODs (first 2 rows), supporting Multipoint npl (family #2 
only). 
 
 
4.7.2 Parametric Linkage Analysis (Dominant) 
I have viewed the npl on chromosome 20 and all other chromosomes in general then focused 
on the region of interest in family #1 (described in ‎4.7.1.2).   
 Dominant analysis for chromosome 20 and others 4.7.2.1
The maximum dominant multipoint LOD for chromosome 20 is 0.59, at a region closed to 
the P-Telomere, but upstream from the region of the interest in family #1 (described 
in ‎4.7.1.2).  
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Two SNPs have single point LODs of 0.29 & 0.59 at the same region of multipoint high LOD 
(Figure ‎4.8). That has supported the region identified in multipoint Analysis. 
In addition the maximum LOD scores on other chromosomes were 0.89 among chromosome 
5, while chromosomes 2, 3, 4, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 20, 21 & 22 showed 
maximum LOD scores of 0.59. In addition chromosome 19 showed Maximum LODs of 0.30. 
In contrast no LOD > 0.0 value was obtained for chromosomes 1, 6, 7 & 12. Chromosome X 
showed 0.0 values of both maximum and minimum LODS. (Figure ‎4.9) and (Table ‎4.2) 
showed a summary of LODs on all chromosomes.  
 Analysis of family #2 at the region of interest in family #1 4.7.2.2
The region of interest in family #1 (described in ‎4.7.1.2) was focused on and the dominant 
multipoint analysis of family #2 at that region showed LOD score of -1.55 among the whole 
region (Figure ‎4.8).  
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.8; Graph showing a regional plot of chromosome 20, comparing LOD scores obtained 
using multi-point dominant (blue solid line) and single point dominant (red dots), linkage analysis. 
The maximum LOD score was 0.59, at a region close to the P-Telomere of the chromosome, but 
upstream from (20p
12.3
-p
11.23
, where maximum LOD obtained in family #1), and was supported by 
LOD score of 2 SNPs of single point analysis single (0.29 & 0.59). 
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Figure ‎4.9; Graph showing the maximum and minimum LOD scores (of all 
chromosomes), obtained by dominant linkage analysis on family #2 data. All 
chromosomes showed maximum LOD score <1.00, including chromosome 20 
where the maximum LOD score in family #1 was obtained. 
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Chromosome Maximum 
LODs 
Minimum 
LODs 
1 -0.73 -1.55 
2 0.59 -1.55 
3 0.59 -1.55 
4 0.59 -1.55 
5 0.89 -1.55 
6 -1.34 -1.55 
7 -1.34 -1.55 
8 0.59 -1.55 
9 0.59 -1.55 
10 0.59 -1.55 
11 0.59 -1.55 
12 -1.29 -1.55 
13 0.59 -1.5 
14 0.59 -1.5 
15 0.59 -1.55 
16 0.59 -1.55 
17 0.59 -1.55 
18 0.59 -1.55 
19 0.3 -1.5 
20 0.59 -1.55 
21 0.59 -1.55 
22 0.59 -1.5 
X 0 0 
Table ‎4.2; Maximum and minimum LOD scores of dominant analysis for all Chromosomes. First column 
(chromosome) shows chromosome ID, second maximum LOD and third minimum LOD. Maximum LOD 
score is 0.59 across most chromosomes  
 
 
4.7.3 Parametric Linkage Analysis (recessive, multipoint) 
I have viewed the npl on all chromosomes in general then focused on the region of interest in 
family #1, on chromosome 20, (described in ‎4.7.1.2).   
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 Recessive analysis for all chromosomes 4.7.3.1
The maximum LOD scores on all chromosomes were; 0.28 among chromosomes 1, 5, 6, 7, 
12 & 20, while chromosomes 2, 3, 4, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 21 & 22 showed 
maximum LODs of 0.35. In addition chromosomes 19 & X showed maximum LODs of 0.30. 
The minimum LOD scores were <-2.0 in all chromosomes, as summarised in (Figure ‎4.9).  
 Analysis of family #2 at the region of interest in family #1 4.7.3.2
The region of interest in family #1 (described in ‎4.7.1.2) was focused on and the recessive 
multipoint analysis of family #2 at that region showed LOD score of 0.28 among the whole 
region (Figure ‎4.10). Different from the results in npl and Dominant of this family, the 
maximum recessive multipoint LOD for chromosome 20 (LOD = 0.28), was away from the 
P-Telomere and closer to the region of the interest in family #1.  
Twenty six SNPs have single point LODs > 0.28 at the same region of multipoint high LOD 
(Figure ‎4.10). That has supported the region identified in multipoint Analysis. 
The maximum recessive LOD score across all chromosomes was <1 while minimum was ~ -
2 (Figure ‎4.11). 
 
 
 
Figure ‎4.10; Graph showing regional plot of chromosome 20 comparing LOD scores obtained 
using multi-point recessive (blue solid line) and single point recessive (red dots). The maximum 
LOD score was 0.28 obtained at region away from the P-Telomere and closer to the region of 
the interest in family #1. Single point LODs were > 0.28 and have supported the Multipoint. 
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Figure ‎4.11; Graph showing the maximum and minimum LOD scores (of all 
chromosomes), obtained by recessive linkage analysis on family #2 data. All chromosomes 
showed maximum LOD score <1.00, including chromosome 20 where the maximum LOD 
score in family #1 was obtained. 
Figure ‎4.12: Graph showing non-parametric linkage (npl) LODs of the data of Family #1 (red line) vs. 
Family #2 (blue line) on chromosome 20. Family #2 data show maximum LOD score at a region close 
to the P-Telomere of the chromosome, but the this region is not where maximum LOD obtained in 
family #1. Thus family #2 data do not support the findings in family #1  
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4.7.4 RESULTS (merged data of family #1 & #2) 
 Non-parametric Linkage Analysis 4.7.4.1
I have viewed the npl on chromosome 20 and all other chromosomes in general then focused 
on the region of interest in family #1 (described in ‎4.7.1.2).   
4.7.4.1.1 Npl for chromosome 20 and others  
The maximum multipoint npl LOD score for chromosome 20 is 2.04, at a region closed to the 
P-Telomere, but upstream from the region of the interest in family #1. Another region with 
LOD score of 2.00 downstream from the region of interest in family #1.  
Three SNPs have single point LODs >2.0 and they are; rs2327790 at 33.25 cM with LOD 
score of 2.7, rs1028846 at 29.01cM and rs1535487 at 41.86cM, both provide LOD score of 
and 2.4. Further 23 SNPs have LODs > 1.0 (out of 58 SNPs) at the same region of maximum 
multipoint LOD score (Figure ‎4.13). That has supported the region identified in multipoint 
analysis. 
In addition the maximum LOD scores on other chromosomes were between 0.12 & 0.17 
among chromosomes 1, 9, 10, 11, 13, 15 & 22, while maximum LOD scores on 
chromosomes 2, 3, 8 & X were 0.67, 0.59, 0.84 & 0.97 respectively. In addition maximum 
LOD scores between 0.21 and 0.31were obtained on chromosomes 4, 14, 16, 18 & 21. In 
contrast only chromosome 5 showed maximum LOD score of <0.0, while maximum LOD 
scores of < 0.1 were obtained for chromosomes 6, 7, & 12 & 19, as seen in (Figure ‎4.14). 
4.7.4.1.2 Analysis at the region of interest in family #1 
The region of interest in family #1 (described in ‎4.7.1.2) was focused on and the npl 
multipoint analysis of the merge data of family #1 & #2 showed LOD score of 2.0 among the 
whole region (Figure ‎4.13). 
 
 
129 
 
 
 
 
 
 
 
 
 
Figure ‎4.14; Graph showing the maximum and minimum LOD scores (of all chromosomes), obtained by non-
parametric linkage analysis on merge data of family #1 and family #2. All chromosomes showed maximum 
LOD score <1.00, except chromosomes 17 & 20 where the maximum LOD scores are <2 and >2 respectively. 
Figure ‎4.13; Graph showing regional plot of chromosome 20 comparing LOD scores obtained using multi-
point non-parametric linkage (npl), (blue solid line) and single point npl (red dots), for the merged data of 
family #1 & #2. The maximum LOD score was 2.04, at a region close to the P-Telomere of the 
chromosome, but upstream from (20p
12.3
-p
11.23
, where family #1 showed maximum LOD). Another region 
with LOD score of 2 was obtained at a region downstream from (20p
12.3
-p
11.23
). Single point analysis 
supported multipoint with LODs >2.0 and higher ( 2.7 at 33.3cM and 2.4 at 29.01cM and 41.86cM). 
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 Parametric Linkage Analysis (Dominant)  4.7.4.2
I have observed the npl on chromosome 20 and all other chromosomes in general then 
focused on the region of interest in family #1 (described in ‎4.7.1.2).   
4.7.4.2.1 Dominant analysis for chromosome 20 and others 
The maximum dominant (multipoint) LOD score for chromosome 20 is 2.3, at a region 
closed to the P-Telomere, but upstream the region of the interest in family #1.  
Sixteen SNPs have single point LODs > 1.1 (one of which was 1.9), and further 7 SNPs have 
LODs 6 (out of 58 SNPs) at the same region of multipoint high LOD (Figure ‎4.13). That has 
supported the region identified in multipoint Analysis. 
In addition only 7 chromosomes showed maximum LODs > 0.0. These were 2, 3, 4, 16, 17, 
20 & X, with chromosome 20 the highest in all with LOD 2.3. (Figure ‎4.16)  Show the 
maximum and minimum Dominant LODs on each chromosome. 
4.7.4.2.2 Analysis at the region of interest in family #1 
I have focused more on the region of interest in family #1 (described in ‎4.7.1.2), and the 
dominant multipoint analysis of the merged data of family #1 & #2, showed maximum LOD 
scores of 0.5 among the whole region as seen in (Figure ‎4.15). 
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Figure ‎4.15; Graph showing regional plot of chromosome 20 comparing LOD scores obtained using 
multi-point dominant (blue solid line) and single point dominant (red dots), for the merged data of family 
#1 & #2. The maximum LOD score was 2.3, at a region close to the P-Telomere of the chromosome, but 
upstream from (20p
12.3
-p
11.23
, where maximum LOD obtained in family #1), and was supported by single-
point npl in which the maximum npl LOD score was 1.9 & below.  
 
 
Figure ‎4.16; Graph showing the maximum and minimum LOD scores (of all chromosomes), obtained by 
dominant linkage analysis on merge data of family #1 and family #2. All chromosomes showed maximum 
LOD score <1.00, except chromosome 20 where the maximum LOD scores is 2.3 which is higher than 
what obtained by the data of family #1 only  
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4.8 Conclusion 
In view of the family history and phenotypic similarity in family #1 and family #2, I 
hypothesized that genetic variants in both families would be similar and thus analysed the 
only available DNA sample of family #2 (from 6 individuals). By analysing these few 
individuals, the main target was to look at the region of interest in family #1 (between 20p
12.3
 
and 20p
11.23
). My intention was to add the LOD scores for the two families; however the 
analysis of family #2 at that region did not support those for family #1. In fact the findings 
had a negative impact since adding the LOD scores reduced that obtained in family #1 alone. 
Examining the two GWLA data sets (of family #1 and family #2) across chromosomes on 
other than the target region have shown no significant findings with maximum LODs of 0.90 
in npl, 0.89 in Dominant analysis and < 0.5 in recessive analyses. 
Specifically, performing GWLA on the merged data of both families has decreased the 
maximum npl LODs (from 3.01 in family #1 only) to 2.0, at that region of interest. However, 
single point npl has shown a maximum LOD score of 2.7 at rs2327790 (33.25 cM), and 2.4 at 
2 NSPs; rs1028846 (29.01) and rs1535487 (41.86). The gene at the region with LOD score of 
2.7 (rs2327790 at 33.25 cM) is TASP1 (Taspase Threonine Aspartase, 1), encodes a protein 
required for the maintenance of HOX gene expression. The gene at the region with LOD 
score of 2.4 (rs1028846 at 29.01cM) is BTBD3, which is the last gene in the list of the 10 
genes in family #1. The second gene in the region with LOD score of 2.4 (rs1535487 at 41.86 
cM) is SLC24A3, described as solute carrier family 24 and encodes sodium/calcium 
transporter, a member of the family of K(+)-dependent Na(+)/Ca(2+) exchangers [268]. Same 
findings obtained in dominant analysis on chromosome 20, as the maximum LOD for family 
#1 only was 2.03, but for the data of both families it was 2.3, at a region closed to the P-
Telomere, but upstream the region of the interest in family #1.  
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4.9 Discussion (chapter 3 & 4) 
The Study in this thesis is the first study to my knowledge that has used SNPs and performed 
GWLA on a single family with MNG progressing to Thyroid cancer or Familial Non 
Medullary Thyroid Cancer (FNMTC). A similar study [269] used GeneChip Human Mapping 
10K Array Xba 131, and identified a locus on 8p23.1-p22 in a large Portuguese kindred with 
a more classic FNMTC pedigree, but when the authors investigated additional families the 
locus was not found to be linked. This is a common finding in studies of familial MNG 
and/or PTC, and indeed was my experience when testing two families with apparently similar 
disease (clinical and histological features) but which did not share predisposing genetic 
variants. 
Although several studies on thyroid cancer have performed linkage analyses on a single 
family, they have used microsatellite markers rather than SNPs. Canzian et al [85] studied a 
French pedigree with three generations and identified a locus on chromosome 19p13 
(FNMTC 1). FNMTC 2 was localized to 2q21 in a large Tasmanian family [87]. Malchoff et 
al [86] studied an American family and identified a locus on 1q21 (FNMTC 3).  
Identifying a region with 10 genes encouraged me to do some in silico analysis looking for 
any relationship between these genes and thyroid cancer or MNG or GWLA, but I did not 
find any link. Furthermore, I have searched for estrogen response elements in the promoters 
of the various genes in the areas of high LOD score and several were identified. 
There has been increasing interest in exploration using linkage analyses for investigating 
cancers in general  [270]. Some have focused on a specific region on a chromosome (related 
to thyroid cancer) [271], others have performed GWAS on thyroid cancer but on a group of 
families [91]. Some are more focused on specific pathways and pathological data such as 
Auto-Immune Thyroid Disease [272]. Many studies focused more on cancer in general, but 
some on thyroid cancer in particular. Suh and colleagues [273] have performed linkage 
analysis on 38 families with FNMTC with 113 affected and identified susceptibility loci on 
chromosomes 6q22 and 1q2. As mentioned in chapter 1, recently a study of GWAS using 
SNPs was performed on the Icelandic population [91] and has shown association of two 
common variants, located on 9q22.33 and 14q13.3 with thyroid cancer. 
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As mentioned in the summary of my MPhil (‎1.7), I have studied the known loci of MNG on 
chromosomes 14q, Xp and 3q, by linkage analysis using microsatellite markers, and also for 
the known loci for FNMTC, on chromosomes 19p, 2q and 1q. After GWLA using SNPs, I 
have re-checked the same region and have not found any linkage in family #1 data, as shown 
in (Figure ‎3.6) with the maximum and the minimum LOD scores of npl across all 
chromosomes. The same observation was made with the data of family #1 and #2 as shown in 
(Figure ‎4.14). However, npl single point for family #1 has shown a LOD score of 1.5 at 14q
12
 
(rs1952966 at 31.7 cM), a similar LOD score was obtained at 1p
36.21 
(rs763821 at 34.3 cM), 
while dominant single point produced LOD scores of 0.6 and 1.4 for the same two SNP 
markers respectively. 
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Chapter 5 Studies on the region of interest in family #1; (CNV) 
All subsequent studies (other than chapter 4) were performed only on family #1. In this 
chapter further investigations have been made on the region of interest on chromosome 20 
(20p
12.3
-20p
11.23
), which showed the maximum LOD scores in GWLA (as described in ‎3.7.1). 
The region with high LOD score of 3.01 spans 19.5 cM and is large when compared with 
most  GWLA reported in the literature [85-87, 269, 274, 275], I hypothesised that 
chromosomal copy number variants (CNV) such as deletion or duplication might provide an 
explanation. 
In preliminary studies, using the limited CNV data which can be extracted from the 10K chip, 
some evidence for CNV in the region with the highest LOD score was apparent. Thus 
specific analysis for CNV has been performed using Illumina Human 660-Quad BeadChip. 
The chip contains 660,000 Markers (will be described in ‎5.1.4).  
 
5.1 Introduction 
5.1.1 Type of chromosomal variation 
Human cells have 23 pairs of chromosomes with two copies of each, giving a total of 46 per 
cell. Several variations can be detected in abnormal cases. These include deletion of both 
copies (homozygous), deletion of one copy (hemizygous), (also known as loss of 
heterozygosity (LOH)), deletion of one copy and duplication in the available copy, deletion 
of one copy and several duplications of the available copy (Figure ‎5.1) (reviewed in [276]). 
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5.1.2 Copy Number Variation 
The variability of human populations is determined in a large part by environmental factors 
and/or genetic information. It has been confirmed that genetic variations are not caused by 
SNPs only, but there are also polymorphisms that extend over hundreds of thousands 
of DNA base pairs across the whole genome. Such alternations called copy number 
variation (CNV) often include genes and other functional genetic elements [277]. CNV refers 
to alterations in numbers of copies in segments greater than 1kb, (up to 1 mega base). 
Changes between 1 and 1000 bp are referred to as insertions or deletions, depending on 
whether nucleotides are added or lost respectively. Changes in a whole-chromosome (34 
∼230 Mbp), whether gains or losses, are known as aneuploidies [278]. Depending on their 
frequency among population, CNVs can be divided according to their frequency. Those 
occurring in >1% of the population (usually not pathogenic) [279] and those in <1%, which 
can be considered pathogenic, and usually not observed in the unaffected siblings or ethnic 
matching controls [280]. On the other hand there is a counterproductive relation between 
sizes and frequencies of variants [280]. CNV analysis usually refers to the process of 
analysing data to test the variation of chromosomal copy numbers in DNA samples of 
patients vs. their unaffected relatives. Such analysis helps detect chromosomal abnormalities 
Figure ‎5.1; Schematic representation of chromosome pairs illustrating changes in copy number of distinct 
regions detected by chromosome copy number variation studies. A full description is in the text. Adopted from 
http://link.springer.com/chapter/10.1007%2F978-3-540-71681-5_10#page-1  
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that may cause or increase risks of any particular disorder. Data analysis for an array-based 
DNA copy number test can be very challenging  because of the  very high volume of the 
output data of any array platform [281].  
In 2001 the human genome sequencing project was completed and provided a road map 
which has helped in discovering more CNVs. Around 5% of the genetic code was found to 
consist of redundant segments represented many times in different locations across the 
genome. These segments were shown to predispose to copy number variation and have been 
named as “segmental duplications” (SDs). SDs size varies from 1 kb to hundreds and have 
high sequence identity (>99%). They may include genes or noncoding regions but cannot be 
distinguished easily [282]. Since 2004, researches have revealed CNVs as a major source of 
human genetic variation [283-285]. A study has used large-scale copy-number variations 
(LCVs), with gains or losses involving regions up to 2 Mb in size. It demonstrated 
coincidence of markers with comparative gains or losses among samples having 
chromosomal imbalances [284]. Other studies have identified new sites of structural variation 
and named the insertions, deletions and inversions found as intermediate-sized structural 
variants (ISVs). The size of ISVs ranges from 6.3 to 24.7 kb [285, 286]. Several studies [287-
289] demonstrated that small-scale CNVs (<10 kb) are common in the human genome. The 
unique level of genetic diversity identified by CNVs has led to a new stage of discovering 
sources of phenotypic variation, human development and disease susceptibility.  
Considerable evidence indicates that CNV can have a significant biological impact and CNVs 
have been reported to play a role in severe developmental syndromes and familial diseases. 
CNVs can disturb gene expression within and flanking the CNV and CNVs can confer 
susceptibility to infectious and complex diseases [290]. Even small changes in DNA copy 
number are shown to be associated with multiple phenotypes, related to immune or 
environmental response. Many studies have shown that these changes in DNA copy number 
are associated with different types of disorders including Asthma [291], heart [292] and 
psychiatric defects [293], and at least 15% of human neurodevelopmental disorders are due to 
rare and large copy number changes [280] 
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5.1.3 Copy Number Variation History 
The traditional method for detecting CNV was by cell culture and karyotyping analysis [294]. 
In this method the chromosomes are stained (during cell culturing), with certain dyes that 
show a pattern of dark and light bands. The bands are specific for each chromosome and thus 
lead to the identification of each of the 24 types of chromosomes (22 autosomal plus X and Y 
)[295]. Fluorescence in situ hybridization (FISH) was another traditional method for CNV. 
Further improvements in this method made FISH applicable for use in Comparative Genomic 
Hybridization (CGH), which can detect chromosomal copy number changes without the need 
for cell culturing [296]. That is by labelling the abnormal DNA (from tumour tissues) with a 
green fluorescent probe and reference DNA (with normal karyotypes) with red, and 
hybridising to normal human metaphase preparations (reviewed in [296]). As mentioned 
below, CNV studies have been performed on thyroid. For CGH labelling, cell lines of known 
BRAF mutation, can be used as positive control [297]. Consequently it was possible to 
identify regions of relative loss and gain in the test sample, by assuming the reference DNA 
to be diploid in copy number. The green to red fluorescence ratio at any locus represents loss 
or gain of genetic material in the abnormal DNA at that specific locus. The use of CGH has 
been applied mainly in the analysis of genetic changes in DNA extracted from solid tumours, 
and has greatly increased knowledge of chromosomal rearrangements in tumour biology 
[298]. Several studies on thyroid have reported the use of CGH, to detect chromosomal 
instability in PTC. Hemmer et al. [299] reported that DNA copy number changes were rare (3 
of 26, 12%) in PTC. In contrast, Singh et al. [300] reported genetic abnormalities in 10 of 21 
PTC cases (48%), including losses at 1p and 9q and complete loss of chromosomes 17, 19 
and 22, and gains at chromosome 4 and at 5q, 6q and 13q. Bauer et al. [301] reported gain of 
chromosome 20 and loss of chromosome 13 in 4 of 15 PTC samples.  
CGH was used first in 1992 [294] and despite its value, is hampered by low resolution (~20 
Mb). The resources generated for the public-domain Human Genome Project led to 
improvements in the resolution (1 Mb) of CGH [302, 303]. A particularly important study 
was the HapMap project, which catalogued SNPs in four of the major ethnic human 
populations [217]. With these resources it became possible to replace metaphase 
chromosomes for CGH with arrays of clones accurately mapped onto the human genome. 
This increased CGH resolution and is known as matrix-CGH [304], and then as array-CGH, 
139 
 
which has increased resolution to < 100 kb [305] making it  a standard method for clinical 
cytogenetic investigations [306]. Many studies [307-311] have analysed CNV using array-
CGH and have confirmed the importance of such analyses in normal human variation. Many 
further  improvements  in array technology have been made aiming to increase numbers of 
features (spots) and decrease the length of DNA sequences as hybridization targets [312]. 
Cloned arrays were first to be used, in which clones such as BAC (Bacterial Artificial 
Chromosomes), YAC (Yeast Artificial Chromosomes) or PAC (P1-derived Artificial 
Chromosomes) have been used [312]. Array CGH uses oligonucleotides to provide higher 
resolution (than old CGH arrays with clones) [313]. Four different oligonucleotide platforms 
have been used in different studies; Affymetrix commercial CGH platform was the first, and 
contains short probes of 25 oligonucleotides [314].  The second CGH platform was 
introduced by Agilent Technologies [315, 316]. The Agilent platform has already been 
proven highly valuable in a lung cancer study [317]. A third CGH oligonucleotide platform 
offered commercially is by NimbleGen, in which the CGH oligonucleotides are designed to 
be isothermal and vary between 45 and 85 bp in length [318]. A fourth CGH platform is non-
commercial and makes use of oligonucleotide libraries that are spotted as elements on the 
arrays [313, 319]. 
High-throughput array technologies for SNP genotyping from commercial companies such as 
Affymetrix and Illumina, have received considerable attention as a source to identify human 
variation [312]. Illumina Bead Array platforms represent a SNP by a number of beads for 
each allele. Several unique bead types containing different probe sequences are represented in 
each array, with an average 30-fold redundancy of each bead type. Independent of the array 
format, each bead in every array contains hundreds of thousands of covalently attached 
oligonucleotide probes. Affymetrix arrays represent a SNP by probes for each allele. 
Depending on the DNA sequence they target, the beads and or probes have different 
affinities, and thus produce signals of different strengths [320]. Affymetrix and Illumina 
arrays have started focusing more on intensity information, to determine genomic copy 
number, beside their original function of allelic content across the genome. Thus these arrays 
can serve a dual role for SNP- and CNV-based association studies. 
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Furthermore several developments have improved the output of the oligonucleotide array, 
signal-to-noise ratio was improved by digesting the DNA by restriction enzymes then ligation 
with adapters. Hybridization complexity was reduced by amplifying the smaller fragments of 
DNA by universal primers [312]. The reduction of complexity in hybridization (by PCR 
amplification of smaller restriction fragments, ~1.2 kb), brings the possibility of amplification 
bias of different regions of the genome [306]. Noise reductions can be achieved by taking 
length and GC content of the probes into account [321].  
Although most CNV markers are SNPs, non-polymorphic (NP) markers (also known as CNV 
markers), have also been used in probes for better coverage of the gaps that are not covered 
by SNPs. That has helped in avoiding the variable resolution of the array across the genome 
and has increased the limit of CNV detection to >10kb (reviewed in [312]). Nomenclature of 
the markers allows them to be distinguished, SNP markers start with rs in almost all arrays, 
while NP markers start with cnvi in some arrays. 
Although changes in the copy number start and end at a specific base pair, only simple 
duplications and/or deletions can be detected by the experimental platforms, as they measure 
the resolution rather than the size of the CNV. That includes high-density genotyping 
platforms such as SNP arrays with NP markers and ultrahigh-density whole genome tiling 
arrays. These technical platforms cannot detect complex structural variations, such as 
inversions or translocations [276].   
5.1.4 Illumina Bead Array Generation of SNP genotyping array 
Illumina Bead Array is very popular and has several types depending on the number of 
markers used varying from 100K to 650k and a 1 Million chip has also been released (human 
1M).  Furthermore Illumina Omni family of microarrays provides chips with over 4.3 million 
fixed markers per sample (Omni 5), with the ability to add 500K extra custom markers [322]. 
Affymetrix SNP array is another option with the number of markers varying from 10K which 
was released in 2003, 100K and 500K are also available. Similar to Illumina, a chip with 1 
Million SNPs has also been released by Affymetrix (Genome-wide Human SNP 6.0) 
(reviewed in [320]).  
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Illumina Human660W-Quad BeadChip contains over 657,000 genetic markers for the whole-
genome genotyping and CNV analysis. It builds from 550,000 SNPs markers from the 
Human Hap550 BeadChip, plus an additional (more than) 100,000 markers on regions known 
to be associated with copy number variations. Thus the assay utilizes Infinium platform, “an 
extremely high throughout genotyping system that relies on direct hybridization of genomic 
targets to array-bound sequences”. Locus discrimination or copy number determination in the 
Infinium is provided by a combination of sequence-specific hybridization capture and array-
based, single-base primer extension. If there is (sample/probe) perfect match, extension 
occurs and signal is generated, otherwise extension does not occur and no signal is generated. 
Signal amplification of the combined label further improves the overall signal-to-noise ratio 
of the assay. The Infinium platform was used first in December 2008( reviewed in [323]).  
A study comparing different arrays [324] has shown that detection of variants between 1kb to 
50 kb in size for Illumina 660W platform was >95%. On the other hand, studying array 
resolution and distribution of probes, showed that Illumina 660W array specifically targets 
CNVs and has a very uniform distribution of number of probes per CNV call. The study has 
also shown that the ratio of copy number gains to losses of certain arrays to be very biased 
toward detection of deletions, while Illumina 660W array has shown highest ratio of deletions 
to duplications. In terms of reproducibility, Illumina 660W was similar to the Affymetrix 6.0 
and the other two Illumina arrays (1M and Omni) with a value around 80%, when analysed 
with the best performing algorithms. Furthermore the ability to detect variants by Illumina 
660W and Illumina Omni was shown to be higher than Affymetrix, when used in the 1000 
Genomes project ( reviewed in [324]). 
5.1.5 BeadStudio software and calling and normalising 
The main function of this software is normalisation of array intensities in order to make 
comparisons across arrays and background correction for correct interpretation of the data 
(i.e. to reduce the number of false and missing calls) [320]. In the Illumina SNP genotyping 
assay two probes are used to detect the presence of the two different alleles at each SNP. 
There is one intensity channel for each of the fluorescent dyes associated with the two alleles 
of the SNP. The alleles measured by the X channel (Cy5 dye) are called the A alleles, 
whereas the alleles measured by the Y channel (Cy3 dye) are called the B alleles [325]. Two 
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values are automatically generated from Illumina BeadStudio software from the X and Y 
values, the Log R Ratio and the B allele frequency. The Log R Ratio (LRR) is a measure 
proportional to the total signal intensity (and therefore the copy number). The value 
log R ratio is the log (base 2) ratio of the observed normalized R value for the SNP divided 
by the expected normalized R value for the SNPs theta value. Expected R is calculated from 
the values theta and R, where R is the intensity of dye-labelled molecules that have 
hybridized to the beads on the array and theta is the ratio of signal at each polymorphism for 
beads recognizing an A allele to beads recognizing a B allele, (and is different from the theta 
“Recombination Fraction” described in‎3.1.2) [326]. Therefore, the ratio of observed R to 
expected R in any individual at any SNP gives an indirect measure of the binding efficiency 
of detected alleles for each polymorphism and thus of genomic copy number. LRR above 0 is 
indicative of an increase in copy number. If it is between 0 and 1 then it is heterozygous 
duplication, (of one copy), if it is above 1 so it is homozygous duplication, (of 2 copies). 
Values below 0 suggest a deletion, if LRR is below 0 but above -1 then it is heterozygous 
deletion, (of one copy), if it is below -1 so it is homozygous deletion, (of 2 copies). LRR is 
the base-2 log-ratio of the sample’s direct intensity (R) at the given locus, versus a reference 
sample [327]. B Allele Frequency (BAF) is a measure of the relative contribution to the total 
signal from the B allele (and therefore reflects the allelic composition). In other words BAF is 
the “theta” value for an individual SNP corrected for cluster position, this gives an estimate 
of the proportion of times an individual allele at each polymorphism was called A or B; thus 
an individual homozygous for the B allele (BB) would have a score close to 1, an individual 
homozygous for the A allele (AA) would have a score close to 0 and a heterozygous 
individual (AB) have a score of ∼0.5 (Figure ‎5.2) [325],[1]. BeadStudio software calculates 
the LRR and BAF from the X and Y values generated from Illumina as follow;  
Log R Ratio = log2 (X + Y)  
B Allele Frequency = Y/(X + Y). 
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5.1.6 PennCNV Software and CNV analysis 
The signal intensity of genotyping data (pre-computed Log R Ratio and B Allele Frequency 
data), in BeadStudio project file format, can be subsequently analysed by “PennCNV 
software”. It is an integrated hidden Markov model (HMM) designed software for high-
resolution CNV detection in Illumina high-density SNP genotyping data. PennCNV software 
can be used to detect CNV through algorithm [2]. The PennCNV algorithm uses the two 
measures of signal intensity at each SNP, the LRR and the BAF (Figure ‎5.3). While 
BeadStudio software calls the genotypes and normalises the total signal intensity of the two 
alleles (A & B) of SNPs, PennCNV software analyses the CNV for each region across the 
genome (Figure ‎5.2). To derive the LRR and BAF values, a signal pre-processing procedure 
is necessary for SNP genotyping platforms. In the case of NP markers, the R-value is 
Figure ‎5.2; Screen shot of an example for Log R Ration (LRR), lower panel and B Allele Frequency (BAF), upper 
panel, in CNV (duplication) cases. BAF has three values; high for BB call, middle for AB and low for AA. Normal 
LRR value is close to zero and high or low values indicate duplication or deletion respectively. A full description 
is in the text. Adopted from [2].  
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calculated as the signal intensity rather than the sum of two alleles. Also BAF values cannot 
be derived for NP markers. Thus these markers are shown to be non-informative in the 
likelihood calculation, but used for CNV only. PennCNV software summarises the variants in 
each chromosome at the end of the analysis (reviewed in [1]). 
 
 
 
Figure ‎5.3: Diagram showing that the intensity signal created by the match between the probes and the 
single nucleotide polymorphisms (SNPs) in patient DNA, can provide genotyping of these SNPs as well as 
detecting any variation in the copy number of that region. A full description is in the text. Adopted from 
[2]. 
 
 
5.1.7 DNA quantification & PicoGreen 
 For optimal Chip results, it is highly critical that the DNA quantity is accurate. DNA 
quantification plays an important role is success or failure of a library preparation. Higher 
DNA concentration may lead to increased background signal and lower resolution, whereas 
low DNA concentration may result in reduced signals. The ordinary methods of DNA 
quantification are UV-spec based and measure any nucleotides present in the sample 
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including RNA, double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), and free 
nucleotides, which can give an inaccurate measurement of gDNA. For highly sensitive 
protocols such as arrays analysis, fluorometric-based methods (such as PicoGreen) are 
recommended as they provide accurate quantification for dsDNA [328].  
PicoGreen® (PG) is a reagent used for quantitation of dsDNA in molecular biology, due to 
the dramatic increase in its fluorescent emission upon interaction with dsDNA. It is an ultra-
sensitive fluorescent nucleic acid stain that can interact with nucleic acids and help in its 
biophysical studies. When binding DNA, PG fluorescence increases >1000-fold in proportion 
to the quantity of DNA present. An interesting feature of PG is its ability to strongly bind not 
only to highly polymeric DNA but also to short duplexes <20 bp, likewise exhibiting a 
sensitivity in the picogram range (reviewed in [329]). 
 
5.2  Aim 
To identify any variation in the chromosomal copy number (loss or gain) in the region with 
maximum LOD score identified by GWLA. Any CNV detected, will be investigated further, 
by standard PCR and Sanger sequencing, on all family members, to determine whether it is 
found in affected and/or unaffected members.  
This chapter will explain the CNV analysis performed using Human 660-Quad BeadChip, the 
analysis of the data obtained and the further investigations required after data analysis.  
Since GWLA has identified a specific region with significant LODS, CNV in this study will 
not follow the more usual approach to data analysis so rather than comparing the CNV output 
between affected and non-affected members, the analysis will be performed on a DNA 
sample of one member of family #1, the index patient (IV-6). Thus the interpretation will 
focus on the region of interest (20p
12.3
-20p
11.23
) and not study the whole genome for CNV. 
After Quantitation of the DNA sample by PicoGreen
®
 (described in ‎5.1.7), The DNA sample 
was transferred to a Colleague in Psychological Medicine, who has considerable experience 
in CNV analysis.  The sample was processed via several steps (as summarised in Figure ‎5.4), 
which were followed by data collection, pre-processing and signal intensity extraction by 
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Illumina BeadStudio software (described in ‎5.1.5). PennCNV software (described in ‎0), was 
used next for CNV detection and annotation (as summarised in Figure ‎5.5).  
 
 
 
Figure ‎5.4: Sample processing steps in Illumina Human 660W-Quad kit. DNA sample underwent 
denaturation and isothermal amplification. The amplified product was then fragmented by a controlled 
enzymatic process and re-suspended in hybridization buffer. This was followed by Hybridization to 
BeadChip then washing. Single-base extension of the oligos on the BeadChip was then performed, 
followed by scanning and recording the output. The figure is adopted from Illumina Human 660W-Quad 
Protocol Manual. 
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Figure ‎5.5: Flow diagram summarising the steps after Scanning and Recording the output in Illumina 
chip until performing CNV by PennCNV software. Adopted from in [1]. 
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5.3 Data Analysis 
The data have been analysed by PennCNV software, which has summarised the variations 
among each chromosome (Table ‎5.2, as an example). Several variations have been detected 
in each chromosome (Figure ‎5.1). Since chromosome 20 contains the region of interest of 
GWLA, only that chromosome and particularly that region have been investigated further.  
5.3.1 Variation in Chromosome 20 
A total of 9 variants have been detected in Chromosome 20 (Table ‎5.2), three of which were 
in the P arm of the chromosome (20P
12.3
, 20P
12.1
 & 20P
11.21
). One variant out of these three 
was in the region of interest, at P
12.3
 (8358121-8359033 bp) as seen in (Table ‎5.2).  
The variant was a deletion of ~903 bp of one copy and was detected by 14 markers from the 
Illumina Chip ( Figure ‎5.6) & (Table ‎5.3), four of which were SNP markers, while the other 
10 were NP markers (described in ‎5.1.3 ).  The one copy deletion is clearly observed by the 
LRR ratio of the 14 markers as almost all of them obtained LRR below 0 but above -1, which 
indicate a one copy deletion (as described in ‎5.1.5)  
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          Obtainable copies 
Chromosome 
0 copy   1 copy 3 copies 4 copies 
1 10 15 6 - 
2 7 15 7 1 
3 9 15 - - 
4 11 13 2 - 
5 4 13 6 - 
6 6 5 2 - 
7 3 12 3 - 
8 7 6 - - 
9 12 11 3 - 
10 9 9 5 - 
11 5 8 2 - 
12 - 13 3 - 
13 4 7 - - 
14 2 9 3 - 
15 2 10 2 - 
16 1 7 5 - 
17 2 5 3 - 
18 1 6 - - 
19 1 10 1 - 
20 1 8 - - 
21 2 1 - - 
22 3 4 - - 
Table ‎5.1: Summary of the variations detected by PennCNV software on all chromosomes. First column 
is chromosome number. Column 2 is the number of deletions of both copies (0 copies) and column 3 is 
deletions of one copy (1 copy). While column 4 is duplication of one copy (3 copies) and column 5 is 
duplications in 2 copied (4 copies). First row represents copy number variation (CNV) in chromosome 1 
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and shows that a deletion of both copies has been detected in 10 different regions. One copy deletion has 
been detected in 15 regions and a duplication of one copy in 6 regions.  
 
 
 
Table ‎5.2: List of 9 variants on Chromosome 20, detected using PennCNV software. First column reports 
the location of each variant, column 2 the number of markers detecting that variant. Column 3 provides 
the length of each variant, column 4 shows number of copies identified. The last two columns (5 & 6) 
show the markers flanking each variant. The first variant is (loss of 1 copy) in chromosome 20 at 
8358121-8359033 bp, detected by 14 markers, its length is 903 and is in the region of interest in family #1. 
 
Chromosome and location No of markers Length of Variation (bp) No of copies Start Marker End Marker
chr20:8358121-8359023 14 903 1  cnvi0102516  rs6055812
chr20:15249783-15251701 18 1,919 0  cnvi0056722  rs6110571
chr20:24359854-24370253 15 10,400 1  cnvi0110453  rs6036792
chr20:50085800-50087807 18 2,008 1  rs6068046  rs6068047
chr20:61236393-61237260 15 868 1  cnvi0059879  cnvi0059893
chr20:61708979-61711285 15 2,307 1  rs28664002  cnvi0053235
chr20:62066683-62068138 19 1,456 1  cnvi0050179  rs817329
chr20:62195699-62197068 14 1,370 1  cnvi0106384  cnvi0106397
chr20:62233717-62256817 21 23,101 1  cnvi0054409  rs4809258
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 Figure ‎5.6: The two values generated by BeadStudio software i.e. the B allele frequency (BAF), (upper 
panel) and the log R ration (LRR), (lower panel). PennCNV software used these values to calculate the 
copy number variation (CNV). A decrease in the LRR (0> LRR > -1) indicates a single copy deletion 
which has been identified by 14 markers (circled in red).  
 
 
Table ‎5.3: A list of the 14 markers from Illumina Chip that detected the deletion. The four single 
nucleotide polymorphism (SNP) markers start with rs; (rs708911, rs771945, rs6055811 & rs6055812). The 
other 10 non polymorphic (NP) markers start with cnvi. 
Name Position Log R Ratio B Allele Freq
cnvi0102516 8,358,121 -0,3111986 0,9980593
cnvi0102517 8358185 -1,052522 0,03195321
cnvi0112672 8358204 -0,5388463 0,9947988
cnvi0102518 8358334 -0,366732 0
cnvi0102519 8358434 -0,6839929 0,0108272
cnvi0102520 8358539 -0,4034659 0
cnvi0102521 8358590 -0,553011 0
rs708911 8358641 -0,7085187 0
rs771945 8358722 -0,1780442 0,001772681
cnvi0102523 8358825 -0,3786347 1
cnvi0102524 8358880 -0,2455926 0
cnvi0102525 8358931 -0,5293732 0,991891
rs6055811 8358955 -0,05986575 0,995051
rs6055812 8359023 -0,3161553 0,9949234
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5.3.2 Significance of the Chromosome 20 deletion, at the region of 
interest  
This deletion is in the region of chromosome 20 with highest LOD scores and also identified 
as carrying a possible disease allele by haplotype analysis. It is located at the start of the 
region of interest (20p
12.3
-20p
11.23
). It is flanked by rs2250711 at 8,203,369 bp and rs771943 
at 8,362,876 bp (of 10K chip). The LOD score of both Dominant and npl analyses have 
dramatically increased at this region. In npl it has increased from 2.6 before the deletion to 
2.94 after the deletion (very close to the maximum peak of 3.01). In Dominant analysis the 
LOD score has increased from 2.03 before deletion to the maximum peak 2.04 after deletion. 
The haplotype analysis at this region showed that all affected (and the obligate carrier II-3) 
are carrying the assumed disease allele C, as well as two of the unknowns (IV-4 & IV-5). The 
other three unknowns (IV-2, III-3 & IV-8) are not carrying the C allele, in addition to the 4 
founders (II-4, III-4, II-1 and III-1). That could indicate that this deletion might be associated 
with the thyroid defect in the family. 
Out of the 4 Illumina SNPs markers, only rs771945 is present in HapMap data (with 46% 
frequency of A and 54% of G in CEU), no further information is available for the other three 
SNPs which indicates that, they are commonly used in CNV only. 
5.3.3 Using Marker rs6055812 to identify the exact location of the 
deletion 
To find out the exact position and sequence of the deleted region, data of the last SNP 
(rs6055812), in the Illumina list of 14 markers (identified the deletion) have been used. In 
summary, NCBI software (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=6055812) was 
used to search for “probe sequence” of re6055812, (25 nucleotides). That sequence was 
matched with data base and has revealed the exact end of the deleted region (Figure ‎5.15). 
Thus 903 bp were counted upward and that region has been assumed as the deleted region. 
5.3.4 Genes in the deleted region 
Genome Browse software (http://genome-euro.ucsc.edu/cgi-bin/hgGateway) has been used to 
detect the gene(s) located in the deleted region (between 8,358,121 and 8,359,023 bp). The 
deletion was found to be in intron 3 of a huge gene known as PLCβ1 gene. It is the first gene 
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in the list of the 10 genes identified by GWLA (described in ‎3.8.1). The gene is located on 
20p
12.3
. Its DNA is of 749.21 kb with mRNA size of 3663bp encoding 32 exons. It starts at 
position 8,061,296 bp on chromosome 20 and ends at position 8,813,547. Exon 1 is 102 bp 
and followed by Intron one (of 17,524 bp length). Exon 2 is 78 bp and followed by Intron 2 
(of 221,007 bp). Exon 3 is 69 bp and followed by “Intron 3 (256,843 bp)”, where the deleted 
903bp located (after 58,027 bp). Exon 4 is 138 bp (Figure ‎5.7). 
 
 
A 
 
B
 
Figure ‎5.7: (A): PennCNV software output showing the deletion on chromosome 20 with its location in 
base pair (bp), the number of markers detecting this deletion and the type of deletion (one copy). (B): 
Phospholipase C Beta 1 (PLCβ1) gene structure showing the first 4 exons and 3 introns. The deletion is 
also shown at Intron 3.  
 
 
 
 
78bp                      69bp                                         138 bp         
-
E1 E3 E4
102 bp
17,542 bp
Start
8,061,296 bp
221,007 bp 58,027 bp
E2
8078940 bp             8300025bp     8358121bp  
903 197,913 bp
Deletion
8557074 bp
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After data analysis and identification of a deletion at the region of interest on chromosome 
20, the sections below will describe further investigations performed on the deleted region as 
summarised in the workflow (Figure ‎5.8) 
 
 
 
Figure ‎5.8: Flow diagram summarising the investigations undertaken on the identified deletion. 
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5.4 Materials & Methods  
In this section further investigation of the deleted region will take place, including standard 
PCR and direct sequencing of DNA from all family members, to determine whether the 
deletion is in affected and/or unaffected individuals. Studies will be performed to assess the 
frequency of the deletion in additional cohorts and I will investigate the impact of the 
deletion on the PLCβ1 gene. 
5.4.1 PCR1 to amplify the deleted region 
  Designing primers 5.4.1.1
Forward and Reverse Primers have been designed to amplify the deleted region (Table ‎5.5) 
and (Figure ‎5.9). The forward primer was 441 bp before the deleted region while the reverse 
primer was 448 bp after the deleted region (Figure ‎5.15). This PCR set will be referred to as 
PCR1. The primers were designed using Primer3 software and specificity increased by 
elongating the primer sequence taking care to maintain the GC content.   
 
 
 PCR1 preparation, reaction and agarose gel electrophoresis 5.4.1.2
A 50 l reaction volume contained 3 l of DNA (100 ng/l), 5 l PCR buffer (10x) (Applied 
Biosystems), with no MgCl2, 1.25 l dNTP (10 mM) (Promega), 5 l MgCl2 (25mM) 
(Applied Biosystems), 1.5 l forward primer (10 pmol/l) (Invitrogen), 1.5 l reverse primer 
(10 pmol/l) and 1 l AmpliTaq Gold® polymerase (5U/l) (Applied Biosystems). A master 
mix containing all components, except the DNA template, was prepared. This was aliquoted 
and DNA samples were added. (In the negative control H2O was added instead of DNA).  
PCR1 reaction was performed with 45 cycles (Table ‎5.4), using DNA from all family 
members. That was followed by agarose gel electrophoresis, (described in ‎2.4.7.3).  
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5.4.2 Purification of PCR1 products by PEG precipitation 
All PCR products have been purified by Polyethylene glycol (PEG) precipitation. PEG 
solution for DNA extraction was prepared as follows, 8.156 g of sodium acetate were 
dissolved in 50 ml dH2O and the pH adjusted to 5.2 with acetic acid. Twenty six grams of 
PEG (mol. wt. 8000) and 134 mg of MgCl2 were then added and made up to a final volume 
of 100 ml before autoclaving.  
Equal volumes of PCR product (35 µl) and PEG solution were vortexed and incubated for 10 
min at RT, prior to centrifugation at 13,000 g, for 30 min. The supernatant was discarded and 
the pellet washed in 500 µl 70 % ethanol, centrifuged for 10 min at 13,000g and air dried 
before re-suspension in 20 - 40 µl of Milli-Q pure dH2O in proportion to the brightness of the 
bands on the gel. Ten µl from the purified PCR products have then been run on Agarose gel 
again as quality control.  
 
 
Temp Time 
95C  5 minutes 
 
95 
60 
72 
45 cycles of: 
30 seconds 
30 seconds 
30 seconds 
72C 6 minutes 
Table ‎5.4: PCR programme (PCR 1 & PCR 2) used to amplify the deleted region using AmpliTaq 
Gold® DNA polymerase enzyme. Temperature (column 1, Temp), time of incubation and number of 
cycles performed (column 2, Time). 
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5.4.3 Direct Sequencing 
Each sequencing reaction contained 2 µl "Big Dye Terminator Cycle Sequencing Ready 
Reaction", (ABI Prism, PE Biosystems), 1 µl primer (10 pmol/L), approximately 25 ng of 
PEG precipitated PCR product (as quantified by comparison with the 100 bp DNA ladder on 
an agarose gel), and was made up to 10 µl with H2O. Sequencing reactions were performed 
on a Genius (Techne) PCR amplifier, and the sequencing program used was exactly similar to 
the PCR1. 
5.4.4 Sodium Acetate Precipitation 
One µl of 3 M sodium acetate (pH 5.2) and 30 µl of absolute ethanol was added to each 10 µl 
sequencing reaction before vortexing and incubating at RT for 10 min. Samples were then 
centrifuged for 30 min at 13,000 g, the supernatant discarded and the pellet washed with 500 
µl of 70 % ethanol. The supernatant was discarded and samples were air dried, before re-
suspension and analysis on an ABI 3100 Genetic Analyser. 
5.4.5 PCR2 preparation, reaction and agarose gel electrophoresis 
Since primers in PCR1 were flanking the deleted region with ~400 bp apart from both side, a 
second set of primers was designed in which the reverse primer was located inside the deleted 
segment (PCR2) (Figure ‎5.9), (Figure ‎5.15) & (Table ‎5.5). PCR2 forward primer designed to 
be 292 bp upstream from the deletion. Thus the expected gel band for full length is ~1400 bp. 
PCR2 was run on all family members (as in ‎5.4.1). That was followed by purification and 
direct sequencing (as in ‎5.4.2 & ‎5.4.3). Hence PCR2 was employed to amplify the full length 
copy of the region of interest. 
5.4.6 PCR1 to check deletion frequency in general population  
To check how frequent is the deletion in the general population  , PCR 1 (with the primers 
flanking the deleted region) has been run on (unrelated) 105 DNA samples; from a selected 
cohort of GP patients whose thyroid function was assessed because of depression 
DEPTH (DEPression and Thyroid) [330], ( 5.4.1).  
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F1 TATTATCCCC AGAAAGAATG AGAGGAGG         
R1 CATAGCCACC ATGCCAGGCT AATTTTTTAA 
F2 TTTAGGTGTT AACCACCAAA GTGGCTGACA              
R2 TTACCTTGCC TGGGAACAGG ATGGGCCCCA A 
Table ‎5.5: Forward and reverse primers, (F1 & R1) for PCR1 & (F2 & R2) for PCR2. The primers were 
designed using Primer3 software and specificity increased by elongating the primer sequence taking care 
to maintain the GC content.  
 
 
 
Figure ‎5.9; Cartoon showing the location of the forward and reverse primers for PCR1 & PCR2. PCR1 
primers (F1 & R1) are at a ~400 bp distance outside the deletion. In PCR2, a forward primer (F2) was 
292 bp upstream from the deletion and a reverse primer (R2) was inside the deleted region. 
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5.4.7 The deletion impact on the PLCβ1 gene, Exon Skipping 
investigation 
I hypothesised that the deletion in intron 3 of PLCβ1 gene could lead to skipping of one Exon 
or more, either the Exon before deletion; Exon 3, or the Exon after deletion; Exon 4. Samples 
of cDNA from thyroid tissues of 2 affected members (IV-6 and IV-3) and one presumed 
unaffected member (IV-4) were prepared, (as described in ‎5.4.7.2).  
 Designing exonic primers to amplify exons 3 and 4 of PLCβ1 in 5.4.7.1
Thyroid cDNA  
To investigate Exon skipping, PCR primers have been designed to amplify both exons (in 
cDNA) using primer 3 software, and PLCβ1 mRNA sequence. Forward primers have been 
designed in exons 2 and 3 (F2 & F3) and reverse primers have been designed in Exon 4 and 5 
(R4 & R5) (Figure ‎5.10) & (Table ‎5.6). A combination of F2 & R4 amplifies Exon 3 and a 
combination of F3 & R5 amplifies Exon 4. A combination of F2 & R5 has also been used to 
confirm any findings.  
 
 
 
 
 
 
 
Figure ‎5.10:‎Cartoon‎showing‎part‎of‎phospholipase‎C‎beta‎1‎(PLCβ1)‎mRNA‎with‎exons‎2,‎3,‎4‎&‎5‎and‎
locations of forward and reverse primers to amplify exons 3 & 4 in cDNA from thyroid tissues. Size of each 
exon is shown underneath in base pair (bp). 
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F2 TTTTGAGGAC TGACCCTCAG GGATTTTTCT TTTAC 
F3 TCAGCCTTGT CAAAGATGCC AGATGTGGGA GAC 
R4 GGTGTATGGG CCTGACCTCG TGAACATCTC CCATTT 
R5 CCCAAAACAT GTCCAGGGAT GCATTTCTGG AAAA 
Table ‎5.6: Forward and reverse primers used to amplify exons 3 & 4 in cDNA, of family #1 thyroid 
tissues. F2 & F3 are forward primers in exons 2 & 3 respectively. R4& R5 are reverse primers in exons 4 
& 5 respectively, as seen in (Figure ‎5.10) above. 
 
 
 RNA extraction from normal thyroid tissue for amplifying exons 3 5.4.7.2
and 4 of PLCβ1 mRNA 
Messenger RNA was extracted from the thyroid tissues of family members (IV-5, IV-6 and 
IV-4) using TRizol Reagent (Invitrogen) and reverse transcribed in 20-μL reactions using oligo 
dT (OdT) primers. In summary a snap frozen thyroid tissue was put in liquid nitrogen, ground to 
a powder and put in a tube. Five hundred µl of TRizol added to the tube, followed by addition of 
100ul of chlorophorm then centrifugation. The upper layer then has been separated and 500 ul of 
isopropanol was added, and then centrifuged again. The pellet has been washed using 70% 
ethanol, then centrifuged. The final precipitate was reconstituted with RNAse free water. The 
optical density of the RNA has been measured at 260 and 280 nm wave length to obtain 
concentration and ratio. 
 Reverse transcription 5.4.7.3
Six µl of RNA (1ug/6 µl) has been added to 14 µl of reverse transcription Master Mix 
(contains dNTP, OdT primers, buffer, RNAas Inhibitor (RI) and Reverse Transcriptase 
enzyme), then placed in the Thermo cycler on reverse transcription programme (37C for 1 
hour followed by 95C for 5 minutes).  The cDNA produced has been tested by PCR of PGK 
(housekeeping gene; expressed in all tissues, to maintain cellular function [331]), using 
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master mix and PCR program (will be described in ‎5.4.7.4). The PCR product was then 
separated by electrophoresis on an agarose gel (described in 2.3.8.3).  
 PCR amplification & gel 5.4.7.4
After confirming the quality of the cDNA, PCR was performed to amplify PLCβ1 exons 3 & 
4, using the cDNA of both affected family members (IV-6 and IV-5) as well as their 
unaffected sister (IV-4). Seven unrelated thyroid cDNAs were included as controls. Three 
sets of primer were used (F2 with R4, F3 with R5 and F2 with R5). PCR master mix was 
prepared as follow: 
A 50 l reaction volume contained 2 l of cDNA (100 ng/l), 5 l PCR buffer (10x) (1.5mM 
MgCl2) (Promega), 1 l dNTP (10 mM) (Promega), 1 l forward primer (10 pmol/l) 
(Invitrogen), 1 l reverse primer (10 pmol/l) and 2 l Taq polymerase (1U/l) (Promega). A 
master mix containing all components, except the cDNA template, was prepared for each 
primer combination. This was aliquoted and cDNA samples were added. (In the negative 
control H2O was added instead of cDNA). 
PCR reaction programme used was similar to PCR1 in genomic DNA. All PCR products 
have been run on agarose gel (described in ‎2.4.7.3). 
 QPCR for amplifying exons 3 and 4 of PLCβ1 mRNA 5.4.7.5
To investigate the possibility of exon skipping further, Quantitative PCR (QPCR) was 
performed (by a colleague in the department; Dr Fiona Grennan-Jones), using the same 
primers to confirm the presence of both bands (short and long). QPCR was conducted using 
SYBR Green incorporation measured on a Stratagene MX 3000 light cycler. The cDNA 
samples from 3 family members (III-2, IV-6 & IV-4) were investigated along with thyroid 
cDNA samples from 5 unrelated controls. The experiment was performed in 3 sets of 
duplicates. 
5.4.8 The deletion impact on the PLCβ1 gene, mRNA expression 
Several PLCβ1 gene isoforms have been reported in the literature [332], the main two 
(PLCβ1a & PLCβ1b) have been investigated for family #1. Both isoforms are varying in their 
C terminal, with an extra exon (of 118 bp) in PLCβ1b. 
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PCR primers have been designed (using primer 3 software by a colleague in the department; 
Dr Lei Zhang) to amplify both isoforms (Figure ‎5.11). QPCR has been performed (by 
colleagues in the department; Ziduo Li & Dr Fiona Grennan-Jones), on 3 cDNA samples 
from family members (III-2, IV-6 & IV4) and 7 cDNA from unrelated controls. 
 
 
 
Figure ‎5.11; Cartoon showing the C- terminal of Phospholipase C beta 1 (PLCβ1) isoforms (PLCβ1a & 
PLCβ1b). PCR primers designed to amply each isoform are shown. (Fa & Ra) for PLCΒ1a, F (a & b) & 
Rb) for PLCβ1b, and (F (a & b) and R (a & b)) for both isoforms. The extra exon (118 bp) in PLCβ1b is 
shown and R (a & b) primer is located in exon 32 of PLCβ1a which is exon 33 in PLCβ1b, because of the 
extra exon. 
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Fa TCAGATGGAA GAGGAGAAGA CA 
Ra ACCTGCAGCT TGGGCTTT 
F(a&b) GAGGCTAGAA GAAGCGCAAA 
Rb CCTGCACGAA TTCCAAAATC 
R(a&b) CTTGAGAGCT TGAGGGTTGG 
Table ‎5.7; Forward and reverse primers used to amplify phospholipase C beta 1 isoforms. PLCβ1a alone 
amplified by (Fa Ra), PLCβ1b by (F a&b R b) and both isoforms by (Fa&b Ra&b) 
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5.5 Results 
5.5.1 PCR1, gel  
The expected size of the PCR product in PCR1 is 889 bp for the deleted allele but ~1700bp 
for the full length. (Figure ‎5.12) shows that all affected and carriers possess the short band (of 
~800 bp) which comprises the regions before and after the deletion. Five unaffected (IV-2, 
III-3, IV-8, III-4 & III-1) showed no bands. The remaining two unaffected (II-4 & II-1) 
showed full length (of ~ 1700 bp) bands as does the unrelated control.   
From gel images of PCR1 in all members of family #1 (e.g. Figure ‎5.12), it appears that 
members carrying the “assumed disease allele C” (in haplotype analysis, described in ‎3.8), 
displayed the short band in this PCR (Figure ‎3.12).  
5.5.2 PCR1, direct sequencing result 
When the ~800bp product was sequenced and then compared with the NCBI data base, I 
found the first ~350 bp corresponded to the expected sequence before the deletion. This was 
followed by the insertion of (ATAA) and then another ~268bp after the intervening ~1000 bp 
deleted sequence. Thus only the regions before and after the deletion were amplified 
(Figure ‎5.13) & (Figure ‎3.13). Thus the variation in the PLCβ1 is insertion and deletion 
(InDel). 
When the ~1700 bp product was sequenced then compared with the NCBI data base I found 
an exact match with PLCβ1 (the region with deletion), indicating the presence of the full 
length DNA (Figure ‎5.13). 
Since not all unaffected have shown the full length bands, PCR2 primers were designed with 
reverse primers inside the deleted region.  
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Figure ‎5.12: PCR1 products from individuals IV-6 genomic DNA, analysed by agarose gel electrophoresis 
and ethidium bromide staining. The first lane (Lad) contains the 100bp ladder, the second lane is the 
unrelated control (C) and the third lane subject IV-6 (labelled as 3). A clear band of ~800 bp in the 
patient demonstrates the deletion. The control shows a ~1700 bp of full length DNA. 
 
 
 
Figure ‎5.13: Screen shot of National Centre for Biotechnology Information (NCBI) output; (A) Alignment 
of the direct sequencing of PCR1 product for the affected family member (IV-3) and NCBI data base. 
Only a match with the first ~350 bp and the last 268bp can be seen. (B) Alignment of the direct 
sequencing of PCR1 product for the unrelated control and NCBI data base. A clear match with DNA 
without the deletion (full DNA) can be seen with forward and reverse sequences. 
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Figure ‎5.14; Screen shot of the direct sequencing electropherogram showing the deleted region and the 
junction of the regions before and after with the inserted nucleotides ATAA (red box). 
 
 
5.5.3 Exact size of the deleted region 
The sequencing result revealed that a further 77 bp are missing (before the 903 bp deletion, 
identified by Illumina chip), and further 101 bp are missing (after the 903 bp deletion, 
identified by Illumina chip), (Figure ‎5.15). By adding these 2 further missing regions to the 
deleted region and subtracting the 4 nucleotides detected at the junction that will make the 
exact deleted region to be 1076 bp. Thus the deleted region starts at 8358048 bp and ends at 
8359124 bp, at (20p
12.3
). 
5.5.4 PCR2, gel and direct Sequencing 
All family members including the founders and the control showed a single band of ~ 1300 
bp on the gel (Figure ‎5.15). Sequencing data of PCR2 (~1300 bp) were BLASTed using 
NCBI data base. An exact match within the PLCβ1 sequence (containing the deleted region) 
was observed. Thus PCR2 was able to amplify the full length DNA copy, as the reverse 
primer was in the deleted region.  
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ATCCCATGGCAGTTAATATGGAATCTGTTGTGGTTTGTGGATTAGTTGTGTGATTCAGGTGCCATTGGAG 
GTTTCTGGAAGAGAAGGGCCTTTTAAAAGCCTCTGAGAGGCCAGTATTATCCCCAGAAAGAATGAGAGGA 
GGTTTATTGTATGCACGCAAGCAATATCTATGAATCCCTTTACTTGCTTGTATCTTACCCTCTTCTGCCC 
TAGGAACAGGCTCGTGGGAGAAGTGACCCAACTACACCTTCCTGCCAGTCTCGAGCATTTTAGGTGTTAA 
CCACCAAAGTGGCTGACACATGTACTTACTCACTTGGTTTTAATTTGCAGAGTAGGAACAATGGACTTAG 
ATTTTTTTAAACTTCTCTAACTCTTTAATCACTGAATGAAATAACTCATGTTGGAAAGACAAAGAATTTC 
CTGGTAGACCTTTTGAACAAGAGCTCATAGATTTCAGTGCCATTGGTAGCCAATGTGATACCATGGCATT 
GTTGTCTATTGTGTTTTTTAGGTTGTGACCTATTTGTGGGTTATGAATTCAATTTTGTGGATTGGGACCT 
GCAATTTAAAAAAAAGATGAAGGAAATAGAACATAATAGAGTCAAGCGCCATGCAATACAAAATGTCAGA 
GGTATCCCAACTAACAAGGGTGAATGATGGTTTGTAAAACTTCAGTTACGTATGTATACGTGCATGTATG 
AGTGTTCTGAGTGATAATATAAAATGCATTTTTTACTGAGGAGCATGATCAGAACAATATCAAACCATTG 
ACCAACATCAACATATTTCTATTAGAAAGATATTTAAATGAAGTTTGTATAGTAAAAGGAAGAAAGAACA 
CTAAAATATTTGCAAATCTACCCTGCACAGTCACTTTAATCTTTTCAGCTTCTAATTGAGATAGATGCTC 
TATATTACCCTGTTTATTAATAAACCCTCAAAGATCTAAAAAGGTGAATTAACTCTCAGGGGCTTTAACA 
GATAAATTAACTTGAACCTGCCTAGTTGTCTGTTTCAGAGCCAGAATTCGAACATGGATTCATTTTAGCC 
GCAGTAAGCACCTGTGTTAGTCAGAATTCAGTGTGGGTAACAGAAGGGCAGGCCAGATTGGAGAGAGCTG 
GAAACATATTCCAGGTAGAGACAATGGTGCCTGATGAAGCCTAAGGGTCTGAATGCTGGAGTAAAGCCAG 
GGGTTATTTACACTGTGACTGGGTGTGAATCTACAGATAGATCTGAAACTAGAAGATAAGCCCATGAAGG 
AAATGGGAAAATGTGCCCTGATTTTGAGTTACATTAGCAAAAAAAATCAAAGCTGAGTCCAAGATGGAAG 
AACATCTACATAATTAGAGAGGACAGAAGTGATCACGAAGACCTAGGGGACAGGGAGAGGCCTCAGGTAA 
TGCAAAATCTGTACATAATGATTGAGGTCAGGAGAACAGATGCTCTTCCCGGGTCAGTTTTAAGGCTGAA 
ATGTTTCAGGAAAACTGGGAACAAAGCATGGTTGGAAATAGCAGGCTAAGCTGATGCATCAGGAGACTGC 
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AGATCTCAGTGTTACCTTGCCTGGGAACAGGATGGGCCCCAAGTATGGCTGAGAATGCAAGTCTCATGGG 
TATATGTTTAATGAACCTAGTTGGGAGATGTTAGGAGGAAGACTGGTTCTGATGTGAAAGTTTCCTTCCA 
AAGAATAGGCCAACCTAACTGCAGCAGTGCTGATTATGATGGAAATTTCCTATTTTGATTCTTCATCAAA 
AGAAAGAAGAGCCGGTACCATGGTTCTTGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGAGGATC 
ACTTGAGGCCAGGAGTTTGATACCAGCCCCTATAGGAAACATAACAAGACCCCATCTCTACTAAAAATTA 
AAAAATTAGCCTGGCATGGTGGCTATGTGTCTTAACAAGACCCCATCTCTACTAAAAATTAAAAAATTAG 
CCTGGCATGGTGGCTATGTGTCTTTAGTCCTAGCTACTCAGGAGGCTGAGGCAGGAGGCTCTCTTGAGCC 
 
Figure ‎5.15; The region of direct sequencing output showing position of the deletion in phospholipase C 
beta 1 (PLCβ1) gene. The deleted region identified by Illumina chip is highlighted in yellow. The exact 
deletion, identified by direct sequencing is highlighted in both yellow and green. Primer pair for PCR1, 
flanking the deleted region (highlighted in blue). Primers pair for PCR2 (typed in bold). Thus the exact 
deleted region is 1076 bp. The single nucleotide polymorphism (SNP) (re6055812) used to identify the 
exact location of the deletion (A) is in red. 
 
Figure ‎5.16; PCR2 products from all individuals genomic DNA, analysed by agarose gel electrophoresis 
and ethidium bromide staining. The first 9 lanes contain DNA from family individuals (labelled as in 
family tree). Lane 10 (Lad) contains the 100bp ladder and lanes 11-18 contain DNA from family 
individuals. Lane 19 (C) contains unrelated control and lane 20 (-ve) contains the negative control (master 
mix without DNA template). A ~1300 bp amplicons in all family members and unrelated control are 
shown, which indicates a presence of full length DNA (with PCR2).  
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5.5.5 Screening DNA samples from patient with MNG of PTC  
Through collaboration with Dr Clifton Bligh in Sydney Australia, genomic DNA was 
extracted from thyroid tissue of 70 patients (all of self-reported white European ancestry) 
undergoing surgery for non-familial PTC and an additional 81 operated for non-familial 
MNG. PCR1 has been performed on both groups of samples, as screening for “InDel” in 
PLCβ1. The deletion was not detected in any of the PTC patients but 4 of the 81 MNG were 
heterozygous for the deletion. The direct sequencing showed the same picture as in family #1, 
including the insertion of (ATAA). The 4 MNG patients (3 women, 1 man) known to be 
unrelated and with no apparent family history of MNG or PTC at the time of their surgery. 
The age at thyroidectomy was from 27-59 years and the pathology is variously described as 
‘oncocytic neoplasm with variable patterns of growth’ to ‘cystic degeneration with 
calcification’. The histology in the family comprises ‘multiple papilloid adenomata’. 
5.5.6  Rarity of the “InDel”‎in‎PLCβ1 gene. 
To confirm that this deletion is not just a normal variant in the general population, it should 
not have frequency of > 1%. In addition if deletion frequency was >5% in a disease cohort 
then it could be considered as pathogenic (as described in ‎5.1.2). To investigate that 
practically, PCR1 has been performed on 105 DNA samples (from unrelated individuals). A 
literature search has also been done looking for the same deletion and its frequency among 
CEU. 
  Practical investigation; PCR1 on 105 DNA of unrelated people 5.5.6.1
Out of 105 DNA samples from unrelated individuals (Figure ‎5.16), 104 showed no deletion, 
while the deletion has been detected in one sample (17D), making the frequency of 1% in the 
normal population.  
The only sample with the deletion was a 40 years old euthyroid female (limited information 
of disease status is available). Direct sequencing has matched the regions before and after 
deletion, including the ATAA insertion at the junction, as in the affected members in family 
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#1. PCR2 has also been run on this sample and a full length amplicon was obtained (as in the 
members of family #1). 
 
 
 
 
 
Figure ‎5.17; PCR1 products from some unrelated DNA samples (1D-19D), analysed by agarose gel 
electrophoresis and ethidium bromide staining. Lane 1 & lane 20 (Lad) contain the 100bp ladder. Lanes 
2-8, 10-13, 15-19 & 22--24 contain DNA from 1D to 19D respectively. Lane 9 (-VE) contains the negative 
control (master mix without DNA template). Lane 14 (IV-7) contains DNA from affected family member 
and lane 21 (X) is empty. The products are showing the expected ~1700 bp amplicons in most of them 
(and no band in the other). Only (17D) has shown the short band (~800 bp), in addition to the affected 
family member IV-7 which was used as a positive control.  
 
 
 Literature search for frequency of the deletion in CEU 5.5.6.2
By looking in “Databases of Genomic Variant” website (dgv.tcag.ca), (Figure ‎5.18), for the 
deleted region, 7 studies were found which reported CNV (deletion or duplications) in the 
PLCβ1 gene, of which 4 were deletions [308, 311, 333] & [334] (Table ‎5.8). First study “a 
comprehensive, population-wide CNV map of the human genome” [311], has reported a 
deletion of one copy (LRR = -0.645), at the same region (8,358,097-8,359,094), and labelled 
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as “CNVR7782.1”. The deletion was found in 2 out of 180 CEU, but not in 180 YRI, 45 JPT 
neither in 45 CHB, of the same study. The second study [333], has used the same samples as 
the first study [311], including 60 individuals from CEU population. Both studies (1
st
 & 2
nd
) 
have detected “CNVR7782.1” deletion in the same 2 individuals (NA12154 & NA07037). 
Thus the second study was not added to the total. The third study [308] has investigated CNV 
in 270 individuals 90 of which were CEU. Fourth study [334] investigated a large cohort 
(2026 individuals), comprising 1320 Caucasians (65.2%), 694 African-Americans (34.2%), 
and 12 Asian-Americans (0.6%). The last two studies (3
rd
 & 4
th
) have reported intronic 
deletion (of > 0.35 Mb) at 20P
12.3
, a huge region includes CNVR7782.1 region (Table ‎5.8), 
but were unable to detect small deletions.  
Since only the first study was able to detect the CNVR7782.1 deletion, it will be taken in 
account in investigating the rarity of the PLCΒ1 deletion. Thus 180 CEU and 450 other have 
been investigated and two “CNVR7782.1” deletions have been detected in CEU, but none in 
the others, giving deletion frequency of ~1%. 
 
 
 
Figure ‎5.18: Screen shot of the output from databases of genomic variant (DGV)”‎websites‎for the deleted 
region, showing 7 studies at that region. One of the studies reported deletion [311] (red line), one reported 
deletion and duplication [308] (brown line) and one reported duplications (blur line) [335]. A full 
description is in the text and (Table ‎5.8). 
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Study CNV  Starts (bp) Ends (bp) Size (bp) CEU  Other  
Family #1 inDel 8,358,048 8,359,124 1,076 18   
Unrelated control inDel 8,358,048 8,359,124 1,076 105  
Conrad et al 2009 [311] Deletion 8,358,097 8,359,094 997 180 270 
Redon et al 2006  [308] Deletion 8,002,182 8,595,665 593,483 90 180 
Redon et al 2006 [308] Duplication 8,022,116 8,536,318 514,202 == == 
Pinto et al 2007 [335] Duplication 8,050,867 8,517,610 466,743 506 0 
Table ‎5.8: Summary of the studies reporting deletion at the region of interest or closer. First column 
(study) reports the name of the study in which Family #1 and samples of the unrelated control are also 
included. Second column (CNV) reports the type of the Copy number variation (CNV). Third (starts 
(bp)) and fourth (ends (bp)) columns report start and end of each CNV. Fifth column (size (bp)) reports 
the size of CNV. The size is precise in family and unrelated control, due to PCR and direct sequencing, 
but presumed in the other studied as depends on the chip analysis only). 
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  Investigation of exon 3 or 4, skipping, by PCR of cDNA 5.5.6.3
I hypothesised that the deletion might induce exon skipping, assuming that PCR product of 
F2 & R4 primers to be 226bp in normal case and 157bp in case of exon 3 (69bp) skipping. 
PCR product of F3 & R5 primers was assumed to be 265bp in normal cases and 127bp in 
case of exon 4 (138bp) skipping. The gel pictures have shown a clear single band of the 
correct expected sizes, which has excluded exon skipping (Figure ‎5.19). However the band 
obtained could be the product of the full length copy while the deleted copy (with missing 
exon 3 or 4) may not be visible. Therefore further investigation was made by colleagues and 
confirmed that no exon skipping had taken place (as described in ‎5.4.7.5). 
 
 
 
Figure ‎5.19; PCR products from cDNA of three members of the family IV-4, IV-6 & IV-3 and three 
unrelated cDNA controls (C1, C2 & C3), analysed by agarose gel electrophoresis and ethidium bromide 
staining. Three combinations of exonic primers used to amplify exon 3, exon 4 and both exons 3 & 4. Lane 
1 (Lad) contains the 100bp ladder. Lanes 2-7 contain exon 3 of cDNA from IV-4, IV-6, IV-3, C1, C2 & C3 
respectively. Lanes 8-13 contain exon 4 of cDNA from C1, C2, IV-4, IV-6, IV-3 & C3 respectively. Lanes 
14-19 contain exons 3 & 4 of cDNA from C1, C2, IV-4, IV-6, IV-3 & C3 respectively. The gel shows a 
clear single band of both exons (3 & 4), indicating no sign of exon skipping. 
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5.5.7 mRNA expression investigation by QPCR 
Expression of PLCβ1 isoforms (PLCβ1a & PLCβ1b) by QPCR was performed using the 3 
cDNA samples from family members (III-2, IV-6 & IV-4). Comparison between mRNA 
expressions of both isoforms in the three members vs. normal controls indicated high 
expression of both isoforms in the affected and carriers family members compared with the 
unaffected unrelated controls. However, expression of the PLCβ1a isoform was higher than 
the PLCβ1b isoform in all family members as well as the unrelated controls.  
 
 
 
Figure ‎5.20; QPCR output chart showing mRNA expression level of phospholipase C beta 1 a (PLCβ1a) 
& PLCβ1b, on 3 cDNA samples from three affected members IV-6, IV-4 & III-2 of family #1, (labelled as 
#3, #6 & #1 respectively) and 5 normal controls (N1-N5). The data show higher transcript levels (of both 
PLCβ1a and PLCβ1b) in family members compared to normal controls. The PLCβ1a expression is higher 
than the PLCβ1b in all family members as well as the unrelated control 
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5.6 Conclusion  
The PCR amplification and direct sequencing of the deleted region of 903 bp identified by 
Illumina chip, by PCR1 with primers flanking the deletion and ~440 bp apart from both side, 
was expected to show a short band ~880 bp in the individuals having the deletion 
reproducing the ~ 440 bp region before and ~440 bp after the deletion. However, only ~ 270 
bp were seen after the deleted region (Figure ‎5.13). That is because the deletion was not only 
903 as shown by the chip, but 1076 (as described in ‎5.5.3). Several different PCR primers 
were tried before identifying the right pairs, which were able to amplify the region. Even 
though, it was difficult to amplify the undeleted copy in affected family members which 
could suggest that, there may still be more to understand about the variations in chromosome 
20 in the family, especially in light of the negative LOD score on the downstream region of 
20p, at 20P
11.23
 (20.8 Mb, 45.6cM) and below.  
The 2 sets of PCR (PCR1 & PCR2), with primers flanking or within the deletion, have shown 
that both deleted and undeleted regions can be amplified.  
The PCR products of some affected family members show faint bands as seen in 
(Figure ‎5.15), which either indicates less copies of the product or poor quality of DNA 
samples, possibly because some samples were collected many years ago (over 10 years). 
The deleted region identified by Conrad et al, (CNVR7782.1) was shown to be shorter than 
that found in this study. Although not many details are available in the article, it seems that 
the identifications in all CNV studies (shown in Table  5.8) depend only on the chip analysis 
and do not include direct sequencing. Even in my study the deletion identified by Illumina 
chip was of 903bp size, but after PCR and direct sequencing it was found to be 1076bp. 
Since the revolution in Oligonucleotide arrays, plenty of studies have been performed on the 
whole genome, one of which [336] has linked CNVs with recurrent alteration involving a 
region on chromosome 20 (20p
13
) in 55% of primary myelo-fibrosis patients. Another study 
[337] has evaluated the resulting effect of LOH on the gene expression in triple-negative 
breast cancer (TNBC), showing that the majority of mono-allelic expression of TNBC can be 
explained by genomic regions of LOH.  
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My study has used a highly informative array with 660,000 markers including both SNP and 
NP markers, which has given great strength to the output. Identifying a deletion at the same 
region where maximum LOD was obtained is a strong evidence of correlation between the 
two. Furthermore having the deletion in the affected or carriers of the C allele was another 
significant finding supporting that this study is going in the right direction and encouraging 
for further investigation.   
The presence of the deletion in one samples out of 105 DNA investigated in the lab and in 
two samples out of 108 CEU investigated for CNV by Conrad et al, has concluded that the 
deletion is rare in CEU population with 1% frequency. Furthermore, it was not possible to 
obtain more information about the woman, identified with the same deletion out of the 105 
DNA from unrelated individuals screened by PCR1. I cannot exclude the possibility that she 
has MNG, especially as she was in a cohort of people in whom testing thyroid function was 
indicated when visiting their GP (as described in ‎5.4.6). 
Furthermore, I have searched for any open reading frames in the deleted region, (with and 
without ATAA), but none of any great length were found. The first ORF was 110 bp (36 
amino acids) before the deletion (200 bp upstream from the ATAA insertion), and contains 
one start codon ATG and one stop codon TAA. The second was 125bp (41 amino acids) in 
the deletion (40bp before the end of the deleted region), with 4 ATG start codon and one 
TGA stop codon. The third ORF was 110 bp (36 amino acids), located 245bp after the 
deleted region, with 3 ATG start codon and one TGA stop codon. 
In addition an experiment to investigate exon (3 & 4) skipping in cDNA of some affected in 
family #1 was done using standard end-point PCR and also QPCR. Both confirmed that no 
exon skipping had taken place. In standard PCR, I expected to see large (full-length) and 
small amplicons but only the latter were routinely observed. Although the strength of the 
band could give clue of being for two copies or a single copy, but this is not quantitative 
method. Therefore QPCR was necessary at this stage to calculate the number of DNA copies 
and thus identify any deletion of one copy.  
PLCβ1 occurs in several isoforms, the main two are PLCβ1a and PLCβ1b. Expression of 
both isoforms has been investigated in thyroid tissues from family vs. controls (tested for the 
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PLCβ1 deletion), using QPCR measurements, which indicated significantly higher PLCβ1 
transcript levels in thyroids from family members with the deletion, compared with controls 
who do not harbour the deletion. This could give a clue that MNG/PTC in the affected family 
member could be due to over-expression of PLCβ1, which is due to the deletion. Increased 
PLCβ1 expression has been reported in lung carcinoma[338] and high activity of PLC 
enzyme has been reported in thyroid neoplasms[339]. Furthermore CNVs in chromosome 20 
have been reported in breast cancer [340], although these were shown to be associated with 
deletion of the entire PLCβ1 gene [341, 342].   
PLCβ1 generates IP3 and DAG leading to PKC activation via G protein-coupled receptor 
signalling to the MAPK cascade[343]. BRAF is downstream of the Gq/ PLCβ1/MAPK 
signalling route, and activating mutations of BRAF, mainly BRAF
V600E
, which is the most 
common cause of PTC and play role in thyroid proliferation [176]. 
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Chapter 6 General Discussion 
The aim of this work was to characterise the gene-defect behind the novel cause of euthyroid 
MNG of adolescent onset, progressing to PTC in 8 individuals across 4 generations of a large 
European family. The same family has been previously investigated during my MPhil study, 
when I have eliminated the candidate genes on the basis of thyroid/breast and thyroid/kidney 
disorders (PAX-8, NIS), by Sanger sequencing, through which PTEN was eliminated as well. 
I have also excluded the known loci for MNG and FNMTC on chromosomes 14q, Xp, 3q 9p, 
2q and 1q, by Microsatellites analysis [181].  
Thus in this study I have started with mapping the gene disposing to MNG/PTC in this 
family, I performed a dense GWLA, using high density Affymetrix 10k SNPs array. In 
chapter 2, I have processed the microarray protocol and obtained the genotyping of over 
10,000 SNPs for all 18 family members. My study was performed some years ago, when 10K 
chips were more widely used. Several studies have reported the use of this chip, one of which 
reported that the chip was quicker than others [2]. Another study has used the same chip to 
scan the whole genome chromosomal copy number for renal epithelial tumours classification, 
by analysing 20 paraffin-embedded tissues and reported that SNP array can detect 
characteristic chromosomal abnormalities in such samples, thus recommended as a 
supplementary study to classify and test prognosis of such tumours [3]. Bigger chips such as 
500K, which are more preferable these days, started to be available at that time, but obviously 
were more expensive but may have saved me having to use two chips (10K & 660K) in my 
study. The second and larger was for CNV and this data would have been available if I had 
used a chip with a larger SNP set for the GWLA.  
In chapter 3, I undertook a genome-wide linkage analysis after an extensive quality control 
check using several softwares (PLINK, GRR). A Genome-wide significant evidence of 
linkage to chromosome 20P
12.3
-P
11.23
 was obtained, with a maximum non-parametric 
(multipoint) LOD score of 3.01, across 20cM, using Merlin software. The same region 
showed a maximum (multipoint) dominant LOD score of 2.03, based on a disease model with 
0.01 allele frequency, 50% penetrance for males and 90% for females, age of onset for both 
>12. LOD scores on the remaining 21 autosomes and X chromosome were all below 1. The 
software used to perform these analyses (Merlin) is very popular, reliable and has been used 
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for estimating IBD (identity-by-descent) allele sharing probabilities in pedigrees in many 
studies [4], one of which [5],  has used Merlin in linkage analysis and reported Pendrin as a 
new susceptibility gene for autoimmune thyroid disease.  In contrast to other complicated 
software, I have found Merlin straightforward and easy to use, especially for a 
nonmathematical person like me. 
Although haplotype analysis is taken into consideration by Merlin while performing 
multipoint npl, analysing it separately has given me visible data which I can see and judge. 
Thus I found one haplotype, from rs1923876 to rs1099620 co-segregated with the affected 
phenotype in all 8 patients and 4 out of the 6 unknowns, one of which is an obligate carrier 
and has the haplotype, while the 4 founders in the family were not having the haplotype. One 
of the 2 unknowns not having the haplotype (IV-2) has presented telomeric recombination 
events at rs1923876, while the other (III-3) has presented centromeric recombination events 
at rs1099620. Combination of the haplotype region with maximum npl LOD score region 
(starts at rs2223539), has delimited the susceptibility region to an 8.73 cM (3.7Mbp physical 
position) span on chromosome (20p
12.3
-p
12.1
), which encodes 10 genes. Haplotype analysis 
has been used in many studies to represent the assumed disease or risk allele [344]. The 
usefulness of the method has also been increased by the haplotype data released from samples 
in the 1000 genome project [192] or international HapMap project [193].   
The 10 genes found in the candidate region are PLCβ1, PLCβ4, LAMP5, PAK7, ANKEF1, 
SNAP25, SLX4IP, MKKS, JAG1 and BTBD3. I started with an in silico analysis, searching 
for previous reports of any of the 10 genes in either MNG or PTC cases or any GWLA 
reported linkage with disease. Since thyroid diseases are more common in women than men 
[345] and in vitro studies reported that estrogen can promote thyrocyte proliferation[346], my 
in silico analysis has included, searching for binding sites for estrogen receptors in the 
promoters of these genes. In addition, my in silico analysis included expression of these 
genes in different tissues including thyroid. No solid evidence was observed which could 
point out a candidate gene or help in decreasing the number of genes for further investigation.     
After my first publication [181], a second family (family #2) has been introduced to our 
department showing similar signs and symptoms of MNG even similar histopathological 
picture for malignant thyroid cell (multiple papilloid adenomata). GWLA was performed on 
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6 individuals of that family, 4 of which are affected. In case of any positive LOD score in 
family #2 at the candidate region in family #1, both LOD scores would be added to each 
other increasing the maximum LOD score and giving more strength to the study. No common 
genetic variants were found in the families, as the region of interest in family #1 on 
chromosome 20 showed negative LOD scores in family #2 and no shared region with high 
LOD score in both families was obtained. Thus the data from the second family were not 
taken into account for any further analysis.  
I also investigated FOXE-1 gene in family #1. This gene has been reported as the strongest 
genetic risk marker of sporadic PTC in European populations [178]. Subsequent studies 
focussed on the length of poly-alanine tract in the gene, which varies between (9Ala) and 
(16Ala), with 14Ala being the most common and considered as wild type (WT), while 16Ala 
is the second most common. The tract length was shown to be in linkage disequilibrium with 
SNP rs1867277 with FOXE-1 (16Ala) being associated with the allele for PTC. Functional 
studies in vitro showed that FOXE-1 (16Ala) was transcriptionally reduced compared with 
FOXE-1(14Ala) [347]. I have screened all affected family members and some unaffected for 
the poly-alanine tract, but not found any communal picture among the affected only. The 
results of affected were as follow: (I-2) with 14/14, (II-2) with 14/14, (III-2) with 14/14, (III-
5) with 14/16, (IV-1) with 14/14, (IV-3) with 14/14 & (IV-6) with 14/14, while (IV-7) has 
not been tested as she was unaffected at that time. The unaffected have shown (III-1) with 
14/14, (III-3) with 14/16 & (III-4) with 14/14, (Figure App.‎6.1, in Appendix D1a).  
Furthermore rs965513 (located at ~100,556,109 bp) was also reported to be associated with 
thyroid cancer. I have investigated both SNPs, rs965513 which is located close to FOXE-1 
gene and shown to be associated with increased risk of both PTC and FTC [91], and 
rs1867277 (located at ~100,615,914 bp) which is located in the FOXE-1 gene upstream to the 
fork-head domain and showed strong evidence of association with PTC susceptibility and 
linkage disequilibrium with FOXE-1 (16Ala) as mentioned above [347]118. The functional 
study of the latter has shown effect on FOXE-1 transcription [179]. I have studied both SNPs 
region in the GWLA data of family #1, by looking at the SNPs in 10K chip, flanking that 
region and found rs953199 at 99,522,797 bp and rs1407501 at 100,638,262 bp, (Figure 
App.‎6.2, in Appendix D1b). No linkage with either SNPs has been observed as npl LOD 
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score was -0.16 and dominant LOD score was -2.4, the latter suggests rejection of the 
hypothesis of linkage as LOD < -2 (described in 3.2.2  ). The same investigation was 
performed on the combined data for families #1 & #2; npl LOD score was -0.1, while 
dominant LOD score was -1.3, suggesting no linkage. 
I have also genotyped the above 2 published SNPs, by designing flanking primers and direct 
sequencing the region, using DNA samples from all affected members in family #1 and some 
unaffected as control. The risk allele [A] of rs1867277, which show high frequency in PTC 
and was associated with FOXE-1 (16Ala) [347], was not found in the affected members of 
family #1. Same results obtained with risk allele A of rs965513 which showed strong 
association with thyroid cancer in GWAS [91].     
The large region identified with a high LOD score in family #1 on chromosome 20 
encouraged me to perform copy number variation (CNV) analysis, but only on the DNA of 
the index patient (IV-6)  due to expense. I have used Illumina chip (Human 660W-Quad), 
which contains 660K markers, of both SNPs & NP types. That has identified an intronic 
deletion of ~900 bp in one copy of phospholipase-C β1 (PLCβ1) gene, (the first in the 10 
gene list at the region of interest), by 14 markers of this chip. I have used the probe sequences 
of one of these markers to identify the exact region of the deletion and design PCR primers 
flanking and within the deletion. A standard PCR and Sanger sequencing have shown one 
copy of full-length amplicon and one deleted allele in all affected and obligate carrier (II-3), 
but only full-length allele was shown in the unaffected members of family #1 (mainly the 
founders). The output of haplotype analysis in family data was in accordance with this 
finding, i.e. all individuals carrying the assumed disease allele C have the one copy deletion, 
but the other haven’t. Thus I came to a conclusion that there is a possibility of a chance 
finding of a segregation of this CNV (deletion) in family #1. The sequence result (with 
primers flanking the deletion) was matching that upstream and downstream of the deleted 
region but with an additional ‘ATAA’ inserted at the junction. That has indicated a possible 
‘cut-and-paste’ event arising from activity of a transposable element (jumping genes). 
Remarkably, 11kb transposon cluster has been reported in PLCβ1 gene recently [348], at 
20p
12.3
 (between 8,305,141-8,316,644 bp), which is immediately upstream of the 3.7Mbp 
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section on chromosome 20 displaying the non-parametric LOD score of 3.01 in the current 
study. The PLCβ1 gene is located between 8,061,299bp and 8,730,801bp. 
Furthermore, I and Professor Marian have thought to screen known cases of MNG and PTC 
for the same deletion, by the same standard PCR, so collaborated with Thyroid team in Royal 
North Shore Hospital, Sydney (Dr. Martyn Bullock & Dr. Roderick J Clifton-Bligh). The 
screen was performed on genomic DNA from thyroid tissue of 70 patients (European) who 
underwent surgery for non-familial PTC, and on an additional 81 from non-familial MNG 
(European). Samples from PTC patient have not shown any deletion; however, 4 of the 81 
MNG (all unrelated) were heterozygous for the deletion with the same ATAA insertion in the 
direct sequencing at the junction. Thus this variant could be described as an InDel, since it 
includes a combination of deletion and insertion. 
To confirm that the one copy deletion is rare in the population, I have screened 105 DNA 
samples from unrelated individuals who needed their thyroid hormone levels checked for 
psychiatric reasons and thus considered as normal Caucasians. One out of the 105 showed the 
same deletion (heterozygous) and it was an euthyroid woman in her forties. That has given a 
1% frequency of the deletion in a normal population. Realising that 105 DNA samples are not 
enough to confirm normal population frequency, I referred to the database for genomic 
variants webpage: (http://projects.tcag.ca/variation/), in which several deletions (> 5Kbp) 
were reported at that region. Only one was similar (~1Kbp) as in the family #1. That deletion 
was reported on 2 out of 180 Caucasian giving a 1% frequency and not found in more than 
450 people of other ethnicities[311]. That has revealed 3 in 285 Caucasians harbouring the 
deletion, suggesting that it is rare. Furthermore, putting in mind the prevalence of goitre the 3 
identified with the deletion may also have MNG. Evaluation of the frequency of the deletion 
in general population vs. in MNG cases, gives a X
2 
value of 5.076 (1 degree of freedom), p= 
0.024 (two-tailed). Since the same deletion was found in other MNG patients that has re-
assured us that the right choice had been made. Very few analyses have performed study on a 
large population after testing a single family. One such [83], has tested a large family with 
MNG/PTC and identified a locus on chromosome 14q (MNG1), but study of 37 small 
pedigrees revealed a very small proportion was attributable to MNG1. Another study [87], 
tested a large family with recurrent PTC and obtained a LOD score of 1.28 on 2q21, then 
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studied 80 pedigrees and obtained a LOD score of 3.19. Out of the 80 pedigrees 17 family 
were selected (based on the presence of at least one case of follicular variant of PTC), and 
studied again, a LOD score of 4.17 obtained.  
Furthermore, MNG/PTC investigation has been performed on a big cohort including 20 
unrelated PTC patients with a history of MNG (MNG/PTC), other 284 PTC patient but 
without MNG history and 349 healthy controls. TITF-1 (NKX2.1) germline mutation 
(A339V) was detected in 4 out of the 20 PTC patients with MNG history, but not found 
among the 349 healthy controls nor among the 284 PTC patients with no MNG history. These 
4 mutant patients showed more advanced tumours than all other patient (300) in the same 
study. Overexpression of A339V TTF-1 in rat cells was associated with increased cell 
proliferation compared with WT, in addition to TSH independent growth and impaired 
transcription of the TG, TSHR, and PAX-8. This germline mutation was dominantly inherited 
in two families, with some members bearing the mutation affected with MNG, associated 
with either PTC or colon cancer [349].  
I also investigated how the deletion, or the novel junction sequence it generates, might affect 
the thyroid gland so I searched for micro RNA (miRNA), in both sequences against miRBase 
software [350], but did not find any significant hits. I have collaborated with the creators of 
miRBase software; Faculty of Life Sciences, University of Manchester where Dr Antonio 
Marco searched for hairpin structure in the deleted region (with and without ATAA) using 
RNAL fold program, but didn't see any hairpin likely to be a microRNA [351]. 
Goitre prevalence in women is 2 to 10 fold higher than in men in common with MNG, PTC 
and all other thyroid disease [345, 352]. That made me to think about a relation between the 
deletion and any female sex hormones; estrogens. In addition to their effect on reproductive 
cycles, they have shown to activate G-protein coupled receptors [353] besides, enhancing 
normal thyroid cell growth and thyroid cancer cells [346]. Estrogens like other steroid 
hormones, after entering the cell bind (via specific binding sites) and activate estrogen 
receptors (ER) which control several genes expression and are of two types; ERα and ERβ. 
ERα agonist is shown to be promoting thyroid cancer cells proliferation, while ERβ agonist 
reduces this proliferation. Thus thyroid proliferation increases when ERβ is down-regulated 
[354]. A study [355] mapped ERα binding sites in human breast cancer cell line and  
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identified > 1,200 ERα binding sites in the human genome. Only 5% of the mapped ERα 
binding sites were located within promoters and the majority were mapped to intronic or 
distal locations. This information has encouraged me to collaborate with Dr Davy Kavanagh, 
who has been introduced by my co supervisor Dr Marian Hamshere. He explored the deleted 
region in PLCβ1 and identified a presence of binding site for the ERα within the deletion, 
using data from the Encyclopaedia of DNA elements (ENCODE [348]).  
I also conducted experiments on thyroid tissue from three affected family members who 
underwent thyroidectomy. I have extracted RNA from their tissues aiming to study any 
possible mechanisms by which the deletion might affect PLCβ1 function. I hypothesised that 
the deletion in intron 3 may leads to exon skipping, before the deletion (exon 3) or after (exon 
4). To investigate that, I have designed exonic primers to amplify exon 3 & 4 using cDNA 
from the above tissues and standard PCR and direct sequencing; both exons were present, 
with no additional bands that could indicate transcripts missing exons. However this method 
was not enough to calculate the transcription level. Thus two of my colleague in my 
department; (Dr Fiona Grennan-Jones & Dr Lei Zhang), have repeated the exon skipping 
investigation, using QPCR analysis, and calculated the transcription levels, but did not detect 
skipping of exons 3 or 4 (flanking the deletion). They have also investigated mRNA 
expression of two main PLCβ1 isoforms by QPCR using the same cDNA and found higher 
PLCβ1 transcript levels (p< 0.02) in thyroids from the three affected family members, 
compared with normal controls. This could give a clue that the germ-line deletion in PLCβ1 
may lead to over expression and that leads to MNG/PTC in the family. Higher expression of 
PLCβ1 has been reported in small cell lung carcinoma[341] and increased PLC enzyme 
activity has also been reported in thyroid neoplasms[338].  
Furthermore the deletion is in the middle of intron 3 (with 58kb before and 197Kb after the 
deletion), of PLCβ1 gene which encodes phosphoinositide-specific enzyme, that play a main 
role in G protein-coupled receptor signalling to the MAPK cascade, via IP3, DAG, PKC and 
BRAF [343]. BRAF is a downstream element of the Gq/ PLCβ1/MAPK signalling pathway. 
This pathway was shown to be essential in the growth of the gland as seen by Kero et al 
[356], who studied Gqα/Gq11deficient mice and reported absence of TSH proliferative 
effects and  resistance to goitre formation when on a goitrogenic diet. The cascade 
185 
 
involvement has also been reported in thyrocyte proliferation[176]. Several recent studies 
have reported BRAF activating mutations mainly BRAFV600E in many PTC [120]. I have 
screened genomic DNA of all affected members in family #1 for BRAFV600E mutation, and 
was excluded in this family. 
PLCβ1 is not thyroid specific but may have an impact on some feature of thyroid biology 
which is, e.g. H2O2 generation. Production of H2O2 has been shown to be activated by PLC 
and Ca
2+
/DAG, whilst the cAMP cascade was shown to inhibit H2O2 generation [75]. I
- 
oxidation by TPO, requires H2O2, which is generated by the calcium dependent DUOX 
family, that contains calcium-binding sites [6]. Higher concentrations of H2O2 can cause 
DNA oxidation and damage, leading to mutagenesis and apoptosis [73] and has been 
suggested as one mechanism contributing to the formation of endemic goitres in human [74]. 
Thus if PLCβ1 activity is increased due to the deletion, it may lead to higher levels of H2O2 
and could explain why the PLCβ1 deletion has an effect only on thyroid, despite PLCβ1 
being widely expressed in all cells/tissues of the body.  
In some studies [269], after GWLA using SNPs, a further scan used microsatellite markers to 
narrow the candidate region, then sequenced all genes in the region and checked for loss of 
heterozygosity. In my study further scanning using microsatellites was not required since the 
candidate region was small enough to eliminate that screen; however in-depth sequencing of 
the 10 genes could be a future option. This could be performed using next generation 
sequencing or whole exome sequencing which provides data on both exons and introns. 
Sanger sequencing of all exons using standard PCR could be an option, but with recent 
studies confirming several roles of noncoding DNA, data of exons only could miss important 
information. 
The limitation of this study is that it is not showing the percentage of the European 
population, this deletion represents. However, this will be clarified by investigating more 
affected individuals and controls. The work in this part is already started via screening more 
European samples by collaborating with a thyroid groups in German (Prof. Dagmar Führer) 
and in Italy (Prof. Rossella Elisei). Around 400 known MNG cases from areas with varying 
levels of iodine intake are targeted to be screened for the same deletion. That will provide an 
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idea of deletion frequency in patients with MNG and give a chance to compare with healthy 
population (controls) which will also be screened in the future.  
What makes my study unique, is that I have found the deletion in one family then in another 
4 MNG unrelated cases, while almost all previous studies have investigated one family then 
worked on other families which make their finding more family based, while this study 
started with familial MNG/PTC but was found to be relevant to sporadic disease too. 
In conclusion, the deletion I identified in familial MNG also occurs in sporadic MNG, and 
may provide a biomarker to identify MNG patients most likely to progress to PTC. It 
predisposes to goitre formation, possibly by increasing PLCβ1 transcription and thereby 
activating the PKC and MAPK pathways. 
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Appendices 
 (Appendix A) 
(Appendix A1a) 
Using PLINK software: 
In order to use PLINK a Map File has been created with 3 columns of data; the list of all 
markers, chromosomal ID of each marker and position in base pair (bp). In addition disease 
status column is required in the PedFile for all individuals, ending with 6 columns defining 
the family structure for each individual. 
PLINK to remove SNPs with unknown location:  
A list of all these 96 SNPs has been created and removed using --exclude command as 
follow:  
--ped PedFile_NoCall.txt 
 --map MapFile_AffySNPsID.txt 
 --map3 
 --exclude List_96Unk.txt   (described in ‎3.3.1) 
         --recode    (described in ‎3.3.1) 
         --out Data_NoCall_No96Unk  (described in ‎3.3.1) 
(Appendix A1b) 
PedCheck Software:  
In order to use this software, disease status column has been removed from the PedFile for all 
individuals, ending with 5 columns defining the family structure for each individual instead 
of 6. The genotype format has been changed from A & B to be as two consecutive integers (1 
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and 2).  For Mendelian error check, a map file with SNPs ID only was used, so the output 
will be as SNPs list with Mendelian error.  
Commands: -p PedFile_NoCall_No96Unk_1_2.txt –n MapFile_96out_ID_ONLY.txt -4 
Using PLINK to remove the 200 SNPs showing Mendelian errors in PedCheck: 
A list of the 200 SNPs has made and removed from the data as follow: 
--ped PedFile_NoCall_No96Unk.txt 
 --map MapFile_AffySNPsID_96out.txt 
 --map3 
 --exclude 200SNPs_PedcheckError.txt 
 --recode 
 --out Data_PedcheckOK200 
(Appendix A1c) 
PLINK for removing the 5 SNPs in HH file 
--ped Data_PedcheckOK200.ped 
 --map Data_PedcheckOK200.map 
 --map3 
 --exclude Data_PedcheckOK200.HH 
--recode 
--out Data_PedcheckOK200_Nohh 
 
PLINK for Mendelian Error check:       
--ped Data_PedcheckOK200_Nohh.ped 
 --map Data_PedcheckOK200_Nohh.map 
 --map3 
 --mendel 
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(Appendix A1d) 
PLINK for Convert 1 2 to A C G T: 
--ped Data_PedcheckOK200_Nohh.ped 
 --map Data_PedcheckOK200_Nohh.map 
 --map3 
 --update-alleles Convert 1 2 to A C T G 2013.txt 
 --recode 
 --out data_ACGT 
The output has been confirmed by comparing the data of 5 SNPs (extracted) before and after 
conversion, as part of Quality Control  
(Appendix A1e) 
PLINKs for convert –ve starnds to +ve: 
 --ped data_ACGT.ped 
 --map data_ACGT.map 
 --flip All -ve strand SNP ID.txt 
 --recode 
 --out Data_converted_flipped 
The output has been confirmed by comparing the data of 5 SNPs (extracted) before and after 
flipping, as part of Quality Control  
 
(Appendix A1f) 
PLINK for Merging with HapMap: 
Removing the 22 SNPs which showed errors during data merge with HapMap: A list of 
the 22 SNPs was made and removed by PLINK using --exclude command (as described in 
appendix A1c). 
Merging data: 
A standard PLINK-style binary genotype file of HapMap, has been used (.bim is the SNP 
map, .bed is the binary PedFile, and .fam describes the family relationships among your 
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samples). A Notepad file with the name of all HapMap file (.bed .bim .fam of each 
population in one line) has been created and saved as (MergeList.txt). Family data merged 
and the SNPs listed in the map file have been extracted as follow: 
 --ped dataStrand_22out.ped 
 --map dataStrand_22out.map 
 --map3 
 --merge-list MergeList.txt 
 --extract SNPsList_Strand_22out.txt 
 --recode 
 --out Data_HapMap 
 
The output has been confirmed by comparing the data of 5 SNPs (extracted) before and after 
merge with HapMap, as part of Quality Control. 
(Appendix A1g) 
Changing SNPs chromosomal position: 
 Base pair positions changed to cM using Excel work sheets and the below command: 
[=IF(VLOOKUP(B1,D:E,1)=B1,VLOOKUP(B1,D:E,2),"")] 
Column B is for SNPs ID from map file. Columns D & E are for SNPs ID and cM position 
(from Marshfield map) respectively. The above command was typed in F column.  If the cM 
position of SNPs in B1 column was available anywhere in column E that value of cM will be 
typed in F column, otherwise will be kept empty. Same will occur with all SNPs in B column, 
ending with cM position for all SNPs in map file. That is only for the SNPs available in 
Marshfield map.  
(Appendix A1h) 
Merlin for npl Analysis: 
-d DataFile_9111.txt -p Data_9111_1234Formate_No-9_4Affected_No8.txt  
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-m MapFile_Data_9111_cM.txt  
--npl --exp       (described in Appendix  B1b) 
--swap --smallSwap --quiet     (described in Appendix  B1b) 
--markerNames  --pdf --prefix npl_2 > utput_npl_2  (described in Appendix  B1b) 
 (Appendix A1i) 
Merlin commands for Dominant Analysis: 
-d DataFile_9111_AGE.txt  
-p Data_9111_1234Formate_No-9_4Affected_No8_AGE.txt  
-m MapFile_Data_9111_cM.txt  
--model DOMINANT_Age_12.txt    (described in Appendix  B1b) 
--swap --smallSwap --quiet     (described in Appendix  B1b) 
--markerNames  --pdf --prefix Dom  > utput_Dom (described in Appendix  B1b) 
 (Appendix A1j) 
Merlin commands for Recessive Analysis: 
-d DataFile_9111_AGE.txt  
-p Data_9111_1234Formate_No-9_4Affected_No8_AGE.txt  
-m MapFile_Data_9111_cM.txt  
--model RECESSIVE_140509_12.txt   (described in Appendix  B1b) 
--swap --smallSwap --quiet     (described in Appendix  B1b) 
--markerNames  --pdf --prefix Recess  > utput_Recessi  (described in Appendix  B1b) 
(Appendix A1k) 
Merlin commands for Haplotype Analysis: 
-d DataFile_9111.txt -p Data_9111_1234Formate_No-9_4Affected_No8.txt  
-m MapFile_Data_9111_cM.txt  
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--npl         (described in Appendix  B1b) 
--best       (described in ‎3.3.3.1) 
--swap --smallSwap --quiet     (described in Appendix  B1b) 
--markerNames  --pdf --prefix Haplo > utput_Haplo   (described in Appendix  B1b) 
 
 (Appendix B) 
(Appendix B1a) 
Data Preparation:  
Change disease status (Phenotype) format for HapMap data: HapMap data use a different 
phenotype labelling format (-9 rather than 0 for unknown), which was not accepted by 
Merlin. Therefore phenotype format in HapMap data has been changed from -9 to 0.  
(Appendix  B1b) 
Merlin Commands 
A command “--pdf", can be used to obtain graphical output data for each chromosome in a 
PDF file. A command “--prefix label > output_label.out” can be used to create output files, a 
PDF for graphical output data for each chromosome and a note file with lists of markers or 
positions and the LOD score for each marker. To perform the analysis on the basis of markers 
(not positions), “--markerNames” command can be used. A command “--quiet" can be used 
to avoid inclusion of unnecessary details on the screen or in the output file. 
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(Appendix C) 
(Appendix C1a); 
The output data of the linkage analyses on chromosome 20 (the whole chromosome). 
 
chromosome SNP Position (Mb) Position (cM) npl Dominant 
20 rs722829 0.12 0.49 1.65 1.69 
20 rs1342841 0.16 0.68 1.66 1.70 
20 rs2317024 0.69 3.52 1.70 1.75 
20 rs1923876 1.18 6.69 1.95 1.85 
20 rs2013961 2.27 8.55 2.29 1.91 
20 rs1109010 2.41 8.71 2.29 1.92 
20 rs3848810 3.52 9.84 2.34 1.96 
20 rs910652 3.68 10.28 2.35 1.98 
20 rs674110 3.68 10.28 2.35 1.98 
20 rs910952 4.14 11.47 2.37 2.02 
20 rs2422925 4.25 11.69 2.37 2.03 
20 rs3904872 4.26 11.71 2.37 2.03 
20 rs3904864 4.33 11.84 2.37 2.04 
20 rs1411296 6.44 17.96 2.08 2.03 
20 rs723131 6.53 18.07 2.08 2.03 
20 rs2224191 6.76 18.35 2.08 2.03 
20 rs723511 6.79 18.39 2.08 2.03 
20 rs952793 6.92 18.55 2.07 2.03 
20 rs2149642 6.96 18.61 2.07 2.03 
20 rs717074 7.12 18.82 2.07 2.03 
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20 rs720010 7.17 18.96 2.07 2.03 
20 rs2009752 7.19 19.00 2.08 2.03 
20 rs724084 7.22 19.09 2.09 2.03 
20 rs2224053 7.25 19.17 2.10 2.03 
20 rs2223276 7.83 20.69 2.57 2.03 
20 rs2250711 8.20 22.19 2.84 2.03 
20 rs771943 8.36 23.02 2.94 2.04 
20 rs2223539 8.49 23.69 3.01 2.04 
20 rs2327088 8.71 23.93 3.01 2.04 
20 rs2143267 8.76 23.96 3.01 2.04 
20 rs3848831 8.80 23.98 3.01 2.04 
20 rs756374 8.89 24.04 3.01 2.04 
20 rs724089 9.00 24.11 3.01 2.04 
20 rs953021 9.90 24.65 3.01 2.04 
20 rs725565 9.95 24.68 3.01 2.04 
20 rs2327282 10.38 27.42 3.01 2.03 
20 rs973542 10.64 28.17 3.01 2.04 
20 rs2327302 10.66 28.23 3.01 2.04 
20 rs763383 10.85 28.71 3.01 2.04 
20 rs1028846 10.96 29.01 3.01 2.03 
20 rs726867 11.18 30.67 3.01 2.03 
20 rs3887413 11.75 31.90 3.01 2.04 
20 rs2206798 11.85 32.09 3.01 2.04 
20 rs720489 11.90 32.20 3.01 2.04 
20 rs729552 12.13 32.42 3.01 2.04 
20 rs1099620 12.74 32.80 3.01 2.04 
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20 rs2327450 12.93 32.91 3.01 2.04 
20 rs721243 13.17 33.06 3.01 2.04 
20 rs2327790 13.46 33.25 3.01 2.04 
20 rs1358766 13.86 33.50 3.01 2.04 
20 rs724820 15.02 34.23 3.01 2.03 
20 rs763659 15.74 37.09 3.01 2.03 
20 rs726207 15.96 37.41 3.01 2.03 
20 rs718610 16.21 37.82 3.01 2.03 
20 rs2144883 16.27 37.97 3.01 2.03 
20 rs1080954 16.45 38.38 3.01 2.04 
20 rs720592 16.45 38.38 3.01 2.04 
20 rs720593 16.45 38.38 3.01 2.04 
20 rs2328024 16.60 38.72 3.01 2.04 
20 rs724053 16.93 39.08 3.01 2.04 
20 rs956110 17.02 39.18 3.01 2.04 
20 rs2010316 17.08 39.24 3.01 2.04 
20 rs2010307 17.08 39.24 3.01 2.04 
20 rs1078530 17.08 39.24 3.01 2.04 
20 rs726256 17.40 39.60 3.01 2.04 
20 rs16823 17.74 39.96 3.01 2.04 
20 rs1073052 17.79 40.02 3.01 2.04 
20 rs2024673 18.12 40.37 3.01 2.04 
20 rs2328245 18.14 40.40 3.01 2.04 
20 rs2328293 18.31 40.61 3.01 2.04 
20 rs1535487 18.94 41.86 3.01 2.04 
20 rs2328361 19.03 42.05 3.01 2.04 
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20 rs1074615 19.13 42.25 3.01 2.04 
20 rs2328384 19.37 42.72 3.01 2.04 
20 rs2328410 19.49 42.98 3.01 2.04 
20 rs2328411 19.50 42.98 3.01 2.04 
20 rs2328412 19.50 42.98 3.01 2.04 
20 rs725862 19.58 43.14 3.01 2.04 
20 rs720436 19.60 43.19 3.01 2.04 
20 rs1028434 20.11 44.20 2.43 1.47 
20 rs928066 20.26 44.51 1.54 0.68 
20 rs721424 20.29 44.56 0.35 0.08 
20 rs1074440 20.48 44.95 0.35 0.08 
20 rs2038383 20.83 45.64 -1.89 0.08 
20 rs755963 20.93 45.82 0.35 0.08 
20 rs1888610 22.85 48.08 -1.66 0.08 
20 rs717756 22.92 48.13 -1.97 0.08 
20 rs2007743 22.99 48.18 0.35 0.08 
20 rs1112819 23.27 48.38 -2.41 0.08 
20 rs999072 23.30 48.40 -2.41 0.08 
20 rs726217 23.53 48.57 0.35 0.08 
20 rs2254635 23.57 48.60 0.35 0.08 
20 rs2145231 23.57 48.60 0.27 0.08 
20 rs3843776 23.94 48.67 0.35 0.08 
20 rs3843777 23.94 48.67 0.35 0.08 
20 rs3848799 23.94 48.67 0.35 0.08 
20 rs761863 24.03 48.69 0.35 0.08 
20 rs487665 24.12 48.70 0.35 0.08 
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20 rs722834 24.37 48.74 0.35 0.08 
20 rs2387577 25.00 48.85 0.35 0.08 
20 rs2207631 25.00 48.85 0.35 0.08 
20 rs2387733 25.13 48.87 -2.45 0.08 
20 rs1474945 29.31 49.58 -1.18 0.09 
20 rs721220 29.47 49.61 -1.18 0.09 
20 rs725478 31.98 50.46 0.35 0.08 
20 rs2378132 32.31 50.51 0.33 0.08 
20 rs819145 32.33 50.51 0.33 0.08 
20 rs725908 33.43 50.68 0.27 0.07 
20 rs3850528 34.17 50.79 0.23 0.06 
20 rs1073768 35.31 51.16 0.07 0.04 
20 rs724782 35.68 51.29 0.07 0.02 
20 rs910760 35.93 51.46 0.06 -0.01 
20 rs1569608 37.45 54.03 0.00 -1.88 
20 rs718093 37.66 54.37 0.00 -1.88 
20 rs718092 37.66 54.37 0.00 -1.88 
20 rs1408871 37.80 54.61 0.00 -1.87 
20 rs728331 38.42 55.60 -0.01 -1.87 
20 rs723080 38.79 56.20 -0.02 -1.88 
20 rs722728 38.87 56.30 -0.02 -1.88 
20 rs2143233 39.66 56.76 -0.02 -1.88 
20 rs2067084 40.17 57.42 -0.02 -1.87 
20 rs727336 40.32 57.64 -0.02 -1.87 
20 rs986831 40.59 58.05 -0.02 -1.88 
20 rs208179 40.87 58.46 -0.02 -1.89 
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20 rs1397854 40.90 58.51 -0.02 -1.90 
20 rs1397853 40.90 58.51 -0.02 -1.90 
20 rs2868198 42.80 61.35 -0.04 -2.02 
20 rs2157361 43.19 61.98 -0.05 -2.05 
20 rs382515 43.81 63.25 -0.07 -2.13 
20 rs3848731 44.35 64.35 -0.10 -2.21 
20 rs3908612 44.42 64.49 -0.10 -2.22 
20 rs1405567 44.62 64.89 -0.11 -2.25 
20 rs430114 44.62 64.89 -0.11 -2.25 
20 rs928486 44.89 65.69 -0.11 -2.25 
20 rs1815969 45.97 68.90 -0.11 -2.25 
20 rs756529 47.44 72.80 -0.05 -2.08 
20 rs951497 47.76 73.31 -0.05 -2.06 
20 rs967305 47.89 73.51 -0.04 -2.05 
20 rs941798 48.60 74.57 -0.04 -2.02 
20 rs956298 48.73 74.71 -0.04 -2.02 
20 rs2208006 50.14 77.12 -0.04 -2.01 
20 rs726248 50.27 77.35 -0.04 -2.02 
20 rs2904155 50.40 77.59 -0.04 -2.02 
20 rs2078577 50.44 77.67 -0.04 -2.02 
20 rs727662 50.71 77.92 -0.04 -2.02 
20 rs715434 50.71 77.93 -0.04 -2.02 
20 rs715433 50.71 77.93 -0.04 -2.02 
20 rs241792 50.80 77.99 -0.04 -2.02 
20 rs1936973 51.17 78.28 -0.04 -2.01 
20 rs916954 51.29 78.71 -0.04 -2.01 
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20 rs465402 52.10 82.02 -0.04 -2.01 
20 rs290409 52.14 82.18 -0.04 -2.01 
20 rs1418926 52.26 82.72 -0.04 -2.02 
20 rs1293153 52.38 83.27 -0.04 -2.02 
20 rs1293151 52.38 83.27 -0.04 -2.02 
20 rs1407043 52.44 83.51 -0.04 -2.02 
20 rs2870357 52.75 84.01 -0.04 -2.02 
20 rs2065042 52.88 84.21 -0.04 -2.02 
20 rs721437 53.75 85.11 -0.04 -2.01 
20 rs869138 55.06 86.45 -0.04 -2.02 
20 rs869136 55.06 86.45 -0.04 -2.02 
20 rs911901 55.39 86.78 -0.04 -2.02 
20 rs718307 55.64 87.32 -0.04 -2.02 
20 rs728504 55.77 88.09 -0.04 -2.02 
20 rs728506 55.77 88.09 -0.04 -2.02 
20 rs967990 55.77 88.09 -0.04 -2.02 
20 rs1889331 56.03 89.63 -0.04 -1.97 
20 rs717671 56.36 91.34 -0.04 -1.95 
20 rs271950 57.45 96.16 -0.04 -2.04 
20 rs1857285 57.54 96.37 -0.04 -2.05 
20 rs3905228 57.54 96.37 -0.04 -2.05 
20 rs3906935 57.54 96.37 -0.04 -2.05 
20 rs1116089 57.65 96.61 -0.04 -2.03 
20 rs1412197 58.11 97.64 -0.08 -2.04 
20 rs2144880 58.72 99.00 -0.20 -2.06 
20 rs2017286 58.90 99.41 -0.21 -2.08 
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20 rs817710 59.18 100.03 -0.21 -2.13 
20 rs947737 59.22 100.11 -0.21 -2.14 
20 rs2427077 59.33 100.36 -0.21 -2.16 
20 rs1892326 59.38 100.48 -0.21 -2.18 
20 rs944257 59.68 101.15 -0.21 -2.25 
Table Appen ‎6.1; The output data of the linkage analyses on chromosome 20 (the whole chromosome). 
First column (chromosome) shows chromosome name, second (SNP) single nucleotide polymorphisms 
(SNPs) ID, third position of SNPs in mega bases (Mb), and fourth the position in centiMorgan (cM). Fifth 
column is npl multipoint maximum LOD scores and sixth for dominant multipoint maximum LOD 
scores.  
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(Appendix C1b); 
Haplotype study of some members of family #1, across chromosome 20 (whole 
chromosome). 
    Haplotype Haplotype Haplotype 
Chromosome SNP Position 
Mb 
Position 
cM 
III-2 
(II-2, II-1) 
IV-2 
(III-2, III-
1) 
III-3 
(II-2, II-1) 
20 rs722829 0.12 0.49 C : G C : I K : H 
20 rs1342841 0.16 0.68 C : G C : I K : H 
20 rs2317024 0.69 3.52 C | G C | I K | H 
20 rs1923876 1.18 6.69 C | G G / I K \ G 
20 rs2013961 2.27 8.55 C | G G | I K | G 
20 rs1109010 2.41 8.71 C | G G | I K | G 
20 rs3848810 3.52 9.84 C : G G : I K : G 
20 rs910652 3.68 10.28 C | G G | I K | G 
20 rs674110 3.68 10.28 C | G G | I K | G 
20 rs910952 4.14 11.47 C : G G : I K : G 
20 rs2422925 4.25 11.69 C | G G | I K | G 
20 rs3904872 4.26 11.71 C | G G | I K | G 
20 rs3904864 4.33 11.84 C | G G | I K | G 
20 rs1411296 6.44 17.96 C | G G | I K | G 
20 rs723131 6.53 18.07 C | G G | I K | G 
20 rs2224191 6.76 18.35 C | G G | I K | G 
20 rs723511 6.79 18.39 C | G G | I K | G 
20 rs952793 6.92 18.55 C | G G | I K | G 
20 rs2149642 6.96 18.61 C | G G | I K | G 
20 rs717074 7.12 18.82 C | G G | I K | G 
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20 rs720010 7.17 18.96 C | G G | I K | G 
20 rs2009752 7.19 19.00 C : G G : I K : G 
20 rs724084 7.22 19.09 C | G G | I K | G 
20 rs2224053 7.25 19.17 C | G G | I K | G 
20 rs2223276 7.83 20.69 C : G G : I K : G 
20 rs2250711 8.20 22.19 C | G G | I K | G 
20 rs771943 8.36 23.02 C | G G | I K | G 
20 rs2223539 8.49 23.69 C | G G | I K | G 
20 rs2327088 8.71 23.93 C | G G | I K | G 
20 rs2143267 8.76 23.96 C | G G | I K | G 
20 rs3848831 8.80 23.98 C | G G | I K | G 
20 rs756374 8.89 24.04 C | G G | I K | G 
20 rs724089 9.00 24.11 C | G G | I K | G 
20 rs953021 9.90 24.65 C | G G | I K | G 
20 rs725565 9.95 24.68 C | G G | I K | G 
20 rs2327282 10.38 27.42 C | G G | I K | G 
20 rs973542 10.64 28.17 C | G G | I K | G 
20 rs2327302 10.66 28.23 C | G G | I K | G 
20 rs763383 10.85 28.71 C | G G | I K | G 
20 rs1028846 10.96 29.01 C | G G | I K | G 
20 rs726867 11.18 30.67 C | G G | I K | G 
20 rs3887413 11.75 31.90 C | G G | I K | G 
20 rs2206798 11.85 32.09 C | G G | I K | G 
20 rs720489 11.90 32.20 C | G G | I K | G 
20 rs729552 12.13 32.42 C | G G | I K | G 
20 rs1099620 12.74 32.80 C | G G | I C / G 
203 
 
20 rs2327450 12.93 32.91 C | G G | I C | G 
20 rs721243 13.17 33.06 C | G C / I C | G 
20 rs2327790 13.46 33.25 C | G C | I C | G 
20 rs1358766 13.86 33.50 C | G C | I C | G 
20 rs724820 15.02 34.23 C | G C | I C | G 
20 rs763659 15.74 37.09 C | G C | I C | G 
20 rs726207 15.96 37.41 C | G C | I C | G 
20 rs718610 16.21 37.82 C | G C | I C | G 
20 rs2144883 16.27 37.97 C | G C | I C | G 
20 rs1080954 16.45 38.38 C | G C | I C | G 
20 rs720592 16.45 38.38 C | G C | I C | G 
20 rs720593 16.45 38.38 C | G C | I C | G 
20 rs2328024 16.60 38.72 C | G C | I C | G 
20 rs724053 16.93 39.08 C : G C : I C : G 
20 rs956110 17.02 39.18 C | G C | I C | G 
20 rs2010316 17.08 39.24 C | G C | I C | G 
20 rs2010307 17.08 39.24 C : G C : I C : G 
20 rs1078530 17.08 39.24 C | G C | I C | G 
20 rs726256 17.40 39.60 C | G C | I C | G 
20 rs16823 17.74 39.96 C | G C | I C | G 
20 rs1073052 17.79 40.02 C | G C | I C | G 
20 rs2024673 18.12 40.37 C | G C | I C | G 
20 rs2328245 18.14 40.40 C | G C | I C | G 
20 rs2328293 18.31 40.61 C | G C | I C | G 
20 rs1535487 18.94 41.86 C | G C | I C | G 
20 rs2328361 19.03 42.05 C | G C | I C | G 
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20 rs1074615 19.13 42.25 C | G C | I C | G 
20 rs2328384 19.37 42.72 C | G C | I C | G 
20 rs2328410 19.49 42.98 C | G C | I C | G 
20 rs2328411 19.50 42.98 C | G C | I C | G 
20 rs2328412 19.50 42.98 C | G C | I C | G 
20 rs725862 19.58 43.14 C | G C | I C | G 
20 rs720436 19.60 43.19 C | G C | I C | G 
20 rs1028434 20.11 44.20 C | G C | I C | G 
20 rs928066 20.26 44.51 C : G C : I C : G 
20 rs721424 20.29 44.56 C | G C | I C | G 
20 rs1074440 20.48 44.95 C | G C | I C | G 
20 rs2038383 20.83 45.64 C | G C | I C | G 
20 rs755963 20.93 45.82 C | G C | I C | G 
20 rs1888610 22.85 48.08 C | G C | I C | G 
20 rs717756 22.92 48.13 C | G C | I C | G 
20 rs2007743 22.99 48.18 C | G C | I C | G 
20 rs1112819 23.27 48.38 C | G C | I C | G 
20 rs999072 23.30 48.40 C | G C | I C | G 
20 rs726217 23.53 48.57 C | G C | I C | G 
20 rs2254635 23.57 48.60 C | G C | I C | G 
20 rs2145231 23.57 48.60 C | G C | I C | G 
20 rs3843776 23.94 48.67 C | G C | I C | G 
20 rs3843777 23.94 48.67 C | G C | I C | G 
20 rs3848799 23.94 48.67 C | G C | I C | G 
20 rs761863 24.03 48.69 C | G C | I C | G 
20 rs487665 24.12 48.70 C : G C : I C : G 
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20 rs722834 24.37 48.74 C | G C | I C | G 
20 rs2387577 25.00 48.85 C | G C | I C | G 
20 rs2207631 25.00 48.85 C | G C | I C | G 
20 rs2387733 25.13 48.87 C | G C | I C | G 
20 rs1474945 29.31 49.58 C | G C | I C | G 
20 rs721220 29.47 49.61 C | G C | I C | G 
20 rs725478 31.98 50.46 C | G C | I C | G 
20 rs2378132 32.31 50.51 C | G C | I C | G 
20 rs819145 32.33 50.51 C | G C | I C | G 
20 rs725908 33.43 50.68 C | G C | I C | G 
20 rs3850528 34.17 50.79 C | G C | I C | G 
20 rs1073768 35.31 51.16 C | G C | I C | G 
20 rs724782 35.68 51.29 C : G C : I C : G 
20 rs910760 35.93 51.46 C | G C | I C | G 
20 rs1569608 37.45 54.03 C | G C | I C | G 
20 rs718093 37.66 54.37 C | G C | I C | G 
20 rs718092 37.66 54.37 C | G C | I C | G 
20 rs1408871 37.80 54.61 C | G C | I C | G 
20 rs728331 38.42 55.60 C | G C | I C | G 
20 rs723080 38.79 56.20 C | G C | I C | G 
20 rs722728 38.87 56.30 C | G C | I C | G 
20 rs2143233 39.66 56.76 C | G C | I C | G 
20 rs2067084 40.17 57.42 C | G C | I C | G 
20 rs727336 40.32 57.64 C | G C | I C | G 
20 rs986831 40.59 58.05 C | G C | I C | G 
20 rs208179 40.87 58.46 C | G C | I C | G 
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20 rs1397854 40.90 58.51 C | G C | I C | G 
20 rs1397853 40.90 58.51 C | G C | I C | G 
20 rs2868198 42.80 61.35 K / G K \ J C | G 
20 rs2157361 43.19 61.98 K | G K | J C | G 
20 rs382515 43.81 63.25 K | G K | J C | G 
20 rs3848731 44.35 64.35 K | G K | J C | G 
20 rs3908612 44.42 64.49 K | G K | J C | G 
20 rs1405567 44.62 64.89 K | G K | J C | G 
20 rs430114 44.62 64.89 K | G K | J C | G 
20 rs928486 44.89 65.69 K | G K | J C | G 
20 rs1815969 45.97 68.90 K | G K | J C | G 
20 rs756529 47.44 72.80 K | G K | J C | G 
20 rs951497 47.76 73.31 K | G K | J C | G 
20 rs967305 47.89 73.51 K | G K | J C | G 
20 rs941798 48.60 74.57 K | G K | J C | G 
20 rs956298 48.73 74.71 K | G K | J C | G 
20 rs2208006 50.14 77.12 K | G K | J K / G 
20 rs726248 50.27 77.35 K | G K | J K | G 
20 rs2904155 50.40 77.59 K | G K | J K | G 
20 rs2078577 50.44 77.67 K | G K | J K | G 
20 rs727662 50.71 77.92 K | G K | J K | G 
20 rs715434 50.71 77.93 K | G K | J K | G 
20 rs715433 50.71 77.93 K | G K | J K | G 
20 rs241792 50.80 77.99 K | G K | J K | G 
20 rs1936973 51.17 78.28 K : G K : J K : G 
20 rs916954 51.29 78.71 K | G K | J K | G 
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20 rs465402 52.10 82.02 K | G K | J K | G 
20 rs290409 52.14 82.18 K | G K | J K | G 
20 rs1418926 52.26 82.72 K | G K | J K | G 
20 rs1293153 52.38 83.27 K | G K | J K | G 
20 rs1293151 52.38 83.27 K | G K | J K | G 
20 rs1407043 52.44 83.51 K | G K | J K | G 
20 rs2870357 52.75 84.01 K | G K | J K | G 
20 rs2065042 52.88 84.21 K | G K | J K | G 
20 rs721437 53.75 85.11 K : G K : J K : G 
20 rs869138 55.06 86.45 K | G K | J K | G 
20 rs869136 55.06 86.45 K | G K | J K | G 
20 rs911901 55.39 86.78 K | G K | J K | G 
20 rs718307 55.64 87.32 K | G K | J K | G 
20 rs728504 55.77 88.09 K | G K | J K | G 
20 rs728506 55.77 88.09 K | G K | J K | G 
20 rs967990 55.77 88.09 K | G K | J K | G 
20 rs1889331 56.03 89.63 K | G K | J K | G 
20 rs717671 56.36 91.34 K | G K | J K | G 
20 rs271950 57.45 96.16 K | G K | J K | G 
20 rs1857285 57.54 96.37 K | G K | J K | G 
20 rs3905228 57.54 96.37 K | G K | J K | G 
20 rs3906935 57.54 96.37 K | G K | J K | G 
20 rs1116089 57.65 96.61 K | G K | J K | G 
20 rs1412197 58.11 97.64 K | G K | J K | G 
20 rs2144880 58.72 99.00 K | G K | J K | G 
20 rs2017286 58.90 99.41 K | G K | J K | G 
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20 rs817710 59.18 100.03 K | G K | J K | G 
20 rs947737 59.22 100.11 K : G K : J K : G 
20 rs2427077 59.33 100.36 K | G K | J K | G 
20 rs1892326 59.38 100.48 K | G K | J K | G 
20 rs944257 59.68 101.15 K | G K | J K | G 
Table Appen ‎6.2; Haplotype study of some members of family #1, across chromosome 20 (whole 
chromosome). The first 4 columns show; chromosome ID, position in mega base (Mb) and position in 
centi Morgan (cM). The next 3 big columns are for the haplotype of individuals; II-2 & IV-2 and III-3. 
Each of the three big columns contain 3 small columns showing haplotypes inherited from mother, 
information about recombination (as detailed below) and haplotype inherited from father, respectively. 
Merlin software has marked founders with (F) and for non-founders, added parent ID in brackets 
(instead of F). Haplotype pairs are separated by a | for no recombination, : for no information on 
recombination and /, \, + for recombination (in the maternal, paternal & both haplotype respectively). 
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(Appendix D) 
(Appendix D1a) 
FOXE-1 Poly-Alanine tract investigation  
 
 
Figure App.‎6.1; Ethidium bromide stained agarose gel of FOXE-1 poly-Alanine tract screening for all 
affected family #1 members labelled as I the family tree and some unaffected in addition to unrelated 
controls. Double band represent heterozygous 14/16, while single band represents homozygous 16/16 
14/14. 
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(Appendix D1b) 
Investigation of the SNPs close to FOXE-1 and associated with PTC and FTC 
 
 
Figure App.‎6.2; Image of the SNPs (A & C) flanking the reported SNP (B) to be located close to FOXE-1 
gene and associated with increased risk of both PTC and FTC   
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